var title_f5_62_6112="Fungal keratitis";
var content_f5_62_6112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fungal keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With satellite lesions and hypopyon (layering of white blood cells in anterior chamber).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6112=[""].join("\n");
var outline_f5_62_6112=null;
var title_f5_62_6113="Trapidil: International drug information";
var content_f5_62_6113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trapidil: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avantrin (IT);",
"     </li>",
"     <li>",
"      Rocornal (AT, DE);",
"     </li>",
"     <li>",
"      Travisco (BR, IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2677751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiplatelet Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Growth Factor, Platelet-Derived",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2677752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of ischemic heart disease",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2677754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 400-600 mg/day in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2677755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Capsule: 200 mg",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Tablet: 200 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10507 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6113=[""].join("\n");
var outline_f5_62_6113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369832\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677751\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677752\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677754\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821190\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677755\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10507\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10507|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_62_6114="Patient information: Cataracts (The Basics)";
var content_f5_62_6114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15844\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28465\">",
"         Common eye disorders",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/24/33153\">",
"          How cataracts affect vision",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/11/24754\">",
"         Patient information: Age-related macular degeneration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/35/11826\">",
"         Patient information: Age-related vision loss (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/34/11810\">",
"         Patient information: Diabetic retinopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2258\">",
"         Patient information: Glaucoma (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cataracts (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cataracts-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6373889\">",
"      <span class=\"h1\">",
"       What is a cataract?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A cataract is clouding of the lens in the eye. The lens is the part of the eye that focuses light (",
"      <a class=\"graphic graphic_figure graphicRef76735 \" href=\"UTD.htm?27/51/28465\">",
"       figure 1",
"      </a>",
"      ). Cataracts can cause vision loss.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6373896\">",
"      <span class=\"h1\">",
"       What are the symptoms of cataracts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cataracts make a person&rsquo;s vision blurry or dull (",
"      <a class=\"graphic graphic_picture graphicRef78853 \" href=\"UTD.htm?32/24/33153\">",
"       picture 1",
"      </a>",
"      ). They can also make everything look slightly brown in color. Some people notice a problem when they keep needing new eyeglass prescriptions. For some, headlights and other lights develop a glare.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6373903\">",
"      <span class=\"h1\">",
"       Is there a test for cataracts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse might be able to see your cataracts just by looking in your eye. But if it looks like you have cataracts, your doctor or nurse will probably send you to an eye doctor. Eye doctors can usually diagnose cataracts in minutes. &nbsp;",
"     </p>",
"     <p>",
"      If you have vision loss, it could be caused by more than one thing. An eye doctor can check you for the most common causes of vision loss by doing a &ldquo;comprehensive eye exam.&rdquo; During this exam, the doctor will:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Check how well you see things up close and far away",
"       </li>",
"       <li>",
"        Check how well you see things that are at the center of focus and how well you see things that are off to the sides",
"       </li>",
"       <li>",
"        Measure the pressure inside your eye using a special device",
"       </li>",
"       <li>",
"        Look into the back of your eyes to check for signs of nerve damage",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6373910\">",
"      <span class=\"h1\">",
"       How are cataracts treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment for cataracts involves surgery to remove the cloudy lens and replace it with a new man-made one. Not everyone needs treatment. If you have cataracts, it's mostly up to you to decide if and when to have surgery.",
"     </p>",
"     <p>",
"      Cataract surgery is pretty simple, but it can lead to problems, such as infection or pain. At the same time, the surgery can greatly improve vision in people with severe cataracts.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6373917\">",
"      <span class=\"h1\">",
"       How do I decide about surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are thinking about surgery, ask your doctor these questions:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        What are the risks of surgery for me? (If you have any other health problems, ask how they might affect the results of the surgery.)",
"       </li>",
"       <li>",
"        How much is my vision likely to improve if I have the surgery?",
"       </li>",
"       <li>",
"        Is it possible the surgery will NOT work?",
"       </li>",
"       <li>",
"        Are my cataracts the only thing causing my vision problems? (If you have other eye conditions, surgery may not help with those.)",
"       </li>",
"       <li>",
"        What will my recovery be like?",
"       </li>",
"       <li>",
"        Can both eyes be done at the same time? (If not, ask how it will feel to have one eye treated and the other not. Also ask what is involved in getting the second eye done.) &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After you get all this information from your doctor, ask yourself:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How much do my vision problems limit me?",
"       </li>",
"       <li>",
"        Can I do all the things I need to do with the vision I have left?",
"       </li>",
"       <li>",
"        Have I stopped doing things I love, such as reading or knitting, because I can't see well anymore?",
"       </li>",
"       <li>",
"        How do I feel about the possible risks of surgery?",
"       </li>",
"       <li>",
"        How will I feel if the surgery causes problems or does not work? &nbsp;",
"       </li>",
"       <li>",
"        Will there be someone who can help me while I recover? &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Think it over. Then work with your doctor to decide whether surgery is right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6373924\">",
"      <span class=\"h1\">",
"       Can cataracts be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting cataracts by not smoking, or quitting if you already smoke.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6374021\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=see_link\">",
"       Patient information: Age-related vision loss (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=see_link\">",
"       Patient information: Glaucoma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=see_link\">",
"       Patient information: Age-related macular degeneration (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=see_link\">",
"       Patient information: Diabetic retinopathy (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/62/6114?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15844 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6114=[""].join("\n");
var outline_f5_62_6114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6373889\">",
"      What is a cataract?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6373896\">",
"      What are the symptoms of cataracts?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6373903\">",
"      Is there a test for cataracts?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6373910\">",
"      How are cataracts treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6373917\">",
"      How do I decide about surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6373924\">",
"      Can cataracts be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6374021\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15844\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28465\">",
"      Common eye disorders",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/24/33153\">",
"       How cataracts affect vision",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=related_link\">",
"      Patient information: Age-related macular degeneration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=related_link\">",
"      Patient information: Age-related vision loss (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=related_link\">",
"      Patient information: Diabetic retinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=related_link\">",
"      Patient information: Glaucoma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_62_6115="Patient information: Common breast problems (The Basics)";
var content_f5_62_6115=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/10/44193\">",
"         Patient information: Breast biopsy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/19/2357\">",
"         Patient information: Breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/59/19379\">",
"         Patient information: Breast cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/59/6066\">",
"         Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/56/12167\">",
"         Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36481\">",
"         Patient information: Breast cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/56/6018\">",
"         Patient information: Common breast problems (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/6/44134\">",
"         Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Common breast problems (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/common-breast-problems-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13005180\">",
"      <span class=\"h1\">",
"       What kinds of problems can women have with their breasts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women can have a few different kinds of problems with their breasts. The important thing to know is that in most cases, these problems are",
"      <strong>",
"       not",
"      </strong>",
"      caused by breast cancer. Some common breast problems include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Breast lumps",
"       </li>",
"       <li>",
"        Breast pain or tenderness",
"       </li>",
"       <li>",
"        Nipple discharge (meaning fluid or blood is leaking from the nipples)",
"       </li>",
"       <li>",
"        Nipple inversion (meaning the nipples point inward instead of out)",
"       </li>",
"       <li>",
"        Changes in the skin of the breast",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These problems can happen in women of all ages. If you develop 1 of these problems, try not to panic. It's normal to get scared if you find a new problem with 1 or both of your breasts. But there are lots of reasons besides cancer that can cause the breasts to change.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13005187\">",
"      <span class=\"h2\">",
"       Breast lumps",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you find a lump in your breast, see your doctor or nurse and have your lump carefully checked.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Women younger than 30",
"        </strong>",
"        &ndash; If you are younger than 30 and you find a lump just before you get your period, your doctor or nurse might ask you to wait until your period is over and then check if the lump is still there. Women younger than 30 often have lumps that are brought on by normal hormone changes. These lumps usually go away after a woman has her period. If your lump does not go away after your period ends, you will need a breast exam and 1 or more tests. Common tests used to evaluate breast lumps include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Breast ultrasound &ndash; This is an imaging test that uses sound waves to create pictures of the inside of your breast. It can show whether your lump is solid or filled with fluid.",
"       </li>",
"       <li>",
"        Breast biopsy &ndash; During a biopsy, a doctor will take 1 or more tiny samples of the lump using a needle. The samples can go to the lab and be checked for cancer or other problems.",
"       </li>",
"       <li>",
"        Mammogram &ndash; Mammograms are special X-rays of the breast. They are not usually done on women younger than 30. But you might have a mammogram if your ultrasound does not give enough information.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Women age 30 and older",
"        </strong>",
"        &ndash; If you are age 30 or older and you find a breast lump, you will need a breast exam and mammogram. You will also need to have a breast ultrasound and might need a biopsy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If it turns out that your lump is filled with fluid, it is called a &ldquo;cyst.&rdquo; Cysts are not usually caused by cancer. They only need to be treated if they cause pain or discomfort. Treatment usually involves draining the fluid with a needle.",
"     </p>",
"     <p>",
"      If it turns out that your lump is solid, you will need a biopsy to find out what kind of cells are inside the lump. The biopsy will show whether you have cancer. Not all solid lumps are caused by cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13005194\">",
"      <span class=\"h2\">",
"       Breast pain or tenderness",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common cause of breast pain is the hormone changes that happen during a woman's monthly cycle. When hormone changes are the cause of pain, they usually cause pain in both breasts, and the pain usually starts a few days before the woman&rsquo;s period. Pain that comes and goes because of changes in hormones is not usually caused by breast cancer or other serious problems. Hormone medicines, such as the birth control pill, can also cause breast pain.",
"     </p>",
"     <p>",
"      Other causes of breast pain include wearing a bra that is too tight or too loose, drinking coffee and smoking, and infection. (If your breast is red and tender, it could be infected.)",
"     </p>",
"     <p>",
"      If you are worried about breast pain or an infection, see your doctor or nurse to find out if you need any tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13005201\">",
"      <span class=\"h2\">",
"       Nipple discharge",
"      </span>",
"      &nbsp;&mdash;&nbsp;If fluid or blood is leaking from 1 or both of your nipples, you should see your doctor or nurse. Common reasons for nipple discharge include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Recent childbirth &ndash; Women who had a baby in the last year often leak fluid that looks like milk.",
"       </li>",
"       <li>",
"        Hormone imbalances",
"       </li>",
"       <li>",
"        Side effects from medicines",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Many women who have no health problems can squeeze out a small amount of yellow, green, or brown fluid from their nipples. This is usually nothing to worry about, and it is best not to squeeze your nipples. But if the discharge is clear or bloody, or happens without squeezing, it could signal a problem or possibly cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13005208\">",
"      <span class=\"h2\">",
"       Inverted nipples",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many women are born with nipples that naturally invert (point inward) at times and evert (poke out) at other times. Other women find that their nipples invert after they have breast-fed. Nipple inversion of this type is nothing to worry about.",
"     </p>",
"     <p>",
"      But if your nipples have always pointed out and then start to invert for no reason, you should see your doctor or nurse. He or she will probably give you a breast exam and order a mammogram. Most causes of nipple inversion are not serious. But in some cases, this is the first sign of a breast cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13005215\">",
"      <span class=\"h2\">",
"       Breast skin changes",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you develop some sort of skin problem on or near your breast and it does not get better within a few days, see your doctor or nurse. The skin on the breast can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Become itchy, red, or swollen",
"       </li>",
"       <li>",
"        Form scales or crust over",
"       </li>",
"       <li>",
"        Form dimples",
"       </li>",
"       <li>",
"        Look swollen, or pitted, like the skin of an orange",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These kinds of skin changes are not usually caused by anything serious. But in rare cases they can be a sign of uncommon forms of breast cancer. Your doctor or nurse can look at your breasts and see if you need any tests or a biopsy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13005222\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you find a new breast problem, make an appointment to see a doctor or nurse within a few weeks. Breast problems are not usually an emergency. But you should get checked out as soon as possible. If there is something serious going on, it&rsquo;s important to find out quickly. Your doctor or nurse might be able to tell what&rsquo;s happening just by doing an exam. If not, he or she can order some tests, or send you to a specialist.",
"     </p>",
"     <p>",
"      If you are still worried even after your doctor or nurse finds nothing wrong, bring it up again. You might need to be followed for a while, or you might need to see a different doctor. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13005259\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=see_link\">",
"       Patient information: Breast cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"       Patient information: Breast cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=see_link\">",
"       Patient information: Breast biopsy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/59/6066?source=see_link\">",
"       Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=see_link\">",
"       Patient information: Common breast problems (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"       Patient information: Breast cancer screening (Beyond the Basics)",
"      </a>",
"      &nbsp;",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"       Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"      </a>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/62/6115?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16170 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6115=[""].join("\n");
var outline_f5_62_6115=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13005180\">",
"      What kinds of problems can women have with their breasts?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13005187\">",
"      Breast lumps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13005194\">",
"      Breast pain or tenderness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13005201\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13005208\">",
"      Inverted nipples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13005215\">",
"      Breast skin changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13005222\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13005259\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=related_link\">",
"      Patient information: Breast biopsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=related_link\">",
"      Patient information: Common breast problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=related_link\">",
"      Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/59/6066?source=related_link\">",
"      Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_62_6116="Tetrahydrozoline (ophthalmic): Patient drug information";
var content_f5_62_6116=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tetrahydrozoline (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/21/19795?source=see_link\">",
"     see \"Tetrahydrozoline (ophthalmic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9600043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Murine&reg; Tears Plus [OTC];",
"     </li>",
"     <li>",
"      Opti-Clear [OTC];",
"     </li>",
"     <li>",
"      Visine&reg; Advanced Relief [OTC];",
"     </li>",
"     <li>",
"      Visine&reg; Original [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703013",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tetrahydrozoline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if solution changes color.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12319 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6116=[""].join("\n");
var outline_f5_62_6116=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600043\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024723\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024722\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024727\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024728\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024730\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024725\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024726\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024731\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024732\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/18/24867?source=related_link\">",
"      Tetrahydrozoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/55/3956?source=related_link\">",
"      Tetrahydrozoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/21/19795?source=related_link\">",
"      Tetrahydrozoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_62_6117="Etidronate and calcium: Patient drug information";
var content_f5_62_6117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Etidronate and calcium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/26/37284?source=see_link\">",
"     see \"Etidronate and calcium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F864486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Etidrocal;",
"     </li>",
"     <li>",
"      Didrocal&reg;;",
"     </li>",
"     <li>",
"      Mylan-Eti-Cal Carepac;",
"     </li>",
"     <li>",
"      Novo-Etidronatecal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off or treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to etidronate, calcium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have GI (gastrointestinal) disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron, zinc, or folic acid within 2 hours of the calcium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696855",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take calcium, iron, or magnesium within 2 hours of the etidronate.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from calcium by 2 hours. Calcium stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bone, joint, or muscle pain may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2927622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A broken leg may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the jaw bone may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699013",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone, joint, or muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2927623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad groin or thigh pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694769",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take the etidronate and the calcium at the same time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695805",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take the etidronate on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695806",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take the etidronate with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695804",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take the calcium with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11731 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C2D6B77659-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6117=[""].join("\n");
var outline_f5_62_6117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864486\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025067\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025066\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025071\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025072\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025074\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025069\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025070\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025075\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025076\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/26/37284?source=related_link\">",
"      Etidronate and calcium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_62_6118="Bleeding Meckels diverticulum on CT scan";
var content_f5_62_6118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Bleeding Meckels diverticulum on CT scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 317px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE9AlYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+L4YJZs+WhYDqewqwlmAw86QAei80AfZH/AA1X4H/6BXiT/wAB4P8A49Sr+1T4Jb7uk+JT9LaD/wCPV8ebIUOFhz7uc08s2XAYAHkYGKAPsUftQ+DiM/2P4mHGebeAf+1qD+1F4MGM6R4k5/6YW/8A8er46cZbdng4z7GmhflyB0PT0NAH2N/w1H4M5/4lHiXj/p3g/wDj1IP2pPBh6aT4k/78Qf8Ax6vjr15+UHr/ACpfujkZHp3FAH2J/wANSeDP+gR4k/8AAeD/AOPUv/DUfgzGf7I8SY/64Qf/AB6vjxDtHJ4Y/MR3FN5CgY+lAH2KP2o/BhxjSfEfP/TC3/8Aj1L/AMNQ+Du2j+JT9LeA/wDtavjcjHYHPb1p4H7tcDnuc9/agD7EP7Ufg0f8wbxP/wCA0H/x6mH9qfwUpwdI8TA+9tB/8er49BK8jPHHX/PWlRnjOd5wvB+h6UAfX/8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8fyEyZDohI6fKOBTGhgfH7tkJ6FT/Q0AfYf/DVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV8byWa4JimVj1wwx+tQS20sX3kOPUcigD7P/AOGq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA/RT4UfFXQ/ib/an9g2upW/9neV5v22NE3eZv27drtn/VnOcdq5XXf2jfCmja9qWk3GleIJLiwuZbSV4oYCjPG5RipMoOMqcZArz/8AYY/5nb/tx/8AbivK9d02LWfjvqWl3Dyx29/4oltJHiIDqkl6yMVyCM4Y4yDQB9EQftOeEJ5kii0bxKZHIAHkW4yf+/1dbonxXi1y5kt9L8JeJZ5Y1DsM2SgDOOrXIFeG+I/h78O/DGva3ZyP4+uG0GOC5vbq3ksDHCkmNjYcKzdRkBTXq/h7w5aeEvFemxWGualc6drGk3F1Ib8QgqYprTYQUiQj5ZnyDnt6UAUNa/aX8J6Lq13pup6L4lgvbWQxTR+TbttYHBGROQfwNU/+Gq/A/wD0CvEn/gPB/wDHq+TPiJqo1vx54g1NVCpdX00igf3S5x+mK52gD7V/4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6viqigD7V/4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6viqigD7V/4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6viqigD7s8O/tEeGvEdybfSNF1+acY/dv9kiY/QPcDP4V1w+INwV3DwX4kI/66WH/yTX56aHdTWWs2VzbbvOimVl29Tz0r7O8E+M5NSsU+0weUyDB3DFAHoQ8c3rAEeCfEuD/01sP/AJKoPji9H/Mk+Jf+/th/8lVDDq9vuAMiYGDUt5qttHEXSZGOM4BoAbN49uoYXlk8F+JFRFLMfNsOAP8At6rGh+MllMm6Pwt4kK5x1sxz/wCBFYWpeIJbpLm3VWwV25HvXNPpn2ZXcSH75AGaAPUIfieJseX4R8Rtnp+8sR/7c1KPiNIQSPB3iPA/6a2H/wAk15nZyTKwaMu21SSB7Vo2Vw00YzIQT70Adq/xQVM7vCPiPjr89j/8k1G3xWiXGfCXiTkZ+9Zf/JNcosIZTmX0HWmTSJHEy7gduRmgDqLn4v2ttA80/hXxIkSDLMTZcD/wJrj2/ap8EKxU6V4kyDg4t4D/AO1q4b4xa4LPwbdC3IMsmI8DsG6mvmKgD7V/4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6viqigD7Xi/an8FSypHHpPiQu7BVH2eAZJ/wC21a1/+0N4esATd6B4kjAOD+7tT/KevhSNzG6uv3lIIr3q50K517wZ/akUTtbyxCXzQPl46/rxQB7Cf2n/AAeOuj+JP+/Fv/8AHqQftQeDiQP7H8SZPT9xb/8Ax6vkSYFHkDDBU9Krsp3ZHrQB9fSftT+Co5GR9J8SBlOCPs8HX/v9Tf8AhqvwP/0CvEn/AIDwf/Hq+OdWj2zxuAAJYw349D/KqFAH6ieHtVg17QNM1ezWVLbULWK7iWUAOqSIGAYAkZwRnBNFYvwn/wCSWeDf+wLZf+iEooA8q/bW/wCSWaV/2Gov/RE9cf8AATQdZ8Ufs3+J9D8O3Fpa3d/rDwSTXLMqrCYbfzMbVJJK5GPc812H7a3/ACSzSv8AsNRf+iJ6+KqAPv8A8CfDLUPA/wAQpdS0rVFu/D93pkVndRXWxJxLCAsTKsUaoVCALzzySc18AUUUAFFFFABRRRQAUUUUAFFT21tJcNiMcDqx4A+pq4LaKBT92Zx1PYUAVIrSWRPMwFjzjc3AqzHBFETuHmcgBj0+uKkLM7AO245wCT1puDg7RzngH0oAeZGxtLfKMgAdKfE4ThgCh/ziouuNveheRgfxDgfzoAfOELB4z8mPyNInMmCPcn1FNPRscbh1oLYIKemfxoAtyWphtYrgyIY5mI2g88dz6e1VQCWAByc9qEbbICnHqD0pUYocqcDH5UAADDGQB9ab1PHIxyO+Kc4O4gk7uTyetJgYzkgqcj3/APr0AAwSByV6ilxkEY46ijBPcihcAEclV5wPX2oATBJYHlhyB6mlbIZumc4PpQg5DA/MBn2oKcEhiCBn3/8A1UAIxwTzwD+VHOR3weAO9P255Ax6CjnIHPTt3oAYMAgE5HIAFCDJG4gcc0AcgHAYdfT60cDbuHPQjpQAjIAuDjHIpcyIQQSmMEetIuTnnI6A0vTGMdKAEkRJGJmi2k45Xg/X0qu9kSMwuH/2Dwwqyfu8Y64GaQ4BznHHJ9zQBmujRsVdSrDqCKbWqX3ELMgkUjnd1H41FLZLIN1qxJP/ACzbr+HrQBn0UrKVYqwIYcEGkoAKKKKACiiigD6q/YY/5nb/ALcf/bivO93/ABkjj/qcv/chXon7DH/M7f8Abj/7cV4r8S2X/hZPjAOAw/tm94Iz/wAvD0AfUfjv4UaxrvjLxfqtvY+G7yLWrOC2tLi/mkWfT3SMKZUAhb5s8jDr0GT2rK+Nljd6Sfh/p8t9Nd3Nrpd5by3TEhpiv2RS5+pGe/418raBbwSa1YpLDE8bSAMrICCPcV9RfCvwLoWorqF1JYWtv++jto5IY1Q8kFhwO/FAHx7dLtuZVznDkZ9eairR8R262niDU7aP7kN1LGv0Dkf0rOoAKUAkgAZJra8J+HbnxJqsdnbHy1P35SpKpXv3g7wJZeG7ZsiK6nGGMrxjJ+melAHjHh34e6vrUCzAxW0Tcgy5z+WK6ux+DVw+PtWpxZIzhENe1uq4CBFXC5AAApOBKzL1Ck0AeQS/ByJAP9P5PtWtonwr0+xnMty0dx5fIDjIP4V6S/71VPooFIm2RlVzgEGgDFsfDOm27jy7S2XHIIjHWtqzsI0ikCNtyRwOKJFC7Av3geafECkbyL91mwDQBJcWjL5hWV9vQnJqvDC4CqJXb5fU+tWmuStlJG3VwtFpiO7SJ+C2AR7UAFrmIlyuS3+NLdDzwPTdmtVraNogYzkxkL+GaqCJUjYA/MDnH40AR6S/2Hz8AN5qkc9s1SkQW7kqTjcP5VovCq8j7oOc/hVW6hZ3fjjANADYpWbqSBt/xqGaAmIfMeeTU8seElHdSFoDjaw7leaAOQ8R+D49YgkjkmIEqFeSeD2NedH4K3qylDq9sT6+Wa9ykO0IPU1EQTdKezHH5UAeEz/B3UowSmpWrYz1Vh0Ncv4k8DatoURlnWOaIdWiyce+MV9QMAsRY4xvK/nzTbyJZrdg0aMegBUGgD43r7O+Bksep/s+W9pOA0axXsbkfwlX3qD+BBrxf4ofD/el1rWmlFKIGe3SPG73GO9dB+zt4qNl4D8T6PMuQrmSHnvLEY2H4bQaAPINXYNqV2y9Gc9PrVRW+9nuKs3kPl3cqHqMiqJzvKjpxQAmrjNnZuOg3p+RB/rWTWzfjGhweouHH/jorGoA/Sr4T/8AJLPBv/YFsv8A0QlFHwn/AOSWeDf+wLZf+iEooA8q/bW/5JZpX/Yai/8ARE9fFVfav7a3/JLNK/7DUX/oieviqgAooooAKKKKACiipYIJJ2KxKWwMk9h9aAIwM9OtadnZQiNpb1nzjKRJ1J9/SkgjjgbMZErdC/YfQf1pwYqpYE5Gd319aAB5MkogCRE7lTtRIeTg4OMYPcfWmscYOOBSkAj0I6+9AAMElW4GBwR+VLtJ+Q9e1AGclhjHBB7j/PelG0KvUsp4BoARBkqD94DNDbix6g+1LJISQyjacdu1ByTliQG7jp9KADBDEHAPXFPKoB5gfBHUEckVHhiSHPNOj8xmBC5GcFaAEG3HBwOlLkAhSB0Pfr7VZtdOurh8W9vI3YAL39a2LDwjqt0iMIBg/Lkn196AOePzKcjlR+dDBmU59Rn2rubP4fT5zcXKgA4wByv1rYtvA2mQELcSyv2XPByP50AeWpnacg5JABFP8pydpUgt6D+lesXem6HpMTvJFEuB91v4jjv/APWrzW/vftF7JIo8qM/cUdvb3oAppFMVUBG65zjqKcyMpztPoQeD/wDrp63c6YPmHtuz69qnk1CSYZlVGAOOnGaAKIQ9h+dNJyVxuKnrn9fwrsvD3h+z1/TZWjZ4bqFhvXPD/Ss3VPC+oWTn5POwTgxjOBQBz6nnGMkd/wCtDLwDnJBOM9PrSzK0UhEisrd88ECmABt3HI/WgBdpIB544pY32Eqfmbg7QOvtTQ4HyjJyD060HGTtBD+/T8aALtm9j5E4vEm83Z+58ojAb3z1qicBRtAJxjjtTihL54OeDigAlWAwcEdOn50ANk++dx99o/rSo2MZBxj7o6mkPIwegOeOTSAYOMd+5/KgC5cT2lxEsD2aptH+uVssP8fpWRdW7QPwQ8Z+64HBq3jkAjnrT0k2nkBkPBQ9DQBk0VeurTIaW2BKZ5Tqy/8A1veqNABRRRQB9VfsMf8AM7f9uP8A7cV4n8Slz8TvF5PQaze/+lD17Z+wx/zO3/bj/wC3FeMfEsD/AIWP4vPY6xfZ/wDAiSgDnbR3t72GVP4SGr6p+DPiiwh8NXn9pTrGbe4W8XJ64jJ/mK+VU3NIAPu44rvPBTNdaRqMD9XTyx9CCKAPLNRunvtQuruX/WTytK31Ykn+dXvC+h3HiDWbewtgwEjAPIFyI19TWdDbTTXS20MbPOzbFQDJJzjFfTfw78KReF9G2o7PdShZJmYYw3oPYUAXfCWhReHdAis7fDiJsmQqAWJ7mujcj7MSPvEDH51HOQqpGv8AFzSEnEPoAQfzoAYXDSbh95QP50nC3LDsVxUltEJd/l9ctu/Co8HO9vX+lABbqVYp36Ux1Af5euAo/OrMWDe++C34VE+weWw6gc/WgBfLzDLKo+fBqTBj0wRn7ykOv1xWta2sbac8h75/LFY0j+bsYf6vgD60AL5QmWNm65UH8DT7gh9RWcHkOVH0BqK0dmkMf4j8+KbdhxExi+9CW3+2aAL7Xf2dkWE5EgG760yITTRPPGucsFH49aXRoofPtmvvubQzfXNaMVzbQQiOI/Irlj/31xQBQ3SEyxOPl2jH171GtxIzuuOMlRTLiZ/Nm9jgfnSJKqSjJ+Y/MKAFd2eGQ/xs+P0plshZiT1Ix+marx3KuhVT+82kn6g4NJptvqNzeLHAMkruFAFiPDeXv678/oafmNZlVj8qH+dWbHw/qk2pCIoMKCas3/hm/ewsDCmZpM+b+eKAMuUblaP+HhzUkgAkQDpn9K3LfwzfC7CSxjbwG+mKm8SeHJ403WSg/MFH0oA5hBvhZSM8HiuMudBttM1S8ubZdrXaiYgDAJ6Vu+KL9tCsGuJTtSOXy3P16Vy+k68uuC8KvuNsoC+wJNAHkniWJ7fXLxWGNsh/xrLcASNt7ium8dlR4jmLfdkwT+WK5qYKnzL6UAR6kpGirntcn/0GsOtzU5PM0VSP+fjJ/wC+f/rVh0AfpV8J/wDklng3/sC2X/ohKKPhP/ySzwb/ANgWy/8ARCUUAeVftrf8ks0r/sNRf+iJ6+Kq+1f21v8Aklmlf9hqL/0RPXxVQAUUUUAFFFTwxDb5jYIB4Xuf/rUAOt7UyKHkby4z0J/iPoKsiTaqohKJ6Adfr61FvLOGckR9h1x7VOo/d5OGjBxgnmgBVXd2UMM5H8/wpBnIJBHY/wCfSlwUPyMDtOOetPAzkvkEnkdz6GgBqqzIFHOM9fTrSIyqSMHnkEdqVn3ncCRk8kdB9aRo2YZGCRznPUUABBYK6nJA6d6QZPTkf56GnBGB4VscZA5NathpM0yiV9sUWcq0hwG9cUAZRO7IOc+v/wBatCy0i8vOII3dOD04A9a6vRdP8OWyrLdXiXDLnMY45z1HrXb+HbiwvVT+yHi8uM/vF4XYAfvZ7elAHEWPgOVgjXs3HJIjIJ6cc112meEtLtMlbUysoCgt8x9c/wA65/VfFs0OoXcNk0aQxyFQ5XO71IrlL7xJql1O6/bJUUEnK8UAevwxQZ2RCJQBxtIAwPT3qxtUI0aEodoJbvgH9MdK8Kj1DUAFlS8l+U54Y5+tXj4k1V41Vr59o5A/vCgD16a6jhjYSDb8xHzMMMPp61yut+LLe13x2Z82VRgr1H1Hpj0rgZb+5nALXD/N1JOORVeX97GWwSqnHvz0+tAE2o31xfSvNdSGQnJwT0+lUdpxnOQO9WVt3deAAwGCzNwRQ21gBGxwvXjhqAITA7kdiOp7E1G4ZX2sAPVT/jU8jqSqRqVT0J6E96iKhcgdscsMZoA7H4Z3ax6hPbMVEcibgzH7rDjNeivlHGGzu+UMVGD714fZzvbXEckLBWHRua7Gx8ezxDF7AsrEYPrQB1ep6Dp2pNi4gTeg6rwf8jrXJ6x4Ckhd20+cMM8K5wSMdAf6VeXx/aja7WEgKsdrDAP5Vf0vxtpd3dGCZPJjx8u7vnsKAPMrywurR8TQGMEcEL1qnuO3IC468V75PBDe2xFykM0eFKjsf85rjtb8DW9yrS6a2yQHBRvuk+lAHmy/eDbRgDihjkgOcr7cVf1HSbrTpHS6iePa2c44OPSs4rtZuB35agB2ME4P4DqaTadp6KBjNIOSTkY7Yp4dTjIGeDmgCMgHHXrjA6mgE8AAL2HrUrKcFlyFHOetRL8vTOeRk0ACkxMGjYhuhbpUV1AJQ0sShWHLIBj8QKlP3vl45696XlGVhncecUAZVFad5aJLE1xbMCw/1kY6j3HtWZQB9VfsMf8AM7f9uP8A7cV4x8TMn4ieMB/1GL4/+TD17P8AsMf8zt/24/8AtxXjXxLUj4j+Lf8Aa1e+P/kzIP6UAc/aMokTf0P+Fd38NQDBdbuu4Yrz+XIDFeNv+FehfBci48U2lpJzHNNGhHr83NAE/wAP/BxX4jajeXEUq2toxlt2I4dm5H5AmvYo2Ks4foQc/Wuh8caVb6brFvc2SCOCdXQoOgZa51hm6DfwE9P0oAmuVRhCy/ejT5qazKYJAv3o8U1lZJrhGPBwB/KkkQ2zoJP+WmQffAoAk0GVUvZQ/wB3yy/51Dcna8g/gLAJ+JpiIY7V5V+86mMfkamwHgjDD5gVNAEUbFrh3T+EbKcyjcU778U6OBlmcLwN4Y/h1pIv+Pw7v7/FAE095Ilm0cbYVDhv6fpWdLOILPzCcRxsHP0IrSKoZZlI4DHP5YFQ3EEcljJCy8hAre/NAGv4XitodHju74ZkkwQfYHNZtzcQXdxd/YuI5HwfwNed/EfxFc6PHY20Uu1G3AAV2GhXUE+l21zDgCS33nnvmgC3JMZJmhQ87WC/nUazAW5J/iGPxzVa8kFvKsgYA7R39c1mR3n2/V7TSbU/v3y3HPXFAGxLc7dzueCxP5Vd0CIazpT30AyiN5IPvmtL/hCb+6udEkUgQxXvmXIx96PByK9GstGsrC0jtbOFY4FkMhUdyaAPNbHQXtrt5LhfkHzH/dIJNd3oNhbRiOaJcP8AKQf9kitGSxjuC7EDa7f+O4xUsVvss0ji+VlwufYGgB9qFChuPMxgn9amAA49Kjgj2RgH73c1KByc+tAB3JoZQwGfrS0UAeLftG6QkXgvUbqNQEfY2B2fcK8a+COn3Gpa/e6VCR9omRQM/XNe3ftPX8dv8PjZk/vriQbfoDXk37MTsnjbVbpuXSyldD6ELmgDlPixYmw10pIMMmY2/wB5Tg1xBJxh+hP869w/aZt4J59K1GzUBLuBZTjjJOQf1FeIdF+b+ECgCK4+bRZQP4LgfyIrIrb8s/2XfKeT8jj/AL65/nWJQB+lXwn/AOSWeDf+wLZf+iEoo+E//JLPBv8A2BbL/wBEJRQB5V+2t/ySzSv+w1F/6Inr4qr7V/bW/wCSWaV/2Gov/RE9fFVABRRT4ozLIqL95jgUASW8atl5ciMcZHc+lWXBZt74K44AHT/69OkRYgVAKlB0PQj1pARt4Y7gOPce9ACP0KsOnIaiIcggZ45x7UT7i23a2eNpXvT4VKAs+Ce4U8j3/lQBKoUxF5O+MOP60jlmwGxjt9fanKHZsgZboRuwfr70saER4GCDgc0AMCk89GHRgeo7ZrQstLnvZgsAJDc7sZGPf0rS0DQHv5MPhEPV2HC5HrXTarfWnhqyihhiUXfO7J+UnFAFB9P0/wAPWsRvf3tywwi56HH6dq57UtQa+YiabjtGF2hT68Vn3dy9yZbjzDKWYs4J3VV3DqRjP4jH1oAl8vuCMdRz6+n+NWra4ubWOZbe5MazIVk2cbx6EetZnmrCQGbJzgqR0HrUqESYMZz6luP09KAJGl3sN5ORjBz+tDEsx+6uPWkHl+TwczFuAeRgUqAtJzw4BABHb1oAEyQcZHbdTwpcbUQZzhsnn6it3QNKt7i9igu7gQIxGQ3H69BXoyeDrE26mwtIpRj54XOXJ7EH09qAPHkRwCEQ7VHzeuafu2osGSTnPpk49fSvRdS8EwzqyLBcWN3sYgOPlc+mD0PpXBPCYmMZzJtfaUx8xY8ADvn2oAgaMsoUjLtgKo53egAH+c1s63ZW2kWBsb8ebrjlTKit8mnqCD5Zxw8p6MDkICRyxO3WhsbjwzBJJawtL4hHyu4OV0wHggHoZ8dSP9X0Hz8ryMsSrIwkKK3OCVyWHriuOEpYiSlF2gv/ACb/AO1/9K/w/FW3qQsqxqWLF+OCq8fhUaOy53MgGOM8j86mOCjANvb1B6/59Kg8sGQDhWPUdq7CR6kOcZILdc8UisvSQHb22jB/D2pAItp3ykcn+HOT9e1JHsEn7xiMHDYOSB/hQApbODjahHPviowuHyp+jHvUlwkMD7Y5hcBuc7SoqMORICpB46ntQBr2Gv6np4Atbtgvo/PH0rqNJ8eo0ey/gbd03px+OK4NAvPAJ9euP8aUk7mAKsOoPTP+PNAHs9td6b4htSC8boV+dCOVz/FXHeKfCBtSZtMVmjPJD9vXFY/hPWl0h7kyRmWC4jMbqThh6YPsafZ+KdTtwR5puIydpWU7uPSgDnZY2jbDoQx6qKYDtPGARxnHUV0tzdQauzGKAQzE8qOB+dYl1avE2SCVxycAYP0oAqZ6YLZ6jBzT8b1+UBD7c00phck8H5s5xQoCkYJU0AC565wDzyOtC8OGHy8fxdTTl/eBsYznvxxUeDn5sjvgDjFADo3dJFkiO0dfc1WvYU2ieHAUnDJ/dP8AhVgYCkj8SaSNxG24qHB+Uq3Q0AfS37DH/M7f9uP/ALcV5D8UMDxz4mlx01rUEP8A4EOf617N+xLCsMvjXy2BR1sXXnJA/wBI4NeLfE3nxv4rX/qYNQP/AJGagDkpG4b0YAflXb/CW7Wy8Y6bM/3UlEh/A1xjqGWNB1B5NX9Ivfst9ZTpxscE49M0AfYviW7S/wDDq3IYMDqLmP1CsM4rmApafI4GBj864+PWJ006ItIzRB1k29ua7PYJEWZGG1gAMfSgBkIIeXedxLGo7rLsVJyQCQfTpT4Modrc7kzn0NIybXlBOSpxQA6FfNkbH+rLDA9KsTBYFimYZSRuB9KqRgoLg9gQBRHKZbSORuQEzj0JoAkMuGd/+erEr7A0rAMkEq4G0Lu9yDzRbQ+bZCcngvsAqhM7RYBbjfs/WgDWmlT7RcSAfKuCfemwRteeaI1PzEjOP8+tYd1qyJqw0xcM8/O4dhXrnhvSIbDTP3hSR2bdn05AoA+YviX4av7aC6urovKsZ3J8vQd65zRPEc9laRQvI21FAx7GvsDxRpmn32lSW0sULG4OwEnp1r428c6adJ8QXtov3URcEdODQBfu/Fst/PbwxuVMu1QfT5sV6N8BbN5fibeNeOJfItztye/NeFrBIqROobLnCnHTnNek/CHXW8P+PGaZjIGj2sfxoA+vYUEabR0BzTjk7SDx/Oq2nXsd7DviIPA6e4q12oAWk6dKMc9ePSg8jjigBaKKKACiiq2p3iafp1zeSkbIIy5z7UAfNX7U2ux3ep2djA2VtmCOB3J5rC/ZqmSHxrOkpG25gaIZ7bkNcR4x1N9f8Q3d47krJKzqD9a0PhfO9t4iaWJipWPgjtzQB2/x7kV9Os7VcE2Mawkg99xP9a8T253nsQP5V6f8RXebS5zKxZnuAMn2FeXl9vPbpQAlplp5rcjPmwOoHvjI/lWFXQ25AubeXH8YU/Q1iXcXk3U0RH3HK/kaAP0k+E//ACSzwb/2BbL/ANEJRR8J/wDklng3/sC2X/ohKKAPKv21v+SWaV/2Gov/AERPXxVX2r+2t/ySzSv+w1F/6Inr4uhiaaQIgyT+nvQAkUbyyKkaM7scBVGSa144orKAplXuZBh27Rj0HqfU0lvi0DJayESEbZJR/EPRf881E+MhjtK9yvb3x2oAFBIBMgOOO1Iw3N8nDjsT1oSIs+GzjO098itvS9M+2SxWyDzGbluOcZ657GgDMsbS91C6js9Ltp5p5W2LHFGXLE9gB/SvW/CX7OXjXVofO1OK20qNgCFuJMyHnn5RnHHrXpf7PNvpugeIXSeCAXE0XlxTcZQk8/nxX0dIr+YGVjgD7uOtAHxjrv7PXivS0aWNbe8hjU7pImww98Vy1j4Re0uQt2VkdhtdVb/V+59uPrX3drd2tho17dyIXWGFpCoGc4Ga+LdU8T2Ud9MWj23UsjMQQQSc5wf896ALf2b7NiCL5LVRuPy/L69PTjqK4WbS08W+MU0yKU2wnkEcbjLqD0Bx6VuQ38+qG/mjkYWkC7uFz+Y7Vl/DDU1sPiLpV44QKtyrsH6de9AHtvgr9l+xsr+WfXvELX0YVkSK0i8vD9CWJJzj0xXmnxk+Ed74Au4rq2m+06VK+IpgNuD3V+wP86+5FKkBlwQ3OR3rzz49rZyfDe/ivlRxI6LGjH7zZ/wzQB+fF7BJDdvG6MGLZAx1B6YqdLW5gBNwkkSqOA4IOfave9H0K6bwnqN9BaF7a3lVY/LTf8hHJB67a4HxFZPc2ZllRGlicgYPOP6fSgDhVxnkDPB3f3fetSwgCxPMw3AHCKOOT6UkdlvhMonjyG5IIP6DnFaulwhbNEAWSKSToTnYw7Z70ATaPpVxPOhZWWIjJkIx16Y9ea9F0+/NrDshUh0wNxbhsd8+tN8P20SKkMkIdm+Uk84J7Ct7U7eOO3dWjJypOHUL/wABBzQBFd6zc6rY+bIJriytYjNcHO5oBuCLkdWJZuB6KxrgtSlXSdYJtIgniGZtm4cjTgeOO32g55I4izj7+SvfeBfH2meEvC17c22nXOpapeTFnBHkxxRqSsas5GSPvPlVYZc8iuK0CFdb8Xi5t7S3trdFM6WttuMaY543Ek8nnoM9AK8alUxOLxFSlWpuNKL0f822jW9r3e1pK3S99GlFJp6nrOheG9Osvh1cTSwIYo2+9gh2A757D17182eIHtl1S6S1IMQc7TtzgV7z458RyaZ4HAlaCO4kjKoqE8kknIH04r5xMn7yQyAhm569Ca9kzHSr/osb7wdxOVzkj0/Oo4ULB1DBVHJ3Hj86RgBDvJOScDjrUDShU3TZbPCr6++ewoAsK0QWRSZCR9zHH5/4VGGO7ayhR12jv7Zqk1zISNpC46bRS/a5dm1trDGPmUH9aAL7urEiNdoByAD0/HvTXZVfKtwMD0qtHchuH+VuxHQfWpQCWTglmOAF5z7CgCUA5LHgdyf8806L5uBxjnHp9KQq0Mq5Yq/cdx7EVI7B3YqADxyFxn8KAEZsHIwXI59BQXBVd7Nux060NjcrMCwJzycY9j607922G/BgBjFAAJOhUlSvYdD+Na2nXQlkWC/BxLwsv8QP9aySoZhsPBGM04706nGOOCMmgDU1XRZbS4bcOnKkjIYHv7ViFcHGGU9wP611/hfVY7mBdO1QeZH/AAPnLKf8KTxD4Yu4Y2uID9piI3BlOOPcdjQBx55AGfl6c8U8/vEYkYI+UH1pzRuDtAOR29/SmHeG65x2FADJF24DNnHt3pgxtOBubuT0FOnRieowPxpuM/KMYA6D+ZNAH0/+xFnzfGxJzkWPP/gRXjPxO+Txv4oc9P8AhIdQH/kY17P+xH/rPGv0sf53FeMfFU/8Vl4lXv8A29qL/wDkdhQBySk+Yfzp0SsGQDt/jRGQME9cip7IiSSORsAF/wCtAHtNpGJNMSJjgmIDn6V0PgfVDqPhW2c/fgJib1OCRmsiws0ul3eZtKoMAfSofh032G5vdOJ4fdKuf96gD0Bgo3jjJ6VVc+Wd2clqRyfMI7g5/M09ov3gBPIfdigBZpSIXULnoxP40tvHyYuzJkU6OQeXKpAy6Y+mDmliO0RP3AIHuKAKxuVtoEtyQAgLZ9T1rltV1nzEIQfdbdkfWmeIr0i78tW+4ByPcVztu+0Nk7snv7mgCxp87L4rtbqViVeFhz0BJr1SHxPIsGQzEbeBn3rx+5LSQlVBDrgjHXiuhsLpZbKzeN92R82OxGeKAOyj1K9eCBx5sm7kD0615v8AEfw/Lc3DXZVhIybCO+Qc19FeEtBt00ewuDtZpEWXBH44qt4r8LQ3skkyKOSz7cdOMYoA+dbDQELvCwGLZFcMe+R/9esM6Y2leJ3t0kMjMCA47bjXd+MJX8P2rv5fLjYcj8K4zw1dDVfErTOeVt8/kf8A69AH0l8HrmSTRrmGdmZopBgnuOlegA8kelcH4BjSzK7G/wBecYru9wDAHv0oAPu7jycnOKdRRQAUUgpaACvJv2hfFS6N4Y/s2J8XF4MHB5C16fql/BplhPd3TqkcSFjk4z7V8TfF7xZN4q8XT3ILeSrAIoPGBQBx0EpKqASWTj65Neh+DdIeyvftGCxeEZHpXnOj5GoQbx8plQHPpur3zTittePhAQUKdOlAHHfENwNNj5HEp/HivM4z+52EcvgZ9K9E+I8RGkiRCT5c4z/wLNedOeYwOzc/nQArZjiJH8DCqfiBNmqSsMYkCyDHuAauTSZh4GdzH9Kr6+ufsUnHzQBfxUkUAfop8J/+SWeDf+wLZf8AohKKPhP/AMks8G/9gWy/9EJRQB5b+2dEZvhjpEakAtrUXLHAH7ievj/atunkxDgn52PV/wDAV9hftmDd8M9IBIA/tqLqM/8ALCevjvcFCiTKgj5XB3KaABVCrhsqB0BGQfxFSRQEoTLnZ2x39h6U6ON5MbSDF6of8mnTkA/NtdgMBlGB+frQBNaxyXU0dvGpkmyFVVH3PcjqD716j4X0JNMt08uRnvG5kWQA89+fp2rnvAukmLN9do7Ow/dSngp7Z967Q/O7NLG6soyzRtk5+nb2oAa9w0F7FLFI1tNGd0bqxwMHOPUV9UfDnXz4j8K217IytKP3blTnJGOfx618jatdrBe2skhJCq2WYjJ/H8+K9y/Zu1dJodU04R7VO25jO3Hy9CCfbigD17xBb/a9D1CDn95A68f7pr5A1nQNNwyzRRLPKvDMCxH4Z6V9nV8v/EbRnstcv9OSNkQTNJC3ytgNzweo60Aeea3Zppfh1oLRBB8ux5NwBbvkHjH0ry6GV/tHmQuRIDndnHPeui8VTXn2qS3uZjIgOVz0b8Oh781yoLAnOXVeM45H+fagD7x+APiv/hKPAUHnPvubI/Z3yfmIA4JFYf7RWsItvpWj27q9zLI0rxY524wOex5NfLfgbx1rXg4zTaNfGDzRtBwHVvqO/PY1eh8dXuqazLe65eeffSHPmEY254O327Y7UAeqtrb+F/AiWNhLLFPcu5ldT2HVFHueuK8pvPMvoLqCHErn9/MS20KAMjPua3de8W6bf6Va28KvGlmuUjc7g7HqxPUGvNbu8kfzFEjxLJlndTk47dO1AA8McZSS4CiNwSrgY+n4VZ0u6NlPFDeZMErB1J6Z/vDH86x3zjyy26MDAAPBH+zU9vCZLqCLzRHtXlnzhB/n9aAPYbC6a1EEryNJaygBNnzgnuc8Z4Na2pXnnWJ3SoJG+UKrAse/zegrxzRtcu9Pla3jlFxbs33XHXHQjPQ/zr046bdPDA1tC5jmiDHnDKfr6YoAxtT3S2hjQkMzggKMEc9//rCvUfhl4MuPDlvaeIbhYFScNudz8ix9OAOSf61F4E8BzeILldxMYA3EuNyj9OPoK6D4w+NdO8JaB/Y9pPBdX4iASOMAiGUHDFT1B/CgD52+KetLqfiSWK1JNvbuQGJ+8c84z7YwDXGXERiySRwOGPzfhT5pDdXUsl1IN8pLFmHJY+9NSLMUhDKPLHzZOd4z0oAifMjBIwAAMDHP1yaoXbFp2HZflH4VdPADEgYG3Gckfj2qvqdv9nuuCSkiiRCe4PNAFOiiigAq3bMWiZNxBj+dcfrVSpbZ/LnRuMZwc9MGgC+HIb5sbs8ljnn1q3ZxvLIPJy8xHOelVrWZIBOGiEnylVYDlT2OasWzhZlwhBXGQcnPvQBfg0570SZKx7OWZj/F6Y7VQkgeOVk8pgynI4JP5V22iaVFfQxvuKgtyRxk9hWzL4g8PaFef2dqHmCaNQB5cYcRkjox/XFAHljqyjL7sHoOh6+nY0+ONmYqF+Zu5HWvVPFHhKzu7FrjT8RXTDzE8oZV/c+h9q8vmDRM6SqQ+cEHop78UATaWTHqMRUqWDc89q9TSB1ljuEUtATh4uxBHavPfCNstxqyEgKo6Bj2+lesFIokYwuEldNrYGAw9aAPMvGGlRWly00ZCK5zsH8NclKy7RjcD2GK+vPD3wKi1PRop9U1NNtyolRUh3EAjIySetYnjX9mmRrJpfD2pfaLhefKkURFh6A5x+eKAPlqDIJYtnPbpQ5Ydfu/TOa0/EGh6l4f1Kax1Szmtp4ThllQrj/GqAJwFZWbHADcbfegD6b/AGJP9b42z1xY5Hp/x8V4x8Vlz4+8QHsdZ1AH/wACXr2f9iRdsnjQdflsefX/AI+K8Z+JzBvHXiYE/d1zUB/5HY0AcdJyIz6c/lRbswhQf9NP5HNIpLKVbsGqQZVQvYOP5UAe4eHLkyPA69HhDfoKqadctaeOdNJ4inWWLPvnNVvBtysdlpzOcBoig+uelPv8n+yLzHNveZY+gLYNAHpi7muElxwQVP8ASrUwDTGduCY84/Go+U3qB8gfg+2Kc/zQJv4BTAoAYsZ8xh6oR+dRyy+RZ+a/CxA8/TFXZNqQbwf3m7aBWD4ql26C0an5nwrfnQBwl9KbiWSZv4nP6HFUo2byFbHJwfyNWLjIiCj7pJ/nTdyCE7T0AAoAW2lLSGZxgqpOPxqn4eufsDz2bsf3chl57ZNWOCNo75B/nXN+Ip2s9aWXOPtEK7vw/wD1UAfT/wAO/GMN3psEN1KqLDGyg/SuzTVbNxMPOX7u8A98ivifRfFV5au8an5Nx79q72Hx7kgmbn7p59BQB0f7Q0lqYAltIreZtPHr1ryD4eTC31/Ex2pJCUJP1p/ijxDc65L8x3CMB15/CqeoBbFbCW2OWaFWb/e3UAfR/hbXEWezO/hCFP6CvQLrxBANRkCSBo4cbT6kjmvkax8X3NqVCt828lue4rSi+IV75YIbl2JPP5UAe/al8R4tNkaOSRQQCQD71p6J8StHvI0+03CI23LEeua+P9f1241W7llnY5UADBqtHNNBnJYA8nn0xQB9zz+LNGjsZbgX0eEHTvXNX/xQ0u306WVJI2nBIC18mza3dS2JQM292243GsS5vZnxuZsseRmgD1z4ofFG81+3urZRstY4c/Ie5IFeR6IYb6UQqWNxgkAjr+Na8emyv4Z1ed0JPkKw79HBNc94Ml8nxHaydhuz9MGgCzeI1pfvFjGyTj8Oa9ns73ztNtrtcFpgufyxXk/iExz+IrhYznHzfjjmu58FXBn8MgSHmCYKv0JBoAr+I5DeaRrO4fKkyqp9xXnTLgZPfBP1r0TxAPs2g6usfJNzv/M155Md0JI7sDQBCMpgAZHNO1hFbSLdgcmOUp+YB/pQjBvlHfrT7vB0W5x2ljP/AKEKAP0K+E//ACSzwb/2BbL/ANEJRR8J/wDklng3/sC2X/ohKKAPL/2y1LfDPSApwf7Zi5/7d56+OUDRyASK20nrHjJ96+xf2zc/8Ky0nb1/tmL/ANET18fwHYC0irxwMfKc/wBaAHzmCAFE3E4zkcEe+DVjTLX7fexxmQeWWy7E4z9az2EkjZbLA8gjqK6TwXGd91MqFgNsZCnBbJ54PegD0ewtha2Q2OytjluCFP8Adb04qaGCWeeZtuCB/Cc5wM59foal8yAQhYWdyq7WiIAJHBwTj69c1XjiDeY0MzeUuCg2BSp+nbHsaAOZ8XCVJLFXiZ2D5BjO4SL6c+nXHWvX/wBn7VFHxD+yxjyhPaOrxbMAEYPf6dq811ZA8ttNdTshh3EFjj5u2PXr+tdT8ELq+X4qaZGzhSd6PFsAIBUk/hjvQB9dV5B8cNJk+02WpQ8JIphkOM4Ycr+fI/CvWbudbaB5XDFUG47eSB3OKwvF+nQ+JfCdzHbvvLJ5sLKP4gDjj8+KAPkrxFpFnqNyHngcTSD5NuACfVe2fwzXnGt6Bd2ZZ1YSRrzlB+VeyapBOsS+ZEREcK0kRUkHvk+vtxWVmC4d4GFtOoABEuUbOOTnsePfmgDxZS8bOjJtcg/eHNImCxVRuBzynIz/AJ713HiXQWVXkt4nyCd6Y39+MHsRXHpbG5ZhEWlKHllXoO5JHegDc8F+HZfEt1JDHKyJHgtLIMgD0z0rsvEvgqz0mxS5tDFewBB5kRwWU+/p+Ndf8DVsLPRZ7eRV86Y5M4k2kHspOOhp3iT4Z3uoX091pE8qRyEE/MSp9VYdx9KAPn3HMgBeJOoBUttH17U6LLyJFbSjzGbG5ugPufSuu8W+BNU0BlN7C4EjEoqtnj+Y+hrl4I2S9iil2hunlvlTg9j3oAfawebrNmskRgj81QSqkL9QT9K95vb1Yza/ZDCYtg2sN21uOSPf615Hqd1b3+lmKeBhPAu2GUnKkLnjjkn3rq/h5rf9oNFaagjlEAVwzbsnseO9AHpOq/EK+0bRbtdEheGMxERoM/I5xlhnrnHXqK+dNXuLrVruW+1B5ZLqT7xY8MPY9a9l8XX0It5YQLdYnOBIvLP6gr2PPtXlfiaSGCNY4g+AMEo2SPb2oA5lkV2XK7OMDnrim5QLIrhhIeFYggfjVi2yZAyLIQQPnIJ2+5461BdN5kzYAC+pyAx9ce9ADFTcVU7G4xl+BTNSy1vFEf8AWW+VwepU8/kOfzpCAH3kMqnkHoCfx96W8muJmU3EjSbfuluePwoAy6KmmU4B24Hf5cVDQAUqnDA0lS2yeZOi9sjJxnAoA0ZiRMQVIPcH1+lPi2tA5LNvUgqGOMj0qzexs1w8ixyOhwd3TA/w9qqxl4ySiKD3z8wx7E0Adf4M1oJM9hOyRRz/AHSORnOQK0Nc8Drqmryapb3aRpLIrPbyYVieM7T0GeetcSpt3VSzAZbJAbGD7elbcHirUUt2i+RypGwsM7R9TxQB6ZHbLYWrGWd5E2jIU7UXHqf73868x8VS29xqTPYbCjAZVFwF/HvVfUNc1DUeLi5JjU8gdP8ADNZgcSyqC59dpWgDsvCmgTTWX2qKfy3zyUXrj3rrfDsc010rTABEbgE7xn3BrnfDNyY7AxLfj5ThYkTO0H2r0DwlYyPKsTBDPIwUKBkEk9aAPpf4fMzeDNJLFjiEAFhg4BIHH0xW+Q28ENhe6461X0q0Ww0y1tEACwxrHx7Csnx3rn/CP+Gbu+QBpguyIHux6UAeN/tGPpWsXFvFHH5l9ZhklPGGQ9AD3wa+Y9e0Q2cmYw21mwpPX8fevWNQnlvrg3VxLvkJyQvPPfOO9Z95pg1C1kDwqFYElQDjHqSefpQB3H7FClZ/Gqt1AsRj0/4+K8M+I0gb4jeNYucprt4/tgzOD/SvoL9kOxk0/VvHFvKQSFsSCO4zc9a+bPihL5PxZ8YOclRrV5kA9R570AZC5L5PfP6U6NmLYboRmnmMqQT0I3D8aRUKspI+XFAHpfgoi60i0Dctb3OfoDXRXMaEPbN/q2IcfUHNcn8OpuJ4QegDn+VdtJCHvEb+AYH5igDuLZ2lsy56bQB+lPJ3KVf7qDA+tM0NlOnIH+6Rn8v/ANVRy3Ecl9Daxf6yYnAoAnnbaEz1Eof8KxNeCXEEoTlc5H1xzXX2fhXU76eKUlFhSVA+7uvU1Y1rwxHpdnJLcFWiZmCbexPSgDw4sGTY3UEg1BsGwBOnStm908pcs6L+7Yvj654qnFblFVSOdxz+VAFKID7QVPcbv0xXFeM7lZtQRc/NFGFP5mvU9J0WW8u1KLnanPHauS+J3ga/0V4rqeLaLlQ4OOozQBzd5pa2NhbM64mlUSH/AHD0NYxGCSn3OT+NaeqahLIII7lsukAjH0HSofD/ANnazu1vPv7dyUAUraUxRBgfmZtv4VNLeGaPaTwgwv51XnKC6VU+4pBqvGpBlI6Yz+tAEk7bJpD33A/nV2yFssbCY4Krn8aoyqXk59f0xTmUsGYdCvNACqofeD97IrTFvLfeZ5I3BV5rORWHmN/FuUV6X4AtbOS0LOOXxmgDz65triylBlXaVYEVoeD9EPiHXbeziTe7MOPaut+ImnxeSHtx82ea1f2eraE+IZbgD99bzIufQYOaAPTrb4ci20+SMQ8BcNx2xXhfjrw1pvhi9E9qWEs+TtI4AzzivqrxV4ljjtyLOTkllk57V8g+PNZOs63IzNugiyqe3NAGHpe2619nk6uzZ+ldr4AcSafqEacoky/pXBQk216JY+MA13PwxK/ZtTQ9TIjfhmgDU8W24j0TUGI+8Qx/SvLgcRKO5Of1r1zx7gaNeL2+Va8iuQQQE7Z/KgAhCJyepzUVy+zSZl7NIi/iATT1U+WSeuOKi1pGgtbKM8eYplPvngfyNAH6J/Cf/klng3/sC2X/AKISij4T/wDJLPBv/YFsv/RCUUAeX/tlqG+GmkAnAOtRc4z/AMsJ6+PGDBQVMTr02n0r7D/bLx/wrPSM5x/bMfT/AK956+Onj6eWdxHcjBIoAYu8chEVepVj/I133hAollZpJFK3nzeYxBBGB0Brg1jdO7xj0YZGOtej+F3ElrZ7bclY4jkxnGBnk7ec0AduDG+EgdR/zzK4Vyv93Bxz+NRPCrTs8sQZcYZ1XDA9MEHkHpzS/ZrWRFMbSJCGPyvjGOnfpzUmySAAiN22qFCnHfsc8c+vSgCt5UZukVlVvkJXeo5B9/zH+NWfBfl6N8RNG1Iia2QXiRyLKMqUPygk+oz1/SqpCtclk8qN9u1lyEyD06H5SPfrV+0lCxxhb54XVwVEiiSIuOR+ZHfJFAH1R4jM0diZ4H2mMEkBSxIP05/CuZ+H2ttPd3en3EPluZGkUh9wJ79QCPxrovDWqJ4g8N2t6ApaaPEiqeFkHDAfjmvKdTuJrLXkJS5t5beZW/0nDZ5xnOO3TOeaAKHxV0NdD8RyT27bLa+TzVCkr5TA8gY6gn+defzqksQEj+fklgq7ck9eoHB/KvpPXrKDxn4SYWsiLdAb4ZOvlSjt/n1r59vNNlsbqcTyGKaFtzp5Zzweehy2DkcUAcnfWlxGpEZKR4wwlG4hen48HOan0mKK2txGIYYmh+XJUIzf7W7oc89a3LlGEZlQRGIN8mxDIR3PXGODnFc9qUn9msL60Nx5BPzpgADPcA0AaU0NtHcRT2E4gvFwShI+Y9uOB/Stf/hb2qaM0dlrMLxQoo8soOSM8jI/kKxYb9ZoI1BXLAEYxtZf7xHXNUvFekJqugywtGZJogZoHQkOp7gJ29yaANfQpZvHE1xqUJ3rBI24HIcA9CR0Nc34z0a0/tmyaBY0vfNBaNidxGOm08Y+h71tfA608RWEMlzGszWNwCnllwxz6lR8wNJqum3ul/Eiy1HXo4TpshIjaU4RvYkUAdBr3h2xi8PwJY2oW+miAnD25GxiMAH1/oK8Mns9V8OalICFiuF6tF6/h/8Arr7c0LXNHt9Otm1K4iW68xjEA+4AHsG6EY9a8V+Nun6Bq091c/aY4tRim8uKFsK+CM547fWgDw3VPEE+ot/pC5ZhzKAQc96xJpWkZQ7qxHy+p/H3/GnXqiK4aMhQc/N84wf8Ki2Ev+9+dDn/AJaklfcUAXYLyWGwuQzv5kmEjyQGxnnGKzmVs8sQxxnc/wAxH1p88quiAqxZDja75B9xjnNNWEy48mNXAGCvXA+lAEb/AD/K4U4GBtPT2NNIjUc5B9c8Yq3NbCAZz8x52yHH5iqmYizBAgfGcAZU+vWgAYNtMZKbT/eJP5VRkQoxHOOxxirwEnAWOM89Vxk0yeSKL5UzJID8xPK//XoArwW8s5xGpI9ewrVgQWSZjCFyMM5bkfQVkvNI+cscHsOBU1hueZY1TzGY8AnigD0jwpYT67bTqihVjXlpY8BsjjBrj76ykgZgrlotxUNkEcHpXefCzw9feJZbvSrB2tm27pZzISoA6AA9/cVj/EDwrdeCteFjNPFLHKBIjIRhwfX3oA5Jg6jc6Mi56k5+oxSKGGSd4PuAAwrptO8MX90nnwxxxRt08xs7voKis9Curm8a2dGRlGTuUsfwGKAMFImkY+Xnb3JHSrlraytOFY5Y/wB4D9T1r0jTvD1nbQqHdJZgclpBgf41dj02znvY7nyod8QwJBGcEDoTxQBS8LeHY4vLnDo8nUZJXH4/5Ne6/BrRFutYN6yA29ou4EqB+8JOAR1yOTXndtHcSOixZlkkbaoWNRnPQY9K+kvBujw+HPDkUT4WUr5s7sOdxHI/DpQB0DKGxnPBz1rwj49a4s/iCz0iF94tojLKu7hWPIJH0/nXt1qZZJZJTMjwNgRoo6fU+tfHPxGmvdT+IGt3izrHG935TOAD5arwB9eKAJfNnW3ll48vOFYMEH045P0qJJTIPMlmRUHOS23n0x1rIjeKCYWRcXFxI+SpB4HqRnAHtWtI0cNuzRtCoQ/fbG0ewAHWgD1b9mfB17xawRUDWunkALt/juutfKPxY/5Kn4y/7DN7/wCj3r6y/ZtZX1/xYyFiDaaecsMZ+e7r5N+LH/JU/GX/AGGr3/0e9AFOP/kGWszD5djIfqGpPMD8L0xUsS48PWSt/G8hH0yBVOM+Wjk+uKAO4+H0gGrOB0kjIH4V6S8gFoso6sVAryvwDkauGzwISRXp5QmBYv7hB/WgDe8P34neSxQgS24Z3ye3+TUuj3cU3xt0SxjwY/LZ9vbIWvJNS1W7sfGWoC2dh5wVAAPXFdB4ei1HT/G8etSyNvt41AJHI9aAPraW4hhmjikkRHkBKqTjIHWsLxiYrvTTZJIpuGdXUZ6AH/CvnrXPFmr6nq/2lLxwkcZVQe1VdU8Qas80Vwt4wzGF696APX73wLcmIOCm15flHsxpY/hlKZXaSeEDt3rC8K+Ppri0sLG4aR38+DL4OMbxn9K9ubG7gjnpz1oA4Tw74Lk0zxBNPLIj2hgUKAOrBuR+Vc3+0hPaQ+GLXzgPOVyV56Lj/GvVtRvbfTrOS6vHEcMYySev4V8d/Gjxo3inxDJ9ndhaRjAT8cCgDz61hl1G4lkByI0Ln6ZqGNyuGXoW2n6VoaUjQ2k9yuRH5bIffNZvTZ6BuRQBKuHZ/WiJkFsVP3uFpjqyh2XgCm/8s29RgmgCK3ZmEYJ+Ysalk3BMKeDxSPGUkQjpjj601dzlYx1XJNAHT+B9AudbuGVBuCOC3Fe06ToNvpsZiEYVlUg9uab+zvpUMnh6S7eMFn8w5/QUnxSnn0+yvXtiytuBBA9+aAIPEa6fFa7rpAwPPUVyPwb1a3tPHt7HH8sNy6sgz6H/AArgta129uSQ0zFQMYqDQNQbT9UjnQkScYI7c0AfWvia3iu5w1mAI2XJ/ka8j8S/DaZbe6kiiwSu4cfjVjwP46DxQ294WeSRhgnsCa9p13ULF9NjhGzzGg5O72oA+MNWtXspXWUHKsVPFdZ8MmHkaif4gqE/nV34rXGnkeRbRATmQZYH86qfDddtzqkfYhV/U0Aavjyb/iVXS55aRCPyJrywvvVWHcf/AK69Q8fRk6fOB1JQ/kteXAbDEvsc0ASsw2KO+P51F4s4vbVR0W2jA/Wmtkjd7fyp3iZSxsZ+zwBSfdf/ANdAH6H/AAn/AOSWeDf+wLZf+iEoo+E//JLPBv8A2BbL/wBEJRQB5d+2b/yTHSeQP+JzFyf+uE9fHBVccvGzDncGIb/Cvsj9stynwz0hh21mP0/5956+Nx5bMF+VdvfO0igBNzIMSDqOH+8G/CvTvArSXFlFG8YRFQkPG20ufUj1rzdfvEOVkLc4wBu/CvSvBDSPBHGyRbUjysQJDjB6q1AHWW8byBjHcKzJgkyybGH+yR0PT0qfaiSNFbx20bNywOUBHcDnaf8AOKURuyhgZJdhOEcBip/vbqZs8pgshBOON25dnseMdaAEu44ngEdzCIJWXaH2ct6biDyPfOadaQTQxKJWDBBsDBgU+pOMk45704W8ewkRW8TY6KWOfYHBGfyqJ7YRoHeUlYvvYPCd/mUnOfbn1FAHpHwp8YR6BqDabexTpp904JmaMqqOcDf6bT3PY9a9T8d6Yl/os0uJJDGvmLgjC4H5818yLqKW9zCv26BkkyCkmcbSOx5wM9uor3D4YeNba4sotJ1O7hdeIbaUnG7jHlsOxHY96AMf4c6pd6Vr5SfdJb3Cs0mDvO3qGwO4xgmtz4oeDPt6NrekJC8yjfMhz8/+0Md8de3ereq+FTp2rSf2HYW6tfgI086mVIx1b5f4c+3FdzpsRt7KJGSINwGEKFV6Yzg9OlAHyuFSK6UTyPEzYBEkeA+R/C445HfildFI8pGmaTayqsw4KjtuI54+te6+L/hvp+qrJc6UkdlflSOMrG+TyCB09civINW0C/0i4ayvIZ9pO0wzylQ49UcAgg88UAcp9hiDxvBCIrlBlBkpyOcBejEipdk/lu8kUlx1P7tQJQcHIP8AeB9K0QXt4jbC0mgVjlUuFIXjpj0+oqleXNkIJzdLCXVcKBklSB3bg/rQB3vgeayuvDlrLp4d4wpXbKoSRHHb1HoRmsD4xXNungK/j1GOWGcOvlbF+Xf656/jkivCdI8S3GjX9zPp181ksjtkKxKE+u3kg+9T+I/F+qaxbeXfXhkToA3KsB3wMc+9AD/DfjTUtPtHhe5lljIH7tznke9Z+t67dawWdRvU8sqjLLnvVCOGOBPMbzoiV3Bo2BHH1qGeZpyIysWV+XLEA8+54oAhVDG+7zhjr/q/T1FO+0RC1/1kIdm5RFKnHcfSmRRwF5BKrk9tpwN3+fpSSwu7kTRFtoJ3KvOB364NAEabApaN0XPAVkBDe2ex+tSWknl3UTMu8BsGMkgkdxxURVjuCFs45Cgcr9aXYXKrIofdgADqP1oA1dXjKTRGNIFXZlS5zkdhu71RmcM5GG8tjuCp90fTH9a2b64iXSdOgmif5MqjyxnH0OeCPpWJcFWGfKCr/wBMx8poAQeXDazzxNyF2rlcEE8Zz9Kxa1dRXFhE+1l3uc574HWsqgAr0/4VfD+fxCr3twZbaAfdlIAG08cE9zz+VcJoGnrf3b+ccW8CGaTtkDtntnpX0V8Db2KfwzdJFxOJstEwYoqY4A4+XA6HpQBYn8MX/giyk1jQLi4Wa2hxLHN0kT14P8/1rlNPWTxFfDX/ABBKst03MMHCiNe2CRx9K9i8VmGy0N4ZWLNdJsVSQWbPUdhXnhBijVGZIwiAp54yAPQAHOKAIHnYJvB+U53lVwGH+9/9eq3nXDmaZomW1VMpIkmCW+vb6UiW9zcyiKWVFAOPLRSCfoOcfqa0HskaIRmJTbcb/NfJx9RzjjvQBTtlllheS6G0sOQhxyeucd8VbggiRBCkAaPbkB2bI56+xqRPJUiNm8l8/KPMIA9hxg/Wtnw5pEviDVU0+y3KznDHe0gGOrNwOPf9KAOy+Dvhs3epyapcwlbe3P7ogAB3/Ln1r0zVtXtJdSt9LivokmL7pFDHJA/hBHfPY1BqF1Y+CvDEUMGwOB5cEeQDJIR/k1xnh62u9Vv0lkSdPMfMpfCKxPPykZ6CgD1GeYQadPcFSoSNpCAOeAT+dfC9zdMbi5P+kIZbnfsk+Ukk/eJ/pX2V8RdRj0PwHqk24jFuYI+eSzDaOfxr49u7eKLRGillaWWTo0zlm8zsAegxQA3T7OSbVLq5lt4lwwRHkbJyPQCteCwYS+Zd7nTGdiMAxX19j9KbodtLptksSNK7hvmdsDkjqc5rR+fzGcxtCx/5a7QT+DUAeofs34/4SPxcVjKA2un4B7/PdV8mfFj/AJKn4y/7DN7/AOj3r60/ZxJPiPxaWlaUm1sPnJ6/Pd/lXyn8SIRP8YPFkZAKnW7wsD0wJ3J/SgClP8thp0Q42QEn6sc1UdfkYAdwasTkSGQjgE/KPQelRbsyj6c0AdV8PY/O15VHAKsPwwK9RHyruPOf6ZrzP4ejdq0jLxiBsV6VnFlFn+LPNAFTwNpFvq3xptra5UGIoJWB77Vzj9K9s13wDHqOs3dxbssEMsQ2qBwGxjFfOdl4r/4Rv4sR6r5ZZbZ9jKP4htwR+tfWGra8LCwhuls55FlRHwF6BscfXmgDwHxp4LutBfLlthjJ3Y4rzmJpbu5ig3FQzADP417/APGzxaI/D62Vtp0800zD5inK/SvP9E+H91rUlg8qvZKtyCWcbc7u1AHqXgPQba28CpeSW4kuJFAU45BVsZrFl1PW/wC0IpIZLkLYzPuAU/MPSvWtG05NL0u3sYm3pCu0Me/NWobeFXIESDe2W+Uck9aAPkX4mePtTvJZLA3Ey7MEg8da8su7jzp3kI/hGa6b4tX0V38Qda+zqqxi4ZRt6feNcvGgdbvOAVTd9fagDo2VIPhwZMDzXvAue+MZrH0qxe9uUjRSd7EcDOKfc3LtpWm6coLByZzj1PGK9h8C+E49D8PT6vqG3MkalEk6jigDyvX9O/stBA5DOUOSKx7lQyqqcZwTV7xHqn2/ULmfGAZGQL7VSjAKBiewP86AFkxvXP8ACB/KosqP3gGMj+lSSxu1uJgp2ltpPYHFMID+g7UAfQP7PfiG2tdNl0+Xap2lBk45avUvE3hqC50ueCTZM7d857V8c6PrM2nalG8TsgzkgV9bfC/UTrUKSTyFhPCuMnvigD5V8S6W1lrF1bspASQgcdeazYUEcwDL0JOTXuvxm8Lw21w17C6ERsFbHfnvXkGqx79OiaJPnMpzjrg0AdbbaN/xLVuoHCmMhuDWZqni29nCFZJBtUR/lxVLT/E01ppstnLA+HPDEV2vhHwautx6cxZU81SDn35zQB5NfXMty5adizAk5NdV8O5tusXaekasffn/AOvR8SPCcvh6ZWGXWVSxI6Lg1S+HE4XX2BHMkLD9c0Adf4pjM2l3yn7yKGzXkzr29GPNeya+AdPviB96Jh+leOMcRY7jn9KAGEBOvIK5pdQiaXSDJ1MEg69lYf4ikb544vUDBqeI+dDd2+Ad0BK59VOaAP0H+E//ACSzwb/2BbL/ANEJRR8J/wDklng3/sC2X/ohKKAPLf2ziR8MtIIOD/bUXP8A2wnr46dDkBoVxxyqcfzr7C/bV/5JZpX/AGGov/RE9fHYkwgyh5AIbODj6UAOSJDIAwMeT3yN30967fwi8NpenN9LESv+rIOT+PauY0BZbjUI4omWUtwYpB1/+tXpmj272bAGxjtpEHQyLIpz6bun50Ab6yMZBhoZwRtJ3hQeOh5/SrDN5ACPGbdX6ZPmKW9eMH/GmW140iCOP7Er7eYkiABHuO9KkkcSMABGzZyUVXRfop/+saAHRP5i+Z9rnQjMYdC2CPTaR8v096YqQrIIzFMzggquRlR327j81EtwJ8tJE8czKNzj92Hx0LKPamwT5V4sxzxkfc3+ame5XjK/55oAq6tpslzG8LxSBW+ZTsxn/aA/hNL4buNYspGt7pDLGAfKufLAZlH8JA6EdjVydSIyA3mIuPlDlwfxYk/h+dQyGe3kSeFp45FHEYgBUpnvz931HbtQB9FfCzxS+tWD2N6zteWw4dzkunuf7w6H8Peur1drtbSY20yRSDlDtGeOSOeDx9K+aPDuuPZXVpqscyLdxPgjzdqv325xjkcc19IHUxf+F31KwIG+3MigrvwccggdccigDFuvFk0emafeR2vnx3AZWaFxiOQdQQc5B/pWnYSWnirQgmo26sWyJIiCNrDuD1FeUjW9Nbw7dWyTQXeJRMDKWVoZD3yVzkHoRwe9ZOmeItStpDKkk4WPLLJFMXQOCNwIxk5HOOaAHfEzwvN4TuI3juLiXSbmQiB3kB2SEfcbPUnt69K8n8ca4LHSGtvtReWQFQrJnaAOVwRkH3Br68lj0rx94KntpGjurG/gMchUEYbHUdCCDyPpXwv450HWtD1q50PU2uJzaS+UoKs+R/Cy+uRzQBzY8m4gknknCCFQcRx4LZ+vFV0gjWFWKkox4O0g49Rk4qa7s7uzlK3FnKjAbssCuR+K8VvxRC90hXktZkTBCmNN0rHsTjj+VAGDJDAIg6yCLHTYpJGfUDP6VVbOBh2YYwpIOMfT+lSxwOsm1o54mB4ZpNpxUN0WSYiSR2bPJZdyk/oaAJpnhW3VN1vK24MSQykcdMGoCqMgXzdm4bgpYHP4HpToYzPJ5SrCCwyPm4/WrcEFur7LtpB6+Sdw/HIoArrZu25hGjKoBG0Hke3OKmhRLYgkbS2QQvIPsMginPfny9lmVgCHA8t8cf8A16qgu6km5jKg4IkfGfwoAtTzrOVMaRxIgA8qWTnH+yuR+lVwikloZJQ3oqHIrpNA8JXWp2f2hp7eK1yQsm8gH8TwQKjGjQQ+IDp+oT2Cx4GycXHzM3YAjg89jx70AYGvQSw2FmHD7AW+92PcCsOvcYPCFm2kX1qp3tLGdhnjGVOOCNvHBxzmuC1PwMbPT/PTVLWSdcb4mwmPXBJ5/KgDN0F0g0TUXGGmnZIVUjsMsT/KtPQde1LQJludLlePcO3GBVaB1tLBdL2JKsjiV5FIDKxAHBz0FWNbstPik8q1nmjmggViLmRG3seuMUAd54Q1XU9a1Fr7VL97iMRHaoJkWLJwcgHiuvZI/MAk+ybWOA5t2LFh2wxwPqK8u+Ft4INYlGEUNFg5Yqpwc57f4V6dFIkzuVt45lY54G8MB1GecEeooAl+zwjbGskmzJONoABPZl6inSQvGwLxRLKrfM2FZix7Ek8Y+hrSj0+4k2C0t7vdIRshVBl89MAZNdl4X+GepXksU+qyNa2+MFJFUyYPZR0H1NAHF6JpWo6vfJb2UDzSycEM2FA9TjoPxr3Lw9pNn4H8OvNc7TPtHnNFkhm7BQa3NH0iy0KxaKxhbAGWbq749T3ry34heLW1CSLSJ4Hsi6kvBMpWTcDw6k8EY78YoAz9Q1W68WasJbq8tLKI70SFnJ2qPp3P4V6N8PdBOmWJlnWJpD8sbiLDbfXceSDx1xWT8NfCSWEa6hJ5Mkcy5j3gSOB2+bt+FM+Jnj7+xEk03TLeeW7ZSskyDCxDH8JPVv0H1oA5r42eIhf31vo1jcx+TavvuBjJeXHCA9sDOT614hfpNq+swxi2kewtf9gAM/qRznHqa3JGlnDrFbzxxuMOPOAOM5O5sZOe/NQRIxDrCbcRoOEVnK4+vGf50ATbPJGHulDKOI1GOB2Jxx9BTWjhdSpm35PUykg5FTBCEGxJBJjj9yNo/EnmnPKc7nV8/wB1lKjPpgCgD0b9nBVXxH4v2MGU2unnIGB9+67V8u+Pkz8VvHcn/PPVL7H1M7D+tfUn7OgA8SeLcI6ZtNPzuzknfd8818yeOlA+IvxBduB/bNymfrcSH+lAHMbjkt2Cj+dRqT+8YjlgR9Oae52pJt5B70pAYMfagDsfhsf+Jk2R0hI/OvQbxzHbxW6jOZBz+NcJ8OU3X0j9lA/nXoFwo8yBuuG/kKAPIvFb7vEuqSKeUm4/ACvtjQvEVhrXha0uoHjdmgj3QnnDBRx+lfEeqoW8QamrdC7fzr2D4AyzgvHI7kLMGVSeCMEUAe/W9jb6zqE099aLshK7Ay8E4rnfjD4pj8PaZZ2yIFklmilDAYwFbgfjitex8TSC5SKS3HlNIVLDjFcP8b9JtvEuoadDDOGdEViFPTa+aAOCk+M+p2+s3Gixxu6RSqhkHUDOTz9TW7L8Xbs6KGcMJZJtsZPUkAnArzBvDs+n+NNWlu1AS5XegI5GSD/Sq/ib7NaaPpphmVpIbsyhf7wKH/AUAcPdl57q7nkLF5ZC5z15OakhiklcBFJEhxx3welSOQ5klYYLEcVs+GAPIkklAEdlmZWPdj0FAG78PPDLa54usrd1IhgcKW7fdrufj/4oS0nHh/T9vlRRoC0fHIGKX4V3/wDZ/hm71aNFMu53zjoa8l1y6m1m8/tWfcTM3OT39KAOeRPMunGeM7vxxUgU4GDwCv8AOmxqInbBzuJNXpIUSzRw3zyEgj0A5FAGvpM0M2jz6dLsXdcrKHPUYHTNc7exPa3bQnOM7gfUVeTTLw6al6InCZwT+NM1a4+2m3lwMgeXx3AoAz5QSQ69RnOK+gPgj4lihsLZLmZYvIfZlj1G2vBoQEdgDkO20+2a20ieB5YrORmbsFOM4oA9S+K3iCJNLuIoZlnaeRT1zjHNYvhXw/HqOmWt07DM7fdPbNeb3c0k9womdieRgnPeu48HeJBaQ21tKwVICApPcUAdV4x8FwLpbxRFd8bBgR1NdZ4ajOkQWjAf6mNWHvxVO41e11CYmOVX/d9Ks32rWyRxwvKqsiIpH1BoA5X4yao82k3YW2DLIoG/b9zJryvwOTH4lsm9SY/rkV6x43vLC48IanCZkLspKepINeUeBT5viSwHZDuJ/DFAHo+pp/od9n+K2Yfzrxth8hfHUgfpXs/iCXZpN5KeAsbKPevH8L9j5POc0AVF++x7ZzUlpiG6gkIyoYZ9we1R8AHJ6kinhsQbR6igD9CvhP8A8ks8G/8AYFsv/RCUUfCf/klng3/sC2X/AKISigDyr9tb/klmlf8AYai/9ET18b2/zRKdjYU43gZxX2R+2t/ySzSv+w1F/wCiJ6+M7FsSld7pkcbRnJ+lAHRaHp81zJGYLqM7WGFK7W/PHSvTrOCaVU8+zkO1QNy3JKj8etcz4MS2WxLSyiJh0eSIsn4+n1rrIjauvmbI/lJObcsyn3PcfiKAJViSUIFBjwcAuvQ9Mhh1+hqSaWa2IE0fmoPl3SBsP6YbnH6ioybaRmVmxJt+R87lP5VPaxzWiLsuYBExOVOOO/J5B/EUAOi1JGx9mfygOf8ASIVV1P8AdVxwQfcUPHJdXRfbGZB97ayxN064GMfUU+7SGVMSqY0xkSRRqFI7g4JCj+VMCqUSJftEsSDOPLjnfHp1Bb2NAEqEFW+0Wke5eRcXDquMZyNwGPx61IkF3HFvglE0XUpZ3Bdj/tAgY/AfjVaH7MXRoyVBPTaEy2ehBGAfapZoFgXzoDBby5B2T4zjuA6ADPoev1oAbpRvrHUriaN7tbSdDHNCYNxz23oeMehFe4/B/WpUeXRbiAJA6m4tJFQKjD+JQATj1/OvFY5hcNLG4k2r8oliuRKwI9V4JH4VseE9eu9F1W0meeI6eZNyFt0fkSdCWHPDdD60Aeh6r4ZjHizU7EwrtuIWkhW2xG+3lh8pID8jBxivPdQ06XS7t4zBdWk7r5mEYghR1yDyMH8MdsV9G3kCatZWl5AIWlTEkbsCwAPUA9f/ANVeLeKbRH1+USSXdwgbzIHt3TavqMt83Hcde3SgDuPgtf8An6PParKu2JixgkIEsZPsByp5Oa5f49WVl4fvIvE0Gm/aL27Kwyvn7pX7rAZ644+grs/hdc2zwS28XlGWNFJZCrcemev4HpWN+0RNLD4VtPKiidTOdzPjcvHbJ7/4UAfIPja81bU9aN9fTvucYiKOVUDPAweK6SLSZJdDDX0c0O3LPe28TgqAM7Tg4P4/hWN4gRLu9iiiEbOWDEMjAAZGRkYr3jVLS21/wi2lyfYkS4hEZniQzMmMbcnggZ9M0AfMWowraypI80r+aMr9oGB/PIqj9pZSTHI6qeMEll+mfSuw8Z+HrjQ3jhurmVCDsV1G9GI9xyPxFcZJvjkDBlcf3sbxn6YAoAkgYZLDzAwGCyZAA98jpTI5zEkqpuBYclTkEevvQ8sxYIwjwTwFTaKcGy6bpUBzgNGwyPwzz+dACxxi8uoobeN2kdhGu/aQfyxiu7tvDmj6ZKlvewNPcjDPNgmJeM4UqSDz3rA8KeX/AMJBZtNLM8YfD5j4Ze+4dR9Tmt22W4m1kC5e1j0syMsc0lwOFzwyqev0oAsalaz6noLz2N1J+5fy1t4QFiiXPO4HJ3flVaK2hd08wXiOQBHbzsoEh9ct05+tdLewWcWk3T6ZdSJcL8xEp/jHVs9GBHYVh6BpBMX2vVb37RI4y0aFQAvUdR39sUAR6YP7N1tZrqGO5ikTyxG8zYgJ4YbhwD+FUPiLBeWep+WqTm1lUFGU/Kw9OnIrr9IgtZlkntrS2SBoz5i3D7Cccng9fwrgvE94+t6y8kLNEiAKIxKxGB3API+lAFa1jt7S3WQhBI+3cgbp74wfyzWh41urTULyGSxi3qY1V9yhSG/EDn6V0Hw/8NR+IfD2rzLqcNtewMsaRpGWJGOrZ5H1qp4k8HapbalbJfzi5VoxtuXXKED+8SeD7UAYvhuxure/FxEyxSW4yQDkgHrnPTNe/wDwt0G78XXEiWlg1npdudsuoyY3O/pHjhv5Dv6Vy3wy+Etzr2stHfPusGAeWZYVChPTPck8cdq+q7dNI8J6Jb2kCxWOnWybI0UcKB9P1PvQBBpmjaN4WsvNVYo2UYe6m2iR/q3H5DAq7HrFo2ntfSP5Nov/AC1fAGPWvOfFurSa/ZPaxyRSszHyoo3VTjs2G5I+nWq+swR6J4P0XRL5oMtmSd5N2NxJIBGe/qfwoA9cVlmj+ViVZchl9COoNcjr/gPSdW1mLVtVu71hbqB5bT7Y9g5we+O55/Gui0htmlQPMQFSIYcngrgHP/668A+LPxQbWLx9C0jKQgkMjHmbnhjg42/7JoA6r4h/E+2tYX0vRHjVSpj3DcGcDgBNvQe9eLg3eoSl5LeUxnjY8p+QD3OT+FJZmS1eRSTPcscu7EEf4/0q15KySkyrBvAztwOPxAoAnFlvhTfL5oXnalzt2j3xwPxPNP8As6+SQ8bPCRnllQLzwcg5ppjhBMkrI2P4Ix099pxmq0ot4b2NIYNzP87Oj5IGO5HT6UAWlgt3wY7iPPQo0xLD8egqRbaaSMCG4uGxztUBgR35J5P0pgic4VHhUHLBpGViB+eaRreb5AxaZcDDRttI/TAH60Aek/s7xPF4m8XCUOHNpp5IcjP37v0r5j+JB2+MvHYzw/iK5H5Syf419Ofs7I6eJfF28FS1pp5Cl92Bvu+9fMfxQX/itvFy/wB7xBet/wCR2FAHLKR5LKpyMUqjaoHrkU2CJlj2sP4f1pxDb13dAxNAHoPw3XfcXCLz+7H867Z23qjejEt7Vw/wvcrqF4F+8UXFdpGjgFHGAyndQB5f4nQW3iPUQOhcMPcEZr6V+C2j6LB4LtdaklH2goTJzjbg4r52+I1sYdR85RxKm0e5Wup+G17rV3Houm2gc6W9vdG5xnHyjcM/pQB9A6TavqSTi3XdGLiRw3sRxXPyeH9WTW7q5t7dnaGNgcntgmqHwg8VXP8Aa+vWd0R9ktrZZosnv0/nXXjxHqNrpup6pdRqLNon2t6HaQv60AfN/wAQfF91davJJtAeKIwnGOuP/r151cXMt99mEmcxscDPtVrXriWe+nlPPnESn6nrVKNSm18ck5FAE4UzvGi8joPetmNjb+Etp4kvLjOP9lBj+dYuntJBcwbhgF9q/nW3rk0KNpcKN+5jt2/76ZiT+tAHqPwotHvvhncIiklpXV/YEGvK9VMmnxyaYVx5Eu4D3xXffCbxIdBs9U0+4fZCybkH+1XF606ajrmo3x5iLDn3IoA520g88OeyrvPsKnjTzigPbP6YqWw/0VpI34WVWjP0BzT9DQLfpHdcAvtb6EigD2XT4NKb4dyQSSqJBG79PQCvC0GJo4F5wx/nXS3uqPbXN3Yqx8gBlHPYiuextvTLH2YMPpigBksRt5Pl+6+CD71NYatPY6l5yDPzEDPoRii4ctbqJOqMSKoz5J3fwjmgDR1UBJ1nTkOhYH3qnJMRNjJACg/mKlcyTWijHywcH2zVeKBpbv5x+6LBc/QYoA7z4bTtOs8twxG09z2xR4qubybxBcPbKzQcYIPpWR4Ye5Waa0shuLggD19K978JeCrW+8MRT3C/6SIS8ox0NAHzjqt9cTQmKbcCrtxmtf4aW27WPMI+VI3Yn3JFHj6yjsvFF1axD5VKk/Wt34c2mLe6lA+UnZn6c0AXfGFyf+EbvFX7u/Z+teVTPiBRnqw/KvRfGz+ToEMXeWQu1ec7Nyxb++QaAIWYkH/fJqZvljH50kKAs+77uSBRskcIMfefb+FAH6HfCf8A5JZ4N/7Atl/6ISij4T/8ks8G/wDYFsv/AEQlFAHlX7a3/JLNK/7DUX/oievixGKOGUkEehxX2n+2t/ySzSv+w1F/6Inr4qoA9m8FXWdKjZwskJGArMVyPfgj8TXQpDaOdwitY5ezQSA7Sfx56V5t8Ob+Z91mjqCv8JIBKn0yeee1ehQqS22S6gBXr5g8sr+I7UAStDAzg3El0Y88LGoYt9V4pq2sSpm3LC2J5WGP51Pc7SSR+PFSLZTO/mQarbkgnHkyBjjHvg/hTZLUH5rk3MuM/vYZAhI+hHH40AIiGNmeCSaUr2eHaT6HOSPzzUsLM7loylwR84LQsm1e/I4/LFOUOqg6fqWpiMYGGCZB/DqKWQGSYSXLCJxli8jFiD6Moxn8qAGXUkiNtudPZkI/vjOPZj1/GprK4lXJtZVaFielwrMmOxBIKn6ZFQpCJIj5Mmm3EZzuFpIFMYPqGGRVW6t7e3YvCbNOMuz3EToQOMHAyfyoA2LqKV5o5Lh1YleGnh6H3KnP45x7VDsmwzzTxNFj5todivY4cA/rxWRJeC0hidmhMA4WSDDoPwXuPStG2uUuIvPsNRiTyxhnyhf/AHsN8w+nIoA9o+BevrF5+gXFxcSIxMtk0zBhjHzxqw6468+prW+I/g1L7Uk1W3QMzYWVG2sCR04dgvYdMH3rwW21C803U4LoahbteW8gkSaIlHUjgBwFwQeh9jX1V4V1qy8V+HLXUbcwzRTLiRBhgrj7y/gaAMX4badcW9iZLq2FswJULs2Mc+o54/Gsb49aZJqfhy1SC8ltXSU5ZY2dCCP4wvavS4kSJFRAFUdBXmnxjt5JpdMkjFuDGHIeSfYQf93cMj3wfpQB8r6t4Vl0a+LXtrbXtoes0Bc4b+6cY/DOK67wHqOqXOt22naX9jtJAhlYXLyWxRQP4euQfX1rXaeeVZvO/erI2HCzHkAfwv0I+tY32O2towsmnorAfLI9+AVz3+U/KfUZIoA4nxvdxahql4txf+bcCdgzJFgbh28xeT+NcbPCFnItZDKW4bCbWH59a6TxR4dGnTedbQyRbmz/AK7apOcn5iST+dcvfGVLWcvu35AOZd+B0oAyrl0D7YXdsdWY5/Kq9XdO0u81HebSEyKhAY9hmr+qeG7jT9PjuHkSSQtteJBkoPX6UAdb8MtNY6Jf6rDZpPcwShFLuFGzHzf7XTuM10V7ZyNeKIVlNuxDRJ53mLHx/eAz+BrF8ATaafCskD6mIbreS0GCGOTjrg5HT0rYa0ubmeSB7VLyIkFXUh3BX2BGB6ZoAlEtxaQRLuWa5ixmB5Dn5hzsVsVlXWrW1zexwXcdp87hEDkxP/vMM8HPpS3ugw3iLBd2l15sTl/MjIMjHPIwc8fjSQ6TK2pFCIXdgDBHeJkoQPTnA9s0AdJBb3FrvkuLq0MMSghRC0hdc/3hj39feuG0W80+Dxsbqe0SKzZm52EhfQ/Lg9ak8WzwrYwWUFt5UsZ/eGKRTHluTz1Az2rnNKt0uLvY90IyDztk5+vPBoA6ceJJtL8YXV9oCSiKR8CJCwjc+hAOQe4r3LwPd3/jO2sItSSaC5nmMdus8THy0UZdg6jBwOOfWvKNC03TkvLaJrvynxjz1UhT9R3/AA5r6N+HySQX8lxDqFjd2qQx2kAtn+YFiCzEE9fbrQB6npOm22lWSWtmpWJemTk1ynj++l+yxm1kzCxKuoIwcdQ2SP8A69djdzC3tZZTkhFLcEA/rx+deR+IvFNvcyyQ3C31u7jDMwXDD6YweKAKehWh1S8a4nlsERJNxklC7l289xnBx0zWv4Xgn8TeMJruU2l1pUK/OVdZMN/AgIzkdyp6VL4WsBc+HbkaZNclZkMStCsb8sevJJX3zXTqmmfD7wfI/wAixxDLNgAzSnj8yf0oA5345X9wPDR060mtIopv+PnzXG5l7Iq5yST/ACr57sNDtlHm26Wq3Kk7sSLIz+vHeux8Ravqmv3LXN0JHhDZxDEGz7n/AArn5STsU2zbj0+1KVYDPqOMfzoARBEkSolq3lv91WiLFsemMAfgaBCFJSO0l+Ubi3kYYe3ByfTNA4VcWunYwwBmmKk89s8c/WmFgIlMkUER6MsbMQfTvg/hQA57qGFtjQ3hcMdshVV2j0JGc0luXiZ5YXEKuRl4VJyPc5OTSRxsz+fN5sij5Yo2G2JD9B1P1qy5kWNnIsXH8KJFIrIf+AnBH1oAZNJjK3c8RcEFhMM7vQjPeopZzGrNDNcLGTnaMsCfzwPbFPSeYplpSEIyfs9v1/E1EbOzkZpNl2h65ltS5yf92gD039myXzvEXjBtmz/RrDjGM/Pdc181/E+RE8c+K93Ua7f4+vnsa+mP2c4zH4m8YAyGTNrp53EEH7112zXy58TG8z4i+MosHKa/dnPs0zj+YoAwp3cRk9yBj+tWUQNKQ3TYuPrVOcMIQH6/MPxzUqOysxzypA/lQB2nw7fydWYHhmTH4ivRnVnkk291GPrXjuhXzW19FMDgByT9M816hpt+ZHiYniR8CgDn/H9lJPpplxloZVk+inr+tRfDjxK+jlbeKTasodAM9mGDWx4tSWaGZEPyeWysPfPFecaCpk1m2hT70b5/AdaAPa9MjNtp+qT6fxcyQCNz7A5rL8R+Orh/BU+lGbIOwlc9q7f4NaLLql9qs11g2LrsUe5GKxX8BpJJ4nuLmIG2soZSPrg7f1oA+dpHkkiMrcxj5Pw7VZuozAsKvwVA3fjzSW+yQRxAfJ5hyPpUut3EdzK0kP3GwB/IUAOlCi5jU/8ALFd3/AsE0uqxBrXT3PV4wR+pqSGI3k80kQ4cbfxxiuy8daba2fhDRmjTFwsTKx9xigDjLi5kSEzg/fO0fkKgkuWjtblEPyPIG/EAVqQabJdadCqjO0bj9WJx/Kkm0C5ghDzL+7bI6d6AM6U+YVJ+8Bn/ABpJZCQ0yffDAn+lMhyzn1VSp+ucVsQaNNLBayID5c0oXp6GgDJvH+0Bpl5kcAH8sUTptXfF0xt/Lmuy1jwRfaZBp2oSJiy85BJx2z/9etEeCLq8ES2yDaSw/MnH6UAcCLKa6snnjGUVRuP4VDb6fPe2EjwDKo3zfSvdvhP4GMwu7XUY9yLKysPbp/Wuw0/wBpmheJ76C6gH9n3cB8gD++KAPmXQrSSa9jt3GY7idUb3ruvFPgO70/SrW6t4sRNyTjuTxXpviT4fQaBJaakIgLaJw7Y7Guk8fX+n2/gEGYf61YzDz0OR/wDXoA8P8HeHrrStat7q8TbEhG449s16/Z+NtJ03QL1VkIkaIgcj0ry/WPF9qsFxFuO/yzjnuV4rzJtSubhFXflGTkfhigB/iHUW1LXbu7dstM2QfpXoHhZDY+HVK8GRs/n0ryyyQ3FzbAc7n2D6mvV7s/ZjplovA3ZYeyigDkfiNej7bBaqfuIhx9TzXHljghuoINaPiaf7bqskwORjaPw6VnzRsjR7u65P4UAPiH7xU9Mk/WrWkFZry1VuV3sx+i81TjJV5Hbp/jUmmkwGWbHEMUjfmuP60AfoN8J/+SWeDf8AsC2X/ohKKPhP/wAks8G/9gWy/wDRCUUAeVftrf8AJLNK/wCw1F/6Inr4qr7V/bW/5JZpX/Yai/8ARE9fFVAE1rN5FwknPynnFemeF9c+07Y5PLWUY+b7zD0OfWvLa0bCchQGuWiKngKuDj1zQB7kDM7fvJVIwMJIAPx455pyStxulj8xuATdMuG/n+leZ6V4ourdVSU3V1EOq+YFyPUEV1+la5FdIAlu67gMgyD5x3wP8OaANl1jf940sccinAJLSbffPp+H5VKGuedlxI6EZCIoyTj09P5VAbuXA2xRSR4wI5EAYA/7ZGakR7mSQqYngx6PvLf98j+dADpQJkJYK5T7vmZ3x+owTmmt9jWQIWht3DbgxBGeOh6/oaPsyhmP7if+4J5WjlUdwuFw341NGLmNGC2txtVeY1t/NyPUNnP9KAKs1tDczEKYZHk53faPmx9MfNx9DWBqmlpErOiyHafmH2aTHH8JY54/DFdBI8UyhJbq5ikYcJcRCFXPuegb/PtSSW0UQHmXEryHgBZzGR7AgYYdqAOGmuCih1jmgcfL+7mAB9ODxXqfwZ+J83hvU4Le9jv5tHn4n2FHWNj/AMtNoORjviuRm0LSrr/XWUwL5UTPL/EOzAKefyrFPhu90PUTd6SrX0IG7dG25x65Gen4UAff1rcQ3dtFcW0iSwSqHR0OQwPcVyvxBsPtFtBOY0kRCVdZLdZVHcHpuHPcEV85/DL4z3ek3kNlqlzK9iW2mJQuYgfbnp7CvoU+JI9f0wtpQWaHyy7TuwZYzjqwXqPbFAHi8ll9p0f7VBZW7mOQwy4ZgqMDxnkYyO+MetczdJbWkzwT2v2KTGQFuzkg9xklSPbjPavV/CWjNfeDNS1C+it9PlNw5jlt4/IZhn+8T0PpjFecXkAFybVoGugpIWGQNuPqAUJJ+mPwoA5rVrEPbStZQPcqw+aJFyD7FTnn6V5Pr0U0EDhdNntbZyPvhkAb6H+tey3NkIY2f+zo4Iecrbyyb8DrhSByPT9K868SaObsM9qr3QkB2TPJhlPUDGf6ZoAlkhNjY2Q0tLMRNGHVkuwC7/xFiD2rK1zVTZWhjWeOXUbgbnkhnZ1jU9uSQSR+Vc3a6jf6bJshlkhaNj8jD7p6Hg1VuZnuZ3mlIMjnJOMUALb3E1u5aCRo2PXacV3fgLXvLhuo7hbae6yGQPADIw74bH8zXn4GTgda6W3tLfStO8y4djqU3SNcjyU9cjvQB2tvqt3cQ3N7a2tqwAzLEJxG/H+yen4Vz95rd9eOUtUu7V2JU/MZPwJPP5ViJIxEjxq8y9JBk4z6nJrR0BY31BVNyYHIwFVN3Pbg0AdHoHhWKRUmv1kDN0ZoNysD7gZ/PmukOhWk6CKOe1LIOIPJKjr/AHzwv061dsmktY9kd3JhyQxKKjZI7A/y5NWPNecqqqiFufNl3LJIvoWHH5CgDQ8N22hpKsF5bJHIxCBoz54XtzkD8wTXs3gHQtOlnWbT2hlWCYmTz7fDcYAKEdPzNeceF7G/kVhFAZY1UkjK7VUDODnn3HSvbfh7YPZ6HBuhe3DgyGIsxxuOQCCSM+4NAG34h83+xbw2+fNEZK4rxJLW91HU0gtra5jKsdvl3ADAnr1OVz6flXvhPIHPNUotLs0vBeC3j+1bdpkxyaAK/hjSl0fSIbVXZ8DJLAAjPb1POeteN/GPxXBq+rw6XYvLc2VkWM0aRkCWbthiNrADI4z1Ndb8TvHgsY5dH0APeag4K3D27jNuOmAem8+navGPtEZcQJaqknIIu3ZGOO52kc++BQBV82AzlobSWOXOCfNEbp9MHH4kVKRLjZDPIFJLOkwdj7Z3Ern6GmzyzRkn/QplXgl5GkUe2ep/HNUHvbaQyR2glgbq0NvOVUHPUAjpQBa81ZXkKypKCMshC8nPbjNV2nsUVQkxdjnMSyBSD6YJyPyqvcPczIT9rR3BxzEUYe54OfxpkD2qyb2ZFYdZIQxP1yO9ACwy7vNDWs8O75c5bn/ayOMflVmKFAjSxA/J0ctJtz7kDH501Lsb/LS8vFwA3MZbA9etTfu/OJgkmlcYPETAr9RmgCC2jwMTw2Vwyk5CyBuPXbmpWgjVN0KlGJ5KygHB9ATU3mySL5UlukqZ6m7MR+mAM5/OoS4jwBZz2w777jeD75HWgD079mtETxD4vEef+PbT8lupO66618v+PSD8YfGERGfM1i9Uc9D57kH9K+nv2aJRN4i8ZMG3Yt9PGef711618tfEX/ksvij/ALD11/6UNQBkHLNHu5GSTT4mHmyhu+G/WnXihL6aNenmFR+dQ5zcgDvkUAa2k2z3N4sEYJaUttAGfevW9IttrxB4mQIM/MpHpWL+ztpol+I2ltcqsiozOAw4yENfUvinwza+ILNYnYW0qniaNBnHoaAPnu4gEjXscgyVgDfjnNeXT250bxErMMZk3g/7Jr2nxLosuha1eafKzPuClJSMB09q878bWIk2XCY3QAhvfPSgD0r4aeKP7Lt32EhJrVwuP+ehzg1f8L6Pr2oG6s5Lg/6V/riRwy9ao/s/6Zb+IvDUvmMFks3VSepORXrnjIJpXhG8mswIZlUBWHXPSgD4yv8ARJrPW9TtgOYd2MDuTVC30uUiOAgl45FDcV6vpVnHqGs3jOmXFuzOT3wOv61Y0XSbeW6lZkX5V59zQBj+GvD6f2RL+6zLBG0jHHXHP8qyfH96LnStMiUEfxEH0zXsHw3nsl16WyuIlKyWsobceOBz/KvOfGtvBqeoSW1pGEFudox065oA5XT7pba0lhb742Ln6f8A669C8EXWm659v02WINO+7yST0K4zXC3WlPHEpzywyf5VT0GS507XI5IXYNGCW29/WgDS8ReDLvTRNc7T5TOAML/tH/CvoXwVouhHwFZXdzbJujDHk4O4CtPSJNH1rwbBNcRwAqNzK5wSV5/rXzl408bXDzz2umzNBawFvkXpycUAa/jHxZBc2c2kA/NncnPA5GK4I+Mb2DKxXBUlxt9sGuV1HU5MZ3bpmOdx7CseSZ3xk9CT+dAHtvw7+Ij6Jqsk19KzxtKCwz1zXZeMPi1Z6ne6fPbZXyW+bn86+dtHnaZwHxlXDH3FaD7jJJKT8nUD8aAPcPiD8UoNc8IDT7ZiLknO7PvXlur+KNQv7cQzXBaCMLtX0rm5HdochuQGFKp80Ljvg/kKAJ5JmklhLnPynd75HFNVdhx6Lmpni3QIRwSQKjkcDcO/SgDd8E6Z9p1VGIzHEd349q0vEWp7JruTPKLsjPoSea1PCES6f4aS9kHzSkyD1x6VxGt3PnTlR3Xcf1oAx5gzBf72Tn86knkV8HsqhfxzTXcfuwB0BBqGZ9uU7jBNAE7kZCegOaZfSrDo86Y+eSRUB9AOT/SkLjDk9TVDWXzJFHx8q7j9TQB+jPwn/wCSWeDf+wLZf+iEoo+E/wDySzwb/wBgWy/9EJRQB5V+2t/ySzSv+w1F/wCiJ6+Kq+1f21v+SWaV/wBhqL/0RPXxVQAU+KR4nDRsVYdwcUyigDTjJdVZ5JQvbaRT0LR5cSFWJ43dT71n27hWwyg+mT0NXAJB1LhW4wP5DrQB1ei+J72zzHPeXMkR67HGPpg11Wn+ILe4XazeRnksGPPsQvWvLI3j3YdZG29y+AR7ipluJCxKTzR4+75fIUUAevglhiKWSFWBI6HH0DHNSxRyIiSpf24jJ6pK0RBz1wMgH2rzTSvEd9Ztk6jEygY2TxrIG/AiutsvFmn3gRZYbaOboWSIJx6YPBFAHR/aLqZR51sk2AQ4+zE5HqcDB/Kq7na7LbRQRzBdpxGY8/8AASevsKbDe28zIsUjEOC3luwKn3BBNStPvxHM12VB+VYQcg+ozxj6GgCNrnUoJmjYxNG2GVmcxn8CckH2OKJ7a2u4h5y2yTbiDKzsVyfU54+vNPumnZMxyzSw8r5UrxsQPQqck1FE8fz+epY4GFM4ViB2GRj8DQBy2uWLxD7Q2VOflltv3sbH69v0rovh74pu7OGTT4klDzYTz0Ty3CnqhbeMg+9MvLOyugF06UxGX5tvmsTxztdF+U+xArHksoY54pGgiEivjzod7g+7I2PzGKAPtHwzazDwja288DKPs4wIpjyMcD/JNeMeOPDl1pt8WkmWOCQZR40Rz7Ky8EemTg16Z8E9YbVvC5S4AF1ZMIJV+ymEtxlWx9O4rc8Y+G5NYtnFlciFiCfL2AqSPfH6EGgD5gf7TaTH5bp8cCSFzEy9xuAOcHsTkGuV8RCBMmSK1ikPLBAwWT0OVHyn+Vd3rWqXGkXl1bSTxLDGSpVoxKi844yQV+mMfSuR8Q67BJYMZUsrsQkFWWJMEZ6bVPX9aAOOuNG0/WAZlY296y7gsMnmI+O+SBz+NU7DwXNczKGukWMnA+Uhj7AetbNvcJc3EI0pigkbISCT7vrjdkj6dq6QzX2m2++N7BkfhXm2ybW9Pl4HPtQBynhrSdMsdevI7q2kuZrYBFje48llk7shAwxx/CcVW8Sm2lv5GhMkL5zsmwpHrkHitO3ur2yW7MhxLcSeZLCwyhJ6sDncKyZ7lhKzYgBbjypSNp+nXP0oAqaTcpFLIly4KSoVV43UEHtgfpWv4egCtHGkZbnJeY42A+uRjNYEcKJcK8fzoxBHl7lA/GvTvCMI+yNKsUgkH3hLIHA991AE+lWlnYndIVyDyCx2/UEc556jpXZ6JbR3k8MS6RM0RYbWjMr7h24fOT+VQaTFeXdwFtCyEDlrZg8Z/wBkqozz79K9s+H3g0adb/brxhFI3IRABge5IoAzoNPeAafo8FterdaiwEks4EaLAnLKCp5JHY16bY28NvFtt4wij5fu4JxwPrXmfxKsdQYWGsac06S2LERMHUooPdQBgkj8a4G4+J2t+HbSYXgAkDGQb5kiYt/useR7UAfSEkiQxtJM6oi8lmOAB7mvB/jF8a4dPtX07wjcFrkuYprwIcJx0Q9z74rw3xd8Sdb8UTtHJJKityypMED/AK4z+FYdj4Za8YFlu2DDJCEAqfXdnB/KgDeXxxHPCzPAHvWbLzMxJdj3OB19Sar/ANo69qKHfAFQ/cmCocfQ45rU0rw5Bp0UbxPeR3DdRM6qCPfGcitII6Oim7tlcAkGE/N9CdvBoAzbO1voismpQQ72H/LaMNHj1G3pW0FZ4k3WtlIRjbJbl8jv0YE0yCVk3Ge3yhIJZLj5unXbjpSC4t93zg7vvZlgK/ybn60AOZZR9+3XI/56xAjH0wP8aYZtoZLi0UohIVoYim3PcHg/iQaENxFG21oWiOSU3bGP5/8A66T7QEYBIgr9wN4YfiOtAEkdyvlHbKdoPVIAxHpz1/SkMszKFLPdKBwJI2XH0ao2LRtvLFWfqux23D8Rk1GAI8LGUQfxxujKG9snkGgCWTcVYm33x8fIyDPA/vHvWddKIIWcCRI8fddQMD61W1HXLLTY23Q2hlBO1VmKNj39frxXD6/4kutSVkQtDB2Bkz+tAH0X+yHMs+r+OXjChSLHG363FfOXxDIX4zeJ2boNeuj/AOTD179+xOSZvGuWJIFjnJB/5+PSvnn4qsU+K3jBl6rrV4R/3/egCs6bpTuPJmbn6VXgBR4mYZIJ/nVl23GM/wB4GTP1p0aiS4IwMHH4UAeh/DC8l07XEurdjHNEVdWH6/pX2BpeoW+q2UV5ZvmJxnBHIPoa+LvCcxWaSXGBGUT617l8JvEhttfNjOzNDeqFTnhGzwf6UAdT8atPEvhlNTjVjNZOFwvdGPOfocV85z3LXN1IkqkJOhi57HnmvrfxfCs/hbVY5ACvkknPsQa+WvEdqC08KrsywlVh7ZoAv/s5a6dB8dTaTcsRBefuMnpu6g19IeLPDv8AwkFr5DXUkIVcBV+6TnPNfHF872jW+pWxKTJNg7eCMd693sfjlaReHbZ57F3vBDtJ3cFhxkigDktNdLGXXbng7bcWwHuXOT/47XNnXBYXcC9fNIY4rHTxOy37223dHdQyOzeh5I/nWbaJ/alzFufbsYLn6CgDpbPxA5ubuS33LIweMMvbdn/CtzT7QyqZG5bABPqa43Q0jtL+7hZgwbLAn16YrtNH1eEWtzGhVmg+9jqGODj8iDQBS1u22WU6Dlo1ByPwNQ+AtPS71a6vJFBiQLEQemTjmpdSu08i4eQgZJQA96PBGpwWng/WJC6ebJKhX1+Ug0Ac18QNdvbDxBfWFldSRwIwAVDxzXBXM7zRu7E5Y4PvzXUnT/7cv768uJfLcybnDH7o5Iz+FZuvaI1hDuGWjOzDe3XNAHHXeRNtJztAWoKnvW3XczDoXNQUAaOkEo8snYLitWJnns4winKHaQO/eodOtcabbEAGS4kPTrgcf416L4Y8MiObdLjbIvQ9sCgDzxFZQwYHk1LbnZIuRwB/Oun8V6KNPuEK/cIK5/WuWYkxZA6MDmgC4JN1vJHggq2c/hUcMDXF4UXpmnR8sxA5k5x+FdD4csFhhNxMccg80AbPiScadoVjbKfuoMgfSvPmcvIGPO0Vt+JdSbUJ/QEEAemKxGIXGBxs5/KgCu64ii5yc5zUBUs7se4xUnSFRnOOakKjyWPQrQBGSquHfhAozWPcymad5GxkntV7UpsRCMEbmJLDHQdqzKAP0q+E/wDySzwb/wBgWy/9EJRR8J/+SWeDf+wLZf8AohKKAPKv21v+SWaV/wBhqL/0RPXxVX2r+2t/ySzSv+w1F/6Inr4qoAKKKKACrltLvwN+2QdGNU6UEg5FAGnhiOJVdRyQX25pWid8FTkDkquB+VQwS+Yp2gb8HICjmn7G+88OAOcNk5H4UASbNp3SRnI+6cgn/wCsafBIIskwK2cZ3EjB/lUCCIkFxhexC7aUG3+bjzT6gsBQBuaT4gutPzH9qEcRPMbxqyfQjH8q7fT9btL+FIZpwkp6eRKQj/4V5YoRSCqP6bSTg1LFuhcELtfthyrH2BFAHsiKjMStxZShujPulLe+7saJNoLRsbdTxyxiAPflf61wGj+LDbFU1CKW5QnBBb5sfXGa7az1nTL6IGES4AwAUCEZPqwzj6UARS2cM7jbfIrkkYtolRh7nB5+tV9S00G2xeWz3RIBWWZiu0jvtAwwI9TWpJcS4eJLi8SM/MY7kZGR/dYHp+FMjWEI3nRpKp6PEARntyMsaAO4/Zr13+yfFb6NNOscV7EVSIbxHuHKlR0z1HWvYtU8eSeH5ZbXVrZVlhJOA7uWXkjkL3Hf86+edJvJdLuLa+ttJ+yywOJI7k4Dqc9QvPFeqn4w3YQJ/ZkT3bKMtcp5Yce3PI/zigC74m0vQPiZpgvbNhBqxXb5LcrJxkc49Oh496+c9U8CX0epS2mmWd/cuTseBLXcwPbjqcHuK+jNJ8e+EPNH9saZZ6RcykKZbZ0cZ687cED6gio/HPhbVQ8XiX4bywXAKFn8qTMjd8p2Y/r2oA4b4R/BK/voVu/FUt7o5Dl0tEMYlkXoGb5cpz9DXrM3wX8KT5+0xXE7MNrtI4yw+oAql8E9d1PU9C1fVvFE0kTxyCLfOvlKgUc8k46kc4qDWPE/iK3E72t15oLZhmi2siAdnBGG+ooAr6r+z74euYnSwu7m15zHvAk2HsM8Ej8a8e+IXwU8ReHbS5vYVhvrCGMlpoByq9c7DyP1r3fwR4j12a8SPVpYZllk+ZUcKykjgKp7d+p/Ct74o+Irjw3oMF3BE8iyTLFJheACD1JBAHbkUAfCtu8y28T27ySNIdvykKB7EqMfnXrHgDQdT8QLGttY7z/GI9rqvuTnj6A5rqYPDEXiC7e/tYLPTIs+ZKgACSnPT92gGfriu1jl8T6RbrZaHpLWtvtybq2sQxbHQMeCfrigDpPCHgiLQDFealJaeZCAQUQoF56k54rsb66t5rKUtJCLQD99JKxVQnqD/wDXryjw4fFmparNa3yXCuwyHmLqpU9eSOR7Gsn4zeLpNEtbfwbpRe4uCm65O1QmCcqpJPH4CgDlfjT4r0/UpY4oPLOm2ZKxjO7c3TcN36V5BZ6Pcardtc3CSW1l1RZQOfqccflWzHoV59pF9qbs0p5VQokX2AUY4+lbWxox88JjL9JFQxbvYEkYIoAxotFmtJhNFGrIvO6Pb/IMc/XFbFuLaeUSbWikPO49WbvjAA/CpVCsy72mZxyrIm9ifXNSbYoo9s77mJx++43exI/nQBE9hGsoMN19ncE5JhwR/vAkg/pU0kt0lsqO1vdRkZQyR7MDudwHX6ml2zxsREpjZ+VWOQyIw+vNNMiworuZYjnkthufwx+ooASCeYKTMJX4/gJyOPUdPwpTOzKFN1bFW+UEs5wcccEVRvNf0+0w0jDevRlJyD68MDj2rltW8cTTEpDGSOcMRkfXB/nQB3q7WV/J+0XAXJYIwH1xk8isXVPFEOmFUkubpCDhUMao4GM/eyM9f0rzv+1ryeULdMjI/HzIMA+3PFZ144JeNnAccAPyG/woA72b4gWp3RSf2o3H3nK5/EA/yrMvPGn2meOIXN/BZfdkZNjuF9QDjn6muOjmKouUXIOFIUflR5wIZZEXbnIBTJDUALJcTSkvKxd+7Hn689aqC6VOQC3XhhwatB4yGG2NSFPykYBrIoA+rP2G2LN43ZuSfsX/ALcV8/fFj/kqfjL/ALDN7/6Pevf/ANhj/mdv+3H/ANuK8D+KMZm+LXi6MdX1u8X853oAymmb7LAAORGBWlpy75Rv4BTr71Vmj2XTIvKpgfhnFXI22FiP4WB/AgigDpvCz7rG7J42yK31xXX6Ne+RFDcIxDqY8EH0cH+lcp4Rs2fSLp2GFIO33OK3Psv2fSYBk792CPoM0AfR/jXxXpv/AAg13cx3CF723KRxg8gt1z9K8S1qBLu2hlQgmOJeneuUsYX1JoIWeQpHGwxuPeul0h3azmSQYKDyx9BQBzs2kpLC8StkSyAt/sk1w14kkGoz28m5VjOV5616TC4tb6VJeI2bfk+ormvEFgNQv2uoxlmABx7UAclayEBQfvBcZq7Y3zWgyvJILfrVGGJ/tzRuMZbNQh8yyfio/GgDWtLyV5YzEjSTGQKqLyXJPAH1OBXsnxN8HN4J8KaBqFqgaURC01N1H35mJcSfTcZF57FB2FeGWE0trfJLbSvFNBIskboxVkYchgexBANdNreqX8+i6JDLqF20V1pbvMrTMRKV1C7ILDPzEFVOT6CvJx9LEyxOHnSmlFN3Xe6f5K9vN+RpFrldytrusSXVsCBtKHdgVmaZM626QtIyo7gnmomUtC277xU8UyUqgiVTzk/n/kV6xmeg6jptu1vqlxbTqzXkSx7V/hxHtz+dQeLJbZvDUdurKZIoI19yVGK5XStYnghITLAoevrmsy4vXuj8xOHk29fSgDm7tSlzIp7MaZEhkkVB1Y4Ga176yWZldGCs5PbrRb2RtZBuw7HkHHQUAb3h9lfWtNikASKGQKeOMCvWLu7hg37WXAjyMe9eKRysjeYvXdWxe6/cyw4AJG0L1oA6Xx5qMdxDaQxENtIJI+mK4hWCW7qcffrQEE8li95MpCYByT71T020N9NGk3yoSST9KANfw7prXeoKZlKwxgEMeh4q34j1BLeB7O3YFd+Mir2q6lFpVmLazYPheuPUVw8u+WR5Dkj7x+tADhKZJmA5ANQ7t0coP8Qx+tIreXuMfIPWmykLCWU5OQKAGhcBVPTpSzyARyH+AdSPrRdHbH8nODWZNc/uBHEx+b7/AL0AV55WmkLuck1HRRQB+lXwn/5JZ4N/7Atl/wCiEoo+E/8AySzwb/2BbL/0QlFAHlX7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAFFFFABRRRQA5GKMGUkEcgir9vL5hxGqhgMktzj6VnUqkqQRwRQBplSmSZyW6krwKQtkKFlJI9TzTYLhXGAuHx0xnJ/GpA67zkqrnsiHj8qAE2yY2ndGCeuev455p0USu6rGcr0Lc8e5NMw4ALFWyem3tTl++cxEd8FuDQA5ziQh9rcd8sx+mafb3EtsyyQSyKy9jn/HioEjGRtbYCM43dTUoLREgwbiRyWb/wCvQB09h4unCxLeyzPCp6uoOPr6/Wus0a/02ebfaTi2u2wQzngjvtUcD8TXlZmwwMYj29TwWANJE6kgGaQ+iqe/tnpQB7EXljkYr5d4Mh2kjlIZf94ZAH5EVBcxW8m6La65+ZFBDfhuz3rz3TtfvbQKgnmWNeFIIOPYk9BWvH4sCxmKe0MLBtwP3kfP+zwAfegDpWtreSPZAqgNyqxxsfwO48ema634TeP7jwjqxilnY6dIQJbQhmUn+8DjCt9ODXks/iSSTcfs0ZTHO2Q7v16/hTDrdrcoN3m7xkY5wpz056UAfeV94f0jxL4Sv7O0d4tP1iLcXgO3BPO9R2OcE+tfP158EfHOkX8MGl6rFe6fK23cZnBiHqwPT8Ca5fwv8a/E/hnTUskb7TZwjaFmTJQHptY849M8VX1D46+IL+9E14JchPLH2YlRt9wpAz70Aek2vwc8bQ3Sxwa3FZW7YWSSGdmO0/ewpGP5V7db+F7SLwvYaJczz3NpaqgZ5pDul2/3j714L8NPjnFbWDWN8Z5SpLo925kYDuN/cegPNYvxL+M954slXS9KlfR9NAPmuTu8/wD4EMED2/OgD0nx18SovCTtpXgix0xvKwZHZsKSf7oGN3+9k15zd/FbxpdSBjPPbDOREfLjA/4EMZHp3rgY3thEqyOzOTu3SPkOP9juDjsfzq/bTZXax3REcJsGRjvgn+X5UAej6b8XfFMcEi+fHM+M/volcp68r1/GuB1eW51G+uL+9JluJiTJcMclm9DkcfiKWL7HJwLmJZM/fIxk+nY59qWViJEleGOM4Kh4Xxu9/mJJP14oAowWGVczWzvEx4KFWUN+HK/hVmyijikHkxjzMHEYPf2ycMfyqrPe2UJbzZ0hcfKwdSgYD3XIP41SuvFFrCu1ju42hgu9SPZuv50Ab6pNJkyQ/MBw6KWA9Mf3fpUcl4bSJ3D7SRhhL0PqAecZri73xlIxMVpEIkz/AL2fc55zWNd6zqF/ybhZVXjaAVP0IBxQB2WpeMrKBiIQ8ueqZzj059K57UfGmo3QKgiOMDbgrkj8cZrmJZGZtzA5/MY/KoywAwbdOOQyNtJ/CgCe5uxcSmSbMrH7wclSagd406q4HQYJB/Onr5bRg+a8RzwrruU/jnimxiSMHZ+8X8+KAHeYrkFTcD23bh+tLcSb5vLnJxjgFOV+nSlTbIv7yJg4/iEef5U2Uc5BWRAcjLEY/A0AJ5ShdiOxbPTHBFMcxIHDXDK/93aSDTJWjjALp0J4Bx+VUZZGkILEnHAz6UALLM8h5PHYDpUVFFAH1V+wx/zO3/bj/wC3FeIePsL8XvGkrdI9XvWH18969v8A2GP+Z2/7cf8A24rxX4kQkfETxq46ya5eL+U7/wCNAGE8ufMcHqMH86lY7I5M8HAzVBQwXyz97PP1FWoyZUnL9MDH4UAereEYv+KZtAf+WhZv8Kua7EUtYmQfMrbm9simaDiPw7pqp94AA1J4lmK6dIY/vcE/QZoAyfBc2Z5H7FW5/wBqusSJYyT6nJrkfBCI1oMfeViW/HpXYykbC3YrzQBzHiJoxkynCHBU+5rEjvJY7eR4OVTGTVjxwZBZRgdY2Ib+lclbahOkLRZ+RgC9AF/UIIm23Ft80oXc31rFTTp202S7VDtRjk/rWpHKPJ/0fksOf61JFqA/sKe0ib5XPT60Ac7G4W5L54KEn8q3PEDCLSfDRU8jTJAPp/aF5WEIyJlQ9zs/rW74gTfpXhkjoNMk/L+0Lyuav8dL/F/7bIa2ZnCVpS5XnBKj6cVGYwz7j1DcVb020kkmYRjKEEitP+yW2A7eSgb8a6RGFBmJEVegfn6Gq4XyYkPdWLH86t3sb28rBuASMVDIBIzL2JwaAGKAxVB1RgR9TStJu+Y/3Sopq/u51fsRuNSwReZ5SDqckUAIAqxYbgZxSwoWQKnOV5+tblj4eubiBXaP5d2fwNbA06w0+3Amysufm+ueKAMyOe6l0pbN1/0ZkUMfocmoLiRLNo/IPGCD+NLc3xACW7fusH+dZcswZGVj8w5oAWUNcMWbrikIAidV6MDn8KS3lJkhXPVcGmsdhIP3WJFAFVE2CUDoeRTfLVYl3cA5NOdiqgH2qhqFz+6EYznnn05oAgvbsOdsJYJ396pUUUAFFFFAH6VfCf8A5JZ4N/7Atl/6ISij4T/8ks8G/wDYFsv/AEQlFAHlX7a3/JLNK/7DUX/oieviqvtX9tb/AJJZpX/Yai/9ET18VUAFFFFABRRRQAUUUUAKDg5HWrkV3lNjjk8bicD8apUUAa0YPzeYDtPQKQv69aFG3kmNB2ySc/nVCKd0OCzbfY81cgdXbcGUrj5txwfxoAdwx2j5sfNkZFNMabWMfOOcMDgU9wzAfKuw8fKOv40K2TkN0PUDHP8AjQAi7jwsZ3HoyjHHtTCgIO4vu/uLyKllIZskfMeSZD1/KkUlQEYjcCTgnjFAAiTtuZYyq46ty360pTawE0zP6KTyfx7ChZzH80Wd2eGYcfhQrEjLjeFOcYzmgAU5VXKkLk4I5YfQ0pl3OodEdehGMOPw703CnLsOc8+n40rMI2wuBnqrdPz60ATmbYyqZbgsONpbnHv/AIVC3yykSEjJ6INoJ+lIjv0T5Ce4HI/rTtiiNldlYE4BHc0ASpIysVQ4HdWO0k+x9aWS9dwBcDjszLxj196rgqV+SZhjjbjODUhkYwMhxGM5Hpn29KAHQzGF98MrAZyVcbgffHWpJ76SRsDcsmeoPyt9KpllONpUsuDnuf8ACmyAhdxIwTwW6fnQBd+1XhBX7SyvnlQS2B7+opr3k5YiSacNwWMcnBPrg1TAbKu/XqrgZH40M5BJfayE+5AoAleQvt3O27rjofr6H6UJIpfds+b/AKZ/KT9V/wAKjVwUHJH9zoQfrTiWBCuPm6qw52/jQBLJKHQuHXdnAB4x9KIyxYkokmOuBg/rUXDNlwCQMEgA5/DvT1TCMyMGA7qe3+7QBGSpU4OxgehyAfagZ2gK2QM4yd31FKnYKfcbgSP06UpUnJQK2OSvHP0oAYjBR8zbS3fkA/UU/aCFKsobsScCnNIhwY12kcH/AOuKYx2R5lAK/wC1kfkaAJIm3cKWTHGMZxUNxPFFwFVmPJ2kiq891k/udyjGCSeTVSgB7uznLEmmUUUAFFFFAH1V+wx/zO3/AG4/+3FeMfFB2HxG8UIp4Os3x/H7TJ/hXs/7DH/M7f8Abj/7cV4x8TufiN4rP93Wb0f+TMlAHPYUASn+4zH60gJWzmA+8zcfTFV95VFibqR+masOQIWPYtgfligD2DRsHRLFl7qG/lUvihANInKfewQfyqt4Z3N4dsST0VV/WrmujzNLu2/hCFv0oAwfA52y3MI6vtdfoAa7W4XeqCP7pP6V5z4Qux9tsJwcKzOje/pXoynggcbQP50AcN8Rw0K4XgOvze5FcZAEW42Sj76mvRfiRbiTRGlA+dZguf515mCXl3DqvH58UAWId0PlH+Fs/lUZKqypFwc/40x5TFKschyEWq6ufMR/Tk/nQBqSRRvaBkH75ZMk/pVvV4XfRvDaL94aa4P/AIML2sS3uG3OmeTuNSQ3McMpwiqzkFiq4LHnr69ayqU+eUZX+F3/AAa/UaZp6RcC12iQ/N5m0fTFbVxehljEROQefpWLHdWn22NGX/lpn9K6C11PSsZaL1HWtRHOapA9w8RXnjJqGx0m5lV5MfKGwa65dU0oMhMXCgZ57UHWdOhtiI0x8m80AYMXhm7mQsF4xgcVqadp1rZRCS7X5kJX8hVS58SZVkt2K4HrWVLezzABnyMkke5oA6a91+KO38uzYgYwOa5K91KW8ZN7ZbOWqtK5DZ7cmq9uR57Z7g4oAnWUGAKn3skfhTADvXcPmYFfxphXCkr/AAnmtnV7QW8VhjG9kDn8aAM1F8oIW++uaJiDGv8AeHNI7hwx9c1U1C6EA4wzZxjNAEGoT+UoyMlunPSsckk5JzSyMXcsepOaAjEZCnH0oAbRTmRl+8pH1FNoAKKKKAP0q+E//JLPBv8A2BbL/wBEJRR8J/8Aklng3/sC2X/ohKKAPKv21v8Aklmlf9hqL/0RPXxVX2r+2t/ySzSv+w1F/wCiJ6+KqACiiigAooooAKKKKACiiigApVJU5BINJRQBbS6zgSD6sKtR/vlJz8p75zj0z2H1rKp6O0ZyjEH2oA0uuQoOf4uMg/jSZaNQoI29doGf1psd9DLhbuJlHTfCcH/vk8H9KtrHbuB9lvYR3Hm5Rv8ADNAFYfMePqFJx+oqUY2gJnnhgeP1qaSwuU+bymk75DZz7cVBsKDbJHJ7ADO2gBFUAjJJHsMkUr7kI807OcHvmpTDLJgErkjHy9aSFGXAlQhO2eaAI1jyGLeYoP3eck/X1FLLHsUMoCuR8xbgH6A12HhjQIJ4WluAxD5Ckc4/Dt9awtWgjt550hbJjbCq/wAxAoAyWQuAoIEh44G0H0/Gg7XRAvD/AHcN3PtQRsVhtCk9mJIHtTZATggBdw+YUAKSQMGPYOMEdPofWnK2SQAoQ84PH5UhYNGQzEg8BscCkdioHzlh6j0+lACADIcOEHcDofrUmQu7HykcDHP5CowvmD5SrZ9RjJ9qBhSoIyo9uQfcelADSybiwOAecjof8KepOzGckcgA55oVTg7W4PUds+lPBYoN2CV4XIxj2NADASTggZ9etSNtB5Vd4AAYNxj1FCxqfm3YxySDg0x9qDe7KCOeODj6d6AHOAQQQMcDcP8ACkKgjBMciD1bBWq73u3hfnB6lhjNVJZXlI3sTjpQBamuU/5ZglhwCaqSSNIcuSaZRQAUUUUAFFFFABRRRQB9VfsMf8zt/wBuP/txXinxNRm+Jfi3B4/tm+/9KJK9r/YY/wCZ2/7cf/bivF/iLz8S/GAz01q9/wDR8lAHMOAoTd94qGB9qkRSZZEJ4+8KjmXfK+Ogj2ipzIA8RwM7gT7igD0/wBObzRrGJTym7d+FafiWYQ6TKezrj865L4dXwgaa3PXPy/ia0vGtyYdNSInJY7fyoA4qwuHhLpG2Njlh7V7Fp9yt1pkE6f3VDe9eGeYY33/3jivSfAOo+Ystm57FhmgDW8cMD4ZnYjIMgYfnXlMMqxyRuw+UnJr1Pxrx4WkB7EfzryWZdtrG+epNACzSiScAjlyT+FSyQ+VbJKejcVXIy4fpVma4DWlvb45Ry5PqKAIFIUf7WM08xHzEb1qsud7k9Pmq+kiunlY+ZV60AQynDs46jkfypsbvkKDzgfmakEZMqrngdfzplsP3oY934/OgCaORgQpPJyPyoEpKYPdcUsmDI5H8Tce2RUSoQsef84oAWIA/NjqcVNE2did+9RrwgTodxbP4UqttTzMdD+dAEd1x5idxUaDbOG7KefpQ/wA1xKfUU4kbiwHfp+FAD2YCJ+OTU81y8jjzGyFXC+1VVG457Cq2p3Qhx5bKXz0oAinu/s4YDDNk8Z6VlyM9xKzYyzc8UYeeQnqxOTWhbW6xjdt+YDk0AV4bZQoaUHucU+XlAE4wc1ZmTCIR/nmmyAfuhjqTQAh8uaEK45Uc1nTwPDt8xcBhlT6irUoKZUfxVPIontfKxmVPumgDJopSCCQeopKAP0q+E/8AySzwb/2BbL/0QlFHwn/5JZ4N/wCwLZf+iEooA8q/bW/5JZpX/Yai/wDRE9fFVfqpRQB+VdFfqpRQB+VdFfqpRQB+VdFfqpRQB+VdFfqpRQB+VdFfqpRQB+VdFfqpRQB+VdFfqpRQB+WEM8sDboZHjb1RiKux63fooXz9ygYAZQa/UKigD8wk1+9TG0QBQc7fKFWU123cq1xZYYdfJbaCfX61+mlFAH5qr401CCVBaCNLdONjKCWHoT/hUjavpd9NuZZLWUjO5uQT3GR0FfpNRQB+Zs9vFy0d1aley+co/QmqyKqD/W2/X/nqOa/TuigD8wlEZbPmxBwcffGCKQToT85RvQ7hxX6fUUAfl8ZI+u5PpmlVo2GPMTA4ALgEH2PpX6gUUAfl68yLks4JxztOd1RNdqPuqWOOGPGK/UeigD8tJLyZ8chccfKMVXJJOTya/VOigD8q6K/VSigD8q6K/VSigD8q6K/VSigD8q6K/VSigD8q6K/VSigD5V/YY/5nb/tx/wDbivDvidIqfE/xkS4B/te9GM/9PD1+jdFAH5gtOnBDrzx1pRNH5gbzExnpur9PaKAPzZ8M6nFbazDLLNGkfcswArZ8caraXd3D9nu4JERf4JAwyfoa/Q2igD8xPPjEh/eIQf8AaHHNbuj6xDp+rW9wJ49qYz84wa/R6igD4V8Ta/pl/wCGZY49QszKy52CZd2c56Zrzm5lge1CCeLK9PnFfphRQB+Zkk8LQACaPP8AvCpS1uYg/wBph3FOnmDINfpdRQB+ZX2iFgWMkYPpuFKs8Id286PsPvCv00ooA/NKO6gWEMZo9248bxmmC4gSWLE0eAQc7hX6YUUAfmet1CZRmaMDfnO4VbF3atGmZ4Qckn5xxX6S0UAfmjPPA6DFxECuf4x6UNfQmCNPMj+UEH5hzkiv0uooA/M37RB5z/vo8HvuFOW4gXZ++iPY/MK/TCigD8x7rUEiVhA6u+cDuPrWSFMxaRnQEtzk4NfqdRQB+YcRt0jj2tGpGM/MOamNxD5gAkjwSc/MK/TaigD8ypZYDDxLGSvbcOaiaWJvJbzIwQTkbhX6dUUAfl9cyRtJlXQ/Q0kbIlyP3q7SQc7hiv1CooA/LbVRGL6UwsrIx3AqcjmqlfqpRQByvwn/AOSWeDf+wLZf+iEorqqKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemorrhage into a Meckel's diverticulum is demonstrated by high-density material within the diverticulum (arrow in A and B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6118=[""].join("\n");
var outline_f5_62_6118=null;
var title_f5_62_6119="Monitoring the HIV-infected patient with chronic hepatitis B virus infection";
var content_f5_62_6119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Monitoring the HIV-infected patient with chronic hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6119/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6119/contributors\">",
"     Barbara H McGovern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6119/contributors\">",
"     Kenneth E Sherman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6119/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6119/contributors\">",
"     David Thomas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6119/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6119/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/62/6119/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H33402171\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The era of potent antiretroviral therapy (ART) has led to declining rates of opportunistic infections and a new focus on other leading causes of morbidity, such as end-stage liver disease (ESLD) secondary to chronic hepatitis B virus (HBV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/1\">",
"     1",
"    </a>",
"    ]. The treatment and prevention of hepatitis B has taken on great significance in light of the negative impact HIV has on the natural history of chronic hepatitis B infection. ART is indicated in all patients with HBV coinfection; two of the three HIV agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ) should have dual activity against HIV and HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, treatment of HBV in the HIV-infected patient can be complicated by drug-induced hepatotoxicity, immune constitution syndromes, and toxicity related to medications. Furthermore, regardless of whether the patient is treated or not, surveillance for development of hepatocellular carcinoma is required. &nbsp;",
"   </p>",
"   <p>",
"    Monitoring of the patient with",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfection, regardless of whether the patient is taking antiviral therapy, will be discussed here. The epidemiology, clinical manifestations, diagnosis, management and prevention of HBV infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44020?source=see_link\">",
"     \"Evaluation of chronic hepatitis B virus infection in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40104?source=see_link\">",
"     \"Prevention of hepatitis B virus infection in the HIV-infected adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37223?source=see_link\">",
"     \"Antiviral medications for the treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402194\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING DURING HBV THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2417845\">",
"    <span class=\"h2\">",
"     HBV DNA and aminotransferase monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory monitoring during hepatitis B virus (HBV) therapy includes serial aminotransferases and assessment of viral suppression. Some experts recommend monitoring HBV DNA and aminotransferases every three months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frequent monitoring of HBV DNA (ie, every three months) facilitates early detection of the emergence of drug resistance, which can lead to hepatic flares. In patients on stable regimens and high predicted levels of adherence, monitoring at six-month intervals may be sufficient. (See",
"    <a class=\"local\" href=\"#H33402549\">",
"     'HBV drug resistance testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402233\">",
"    <span class=\"h2\">",
"     Importance of HBeAg status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on results of serologic testing, HBV-infected patients are classified as having either &ldquo;HBeAg-positive infection&rdquo; or &ldquo;HBeAg-negative infection&rdquo;. Patients with HBeAg-positive infection tend to have higher levels of HBV DNA than patients who are HBeAg-negative. In general, HBeAg-negative patients require chronic HBV therapy for an indefinite period of time, regardless of HIV status, since treatment discontinuation is usually associated with virologic rebound. In contrast, HBeAg-positive patients may be able to have a finite course of therapy if seroconversion (eg, loss of HBeAg with gain of anti-HBe) is achieved.",
"   </p>",
"   <p>",
"    Patients who are HBeAg-positive should have HBeAg and anti-HBe testing repeated every three to six months to determine if seroconversion has occurred. Seroconversion implies a transition from active liver disease to an inactive carrier state. Among HIV-seronegative patients with chronic HBV infection, HBV medications can usually be discontinued after an additional year of treatment after seroconversion. (See",
"    <a class=\"local\" href=\"#H33402578\">",
"     'Duration of HBV therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, most HBeAg-positive HIV-infected patients are taking HBV-active agents as part of their combination antiretroviral therapy (ART) regimen. In this situation, knowledge of seroconversion is only useful if ART needs to be altered in the future due to HIV drug resistance or medication toxicity. However, if all HBV active drugs are discontinued, the patient may be at risk for HBV reactivation and seroreversion, which is associated with rebound viremia and flares of hepatitis. These observations suggest the need for chronic HBV therapy, regardless of HBeAg status, among HIV-infected patients. &nbsp;",
"   </p>",
"   <p>",
"    No monitoring of HBeAg or anti-HBe is required in HBeAg negative patients; only HBV DNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402297\">",
"    <span class=\"h2\">",
"     Importance of HBV DNA suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in patients with HBV alone have demonstrated that normalization of aminotransferases and suppression of HBV DNA (with or without HBeAg seroconversion) are associated with improvements in liver histology and lower rates of cirrhosis, hepatic decompensation and hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/4\">",
"     4",
"    </a>",
"    ]. Studies in coinfection suggest similar benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402304\">",
"    <span class=\"h2\">",
"     Importance of loss of hepatitis B surface antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultimate goal is to achieve HBsAg seroconversion, but this occurs in the minority of patients, regardless of HIV status. Annual testing of HBsAg in patients with ongoing HBV DNA suppression is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402493\">",
"    <span class=\"h1\">",
"     SCREENING FOR HEPATOCELLULAR CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic hepatitis B virus (HBV) infection also should be screened at baseline and serially for the presence of hepatocellular carcinoma (HCC) with a right upper quadrant ultrasound; earlier detection facilitates curative resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    curative liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/6\">",
"     6",
"    </a>",
"    ]. Obese patients may be screened using biphasic or triphasic computed tomography (CT) or enhanced MRI imaging, since ultrasound may provide inadequate survey of the liver in larger patients.",
"   </p>",
"   <p>",
"    Unlike hepatitis C infection, where hepatocellular carcinoma usually occurs only after the development of cirrhosis, hepatocellular carcinoma can occur in HBV-infected patients at any stage of liver disease. The optimum interval for screening in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    patients is unknown. The American Association for the Study of Liver Disease (AASLD) recommends regular screening in certain risk groups, including patients with high levels of HBV DNA (&gt;20,000",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    and elevated alanine aminotransferase (ALT), although these guidelines do not make specific recommendations as to how often these patients should be monitored or at what age to start surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/7\">",
"     7",
"    </a>",
"    ]. Since",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients generally have higher levels of HBV DNA than patients with HBV alone, and HCC occurs at earlier age of onset with more aggressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/8\">",
"     8",
"    </a>",
"    ], a frequent screening interval can be justified. Thus, we and other experts prefer to screen patients every six months, regardless of whether the patient has underlying cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some expert guidelines suggest that alpha-fetoprotein (AFP) has poor sensitivity and should not be employed as a screening modality in patients with HBV infection. However, most experts continue to use AFP as a supplemental test. The sensitivity and specificity of AFP for prospective monitoring for HCC in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients has not been well studied. Abrupt increases in AFP suggest the need to increase level of surveillance (frequency and modality) using",
"    <span class=\"nowrap\">",
"     biphasic/triphasic",
"    </span>",
"    CT or MRI in this situation. Simple contrast CT is not indicated in HCC screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H41#H41\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Monitoring of patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Discovery of a new hepatic lesion characteristic of HCC should result in immediate referral to a transplant center with experience in the management of HIV-infected patients. Multiple modalities that range from resection to organ transplantation must be considered before a treatment plan is initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402500\">",
"    <span class=\"h1\">",
"     MONITORING IN HIV-INFECTED PATIENTS WITH HBV AND HCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hepatitis B virus (HBV)-infected patients with coexisting hepatitis C virus (HCV) infection, one virus typically predominates over another. This phenomenon, called \"viral interference\" refers to a reciprocal inhibitory effect that may explain why one virus replicates to a much higher degree over another. During HBV therapy, it is reasonable to assay for HCV RNA, particularly if aminotransferases rise despite declining HBV DNA levels. However, in one small study in 21 HIV-infected patients with HBV and HCV coinfection, re-emergence of the less dominant virus was uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402514\">",
"    <span class=\"h1\">",
"     ABNORMALITIES OF AMINOTRANSFERASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluctuations in aminotransferases in the patient coinfected with HIV and hepatitis B virus (HBV) may be due to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic hepatitis B infection",
"     </li>",
"     <li>",
"      Immune reconstitution syndrome",
"     </li>",
"     <li>",
"      Drug-induced liver injury",
"     </li>",
"     <li>",
"      Emergence of HBV drug resistance",
"      <span class=\"nowrap\">",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402521\">",
"    <span class=\"h2\">",
"     Chronic hepatitis B virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV/HBV",
"    coinfected patients may have waxing and waning aminotransferases during untreated infection. Data in patients with HBV alone suggest that serial flares of liver function tests can lead to increased rates of fibrosis progression.",
"   </p>",
"   <p>",
"    Mild increases in liver function tests may also occur in the setting of HBV treatment, which are often seen incidentally with routine laboratory monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402528\">",
"    <span class=\"h2\">",
"     Immune reconstitution inflammatory syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune reconstitution after initiation of antiretroviral therapy (ART) in the coinfected patient can be associated with elevation in aminotransferases, possibly because HBV is primarily an immune-mediated disease. The risk of HBV-related immune reconstitution is increased in patients with high levels of HBV viremia and CD4 counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Patients should be instructed to call their provider if they should develop symptoms of acute hepatitis with right upper quadrant pain, nausea, vomiting, anorexia, jaundice, or icterus. Close laboratory monitoring of aminotransferases is suggested during the first three months of therapy (eg, every six weeks), particularly in those with low CD4 cell counts.",
"   </p>",
"   <p>",
"    Most cases of immune reconstitution inflammatory syndrome resolve uneventfully; however, the patient with cirrhosis is at risk for decompensation and should be monitored closely during the first three to six months of therapy. Additional testing for prothrombin time in a cirrhotic patient with marked increases in aminotransferases is prudent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402535\">",
"    <span class=\"h2\">",
"     Drug induced liver injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients with chronic viral hepatitis (either HBV or HCV) are at increased risk for drug-induced liver injury when initiating ART compared with HIV-infected patients without viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/11\">",
"     11",
"    </a>",
"    ]. Although the risk of hepatotoxicity is increased in the coinfected patient, the benefit of ART far outweighs any risk of drug-induced liver injury. Certain antiretroviral medications have a higher risk of drug-induced liver injury and should be used with caution in the patient with liver disease (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HBV DNA should also be drawn in patients with suspected hepatotoxicity to be certain that their flare is not related to the emergence of HBV drug resistance.",
"    <span class=\"nowrap\">",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402542\">",
"    <span class=\"h2\">",
"     Emergence of HBV drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV/HBV",
"    coinfected patients may develop HBV drug resistance with subsequent hepatitis flares associated with rebound viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/13\">",
"     13",
"    </a>",
"    ]. The diagnosis of HBV drug resistance is suspected if the patient has attained viral suppression with subsequent detection of viremia; or in the patient who has an increase in viral load more than 1 log above the previous value. (See",
"    <a class=\"local\" href=\"#H33402549\">",
"     'HBV drug resistance testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk of resistance is high in patients who are being treated with ART that only contains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    as the only HBV-active agent. However, resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , even as the only HBV active agent within combination ART, has not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402549\">",
"    <span class=\"h1\">",
"     HBV DRUG RESISTANCE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although preliminary data suggest that resistance testing may have a role in drug selection, there are few published studies in this area.",
"   </p>",
"   <p>",
"    Hepatitis B virus (HBV) has a high replication rate, with an estimated 10(12) viruses being produced daily in the treatment-naive host [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/14\">",
"     14",
"    </a>",
"    ]. During replication, HBV mutations arise at a frequency of 1 per 10(4) to 10(5) nucleotides [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/15\">",
"     15",
"    </a>",
"    ]. The combination of these two factors leads to a swarm of viral variants called \"quasispecies\", similar to that described for HIV and hepatitis C viruses (HCV). However, despite the high HBV mutation rate, the emergence of drug resistance occurs more slowly for HBV than for HIV or HCV. This may be related to several factors, including slow turnover of covalently closed circular DNA in chronically infected hepatocytes, the constraints on HBV evolution imposed by its overlapping reading frames, and the effect of the host immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug resistance is inferred when a &ge;1 log(10)",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    increase in viral load from nadir is documented on two consecutive serum samples collected at least one month apart in patients who initially responded to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/17\">",
"     17",
"    </a>",
"    ]. Identification of antiviral resistance involves the detection of mutations in the HBV genome (typically polymerase) that have been selected during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have detectable HBV DNA with simultaneous suppression of HIV RNA on a dual-active agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ) most likely have HBV variants that have developed drug resistance to these nucleoside analogs. Drug resistance testing may still be helpful however, if the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , which has overlapping resistance patterns with lamivudine, is being considered. Drug resistance testing may also be informative in an HIV-infected patient who is not on ART, but has a rising HBV DNA on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    with a history of good adherence. Many clinical laboratories now combine resistance testing with genotyping.",
"   </p>",
"   <p>",
"    The emergence of HBV resistance can be associated with significant flares of aminotransferases. (See",
"    <a class=\"local\" href=\"#H33402514\">",
"     'Abnormalities of aminotransferases'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402571\">",
"    <span class=\"h1\">",
"     MONITORING FOR DRUG SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients who are taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    as part of antiretroviral therapy (ART) should have routine monitoring of creatinine, since tenofovir can occasionally cause renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6119/abstract/2\">",
"     2",
"    </a>",
"    ]. We suggest monitoring serum creatinine every four to six months and a urinalysis every six months in patients with normal baseline renal parameters with closer follow-up of those with renal insufficiency at baseline (eg, creatinine clearance &lt;60",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients taking interferon can experience significant side effects, such as depression, flu-like symptoms, nausea, vomiting, hair loss, and other symptoms. They can also develop leukopenia and thrombocytopenia. A full discussion of adverse events and monitoring is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1674?source=see_link\">",
"     \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402578\">",
"    <span class=\"h1\">",
"     DURATION OF HBV THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale to treat both HIV and hepatitis B virus (HBV) is based on reducing morbidity and mortality related to HIV and HBV infections and the availability of simple and well-tolerated drug co-formulations. In 2012, the Department of Health and Human Services (DHHS) and International Antiviral Society-USA Panel have recommended HIV treatment for all patients, regardless of CD4 cell count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link&amp;anchor=H7931840#H7931840\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\", section on 'Rationale to treat'",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H26#H26\">",
"      \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Treatment recommendations'",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402600\">",
"    <span class=\"h2\">",
"     Patients on antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV/HBV-coinfected",
"    patients who are on antiretroviral therapy (ART) will continue therapy for their lifetime to ensure HIV suppression. Dually-active agents for HIV and HBV, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , should be continued within the ART regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402607\">",
"    <span class=\"h2\">",
"     Patients who are not on antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with high CD4 cell counts who do not want to start lifelong HIV therapy, despite counseling regarding potential benefits, should still be evaluated for HBV therapy. Treatment candidates (eg, persistent or intermittent elevated alanine aminotransferases, HBV DNA &gt;2000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    with mild fibrosis or greater) should be managed with HBV agents that do not have anti-HIV activity. However, therapeutic options are limited to pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    . Patients should be encouraged to start ART during serial clinical follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of therapy among patients who are not on ART, but who are receiving HBV antiviral therapy, will depend on the HBV agent that they are taking and on their underlying HBeAg status. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In HIV-infected patients who are undergoing HBV treatment for hepatitis B e antigen-negative infection, we recommend indefinite therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      , since discontinuation will likely lead to viral rebound. Therapy may be discontinued in the rare patient who loses HBsAg.",
"     </li>",
"     <li>",
"      In hepatitis B e antigen-positive HIV-infected patients who are taking pegylated interferon, we recommend 48 weeks of therapy, as is recommended for HIV-seronegative patients with HBV infection. There are scant data on the efficacy of pegylated interferon for HBV infection in HIV-infected patients, although seroconversion rates are higher with this immunomodulatory agent than with nucleoside analogs in patients with HBV alone.",
"     </li>",
"     <li>",
"      In hepatitis B e antigen-positive HIV-infected patients who are taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      , we recommend one year of therapy past seroconversion, if this occurs. If seroconversion does not occur, chronic therapy is indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33402621\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment and prevention of hepatitis B virus (HBV) infection has taken on great significance in light of the negative impact HIV has on the natural history of chronic HBV infection. However, treatment of HBV in the HIV-infected patient can be complicated by drug-induced hepatotoxicity, immune constitution syndromes, and toxicity related to medications. Furthermore, regardless of whether the patient is treated or not, surveillance for development of hepatocellular carcinoma is required. (See",
"      <a class=\"local\" href=\"#H33402171\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory monitoring during HBV therapy includes serial aminotransferases and assessment of viral suppression. Frequent monitoring of HBV DNA facilitates early detection of the emergence of drug resistance, which can lead to hepatic flares. (See",
"      <a class=\"local\" href=\"#H33402194\">",
"       'Patient monitoring during HBV therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic HBV infection also should be screened at baseline and serially for the presence of hepatocellular carcinoma with a right upper quadrant ultrasound and an alpha-fetoprotein. (See",
"      <a class=\"local\" href=\"#H33402493\">",
"       'Screening for hepatocellular carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluctuations in aminotransferases in the",
"      <span class=\"nowrap\">",
"       HIV/HBV-coinfected",
"      </span>",
"      patient may be due to: chronic HBV infection, drug toxicity, immune reconstitution inflammatory syndrome, inadequate adherence, or the emergence of HBV drug resistance. (See",
"      <a class=\"local\" href=\"#H33402514\">",
"       'Abnormalities of aminotransferases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although preliminary data suggest that HBV drug resistance testing may have a role in drug selection, there are few published studies in this area. (See",
"      <a class=\"local\" href=\"#H33402549\">",
"       'HBV drug resistance testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients who are taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      as part of antiretroviral therapy (ART) should have routine monitoring of their renal function with serum creatinine and a urinalysis, since tenofovir can occasionally cause renal insufficiency. (See",
"      <a class=\"local\" href=\"#H33402571\">",
"       'Monitoring for drug side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with",
"      <span class=\"nowrap\">",
"       HIV/HBV",
"      </span>",
"      coinfection should be advised that lifelong ART, including two agents with dual activity against HIV and HBV, is associated with decreased risk of morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H33402578\">",
"       'Duration of HBV therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/1\">",
"      Weber R, Sabin CA, Friis-M&oslash;ller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/ (Accessed on May 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/3\">",
"      Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49:S138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/4\">",
"      Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009; 49:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/5\">",
"      Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718.",
"     </a>",
"    </li>",
"    <li>",
"     file://aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf (Accessed on March 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/7\">",
"      Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/8\">",
"      Br&auml;u N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/9\">",
"      Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/10\">",
"      Soriano V, Barreiro P, Mart&iacute;n-Carbonero L, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis 2007; 195:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/11\">",
"      Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/12\">",
"      Soriano V, Puoti M, Garcia-Gasc&oacute; P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/13\">",
"      Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/14\">",
"      Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:4398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/15\">",
"      G&uuml;nther S, Fischer L, Pult I, et al. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/16\">",
"      Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009; 199:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6119/abstract/17\">",
"      Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12 Suppl 3:H15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16129 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-07C7D38949-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6119=[""].join("\n");
var outline_f5_62_6119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33402621\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33402171\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33402194\">",
"      PATIENT MONITORING DURING HBV THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2417845\">",
"      HBV DNA and aminotransferase monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33402233\">",
"      Importance of HBeAg status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33402297\">",
"      Importance of HBV DNA suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33402304\">",
"      Importance of loss of hepatitis B surface antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33402493\">",
"      SCREENING FOR HEPATOCELLULAR CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33402500\">",
"      MONITORING IN HIV-INFECTED PATIENTS WITH HBV AND HCV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33402514\">",
"      ABNORMALITIES OF AMINOTRANSFERASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33402521\">",
"      Chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33402528\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33402535\">",
"      Drug induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33402542\">",
"      Emergence of HBV drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33402549\">",
"      HBV DRUG RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33402571\">",
"      MONITORING FOR DRUG SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33402578\">",
"      DURATION OF HBV THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33402600\">",
"      Patients on antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33402607\">",
"      Patients who are not on antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33402621\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37223?source=related_link\">",
"      Antiviral medications for the treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44020?source=related_link\">",
"      Evaluation of chronic hepatitis B virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1674?source=related_link\">",
"      Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40104?source=related_link\">",
"      Prevention of hepatitis B virus infection in the HIV-infected adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_62_6120="Shock in adults: Types, presentation, and diagnostic approach";
var content_f5_62_6120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Shock in adults: Types, presentation, and diagnostic approach",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6120/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6120/contributors\">",
"     David Gaieski, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6120/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6120/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/62/6120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a physiologic state characterized by a significant reduction of systemic tissue perfusion, resulting in decreased oxygen delivery to the tissues. This creates an imbalance between oxygen delivery and oxygen consumption. Prolonged oxygen deprivation leads to cellular hypoxia and derangement of critical biochemical processes at the cellular level, which can progress to the systemic level [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellular effects include cell membrane ion pump dysfunction, intracellular edema, leakage of intracellular contents into the extracellular space, and inadequate regulation of intracellular pH",
"     </li>",
"     <li>",
"      Systemic effects include alterations in the serum pH, endothelial dysfunction, and redox state, as well as further stimulation of inflammatory and antiinflammatory cascades",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of oxygen deprivation are initially reversible, but rapidly become irreversible. The result is sequential cell death, end-organ damage, multi-system organ failure, and death. This highlights the importance of prompt recognition and reversal of shock [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The types, stages, clinical presentation, and differential diagnosis of shock are reviewed here. A recommended diagnostic approach is also presented. Treatment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic tissue perfusion is determined by the cardiac output (CO) and systemic vascular resistance (SVR):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CO is the product of heart rate and stroke volume. The stroke volume is related to preload, myocardial contractility, and afterload.",
"     </li>",
"     <li>",
"      SVR is governed by the vessel length, blood viscosity, and vessel diameter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decreased systemic tissue perfusion is a consequence of diminished CO, SVR, or both. The CO or SVR may be elevated in shock if the other is disproportionately low. As an example, SVR is decreased out of proportion to the elevation of the CO in hyperdynamic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, complex interactions between humoral and microcirculatory processes cause patchy regional blood flow and reduced effective tissue perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/5\">",
"     5",
"    </a>",
"    ]. This results in derangement of cellular metabolic processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF SHOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three types of shock are recognized: hypovolemic, cardiogenic, and distributive.",
"   </p>",
"   <p>",
"    Distributive shock can be distinguished from hypovolemic and cardiogenic shock on the basis of the cardiac output (CO) and systemic vascular resistance (SVR). The pulmonary capillary wedge pressure (PCWP, also called pulmonary artery occlusion pressure) distinguishes hypovolemic from cardiogenic shock (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypovolemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemic shock is a consequence of decreased preload due to intravascular volume loss. During hypovolemic shock, the diminished preload decreases the CO and the SVR increases in an effort to compensate for the diminished CO and maintain perfusion to the vital organs. The PCWP is decreased (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ). Potential causes of hypovolemic shock are described below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hypovolemic shock'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiogenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiogenic shock is a consequence of cardiac pump failure. During cardiogenic shock, the cardiac pump failure decreases the CO and the SVR increases in an effort to compensate for the diminished CO and maintain perfusion to the vital organs. The PCWP is increased (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ). Possible causes of cardiac pump failure are described below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Cardiogenic shock'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Distributive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distributive (vasodilatory) shock is a consequence of severely decreased SVR. The CO is typically increased in an effort to compensate for the diminished SVR. The PCWP may be low or normal (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ). There are many causes of distributive shock, which are mentioned below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Distributive shock'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Combined",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different types of shock can coexist. As an example, patients with septic shock often have a hypovolemic component (due to decreased oral intake, insensible losses, vomiting, diarrhea), a cardiogenic component (due to sepsis-related myocardial dysfunction), and a distributive component (due to the effects of inflammatory and antiinflammatory cascades on vascular permeability and vasodilation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     STAGES OF SHOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the type of shock, there is a physiologic continuum. Shock begins with an inciting event, such as a focus of infection (eg, abscess) or an injury (eg, gunshot wound). This produces a systemic circulatory abnormality that may progress through several complex and intertwined stages: preshock, shock, and end-organ dysfunction. This progression can culminate in irreversible end-organ damage and death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Preshock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preshock is also referred to as warm shock or compensated shock. It is characterized by rapid compensation for diminished tissue perfusion by various homeostatic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, compensatory mechanisms during preshock may allow an otherwise healthy adult to be asymptomatic despite a 10 percent reduction in total effective arterial blood volume. Tachycardia, peripheral vasoconstriction, and either a modest increase or decrease in systemic blood pressure may be the only clinical signs of shock [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;During shock, the compensatory mechanisms become overwhelmed and signs and symptoms of organ dysfunction appear. These include tachycardia, dyspnea, restlessness, diaphoresis, metabolic acidosis, oliguria, and cool clammy skin.",
"   </p>",
"   <p>",
"    The signs and symptoms of organ dysfunction typically correspond to a significant physiologic perturbation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ]. Examples include a 20 to 25 percent reduction in effective arterial blood volume in hypovolemic shock, a fall in the cardiac index to less than 2.5",
"    <span class=\"nowrap\">",
"     L/min/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in cardiogenic shock, or activation of innumerable mediators of the systemic inflammatory response syndrome (SIRS) in distributive shock [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     End-organ dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive end-organ dysfunction leads to irreversible organ damage and patient death. During this stage, urine output may decline further (culminating in anuria and acute renal failure), acidemia decreases the cardiac output and alters cellular metabolic processes, and restlessness evolves into agitation, obtundation, and coma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation varies according to the type of shock, its cause, and its stage of presentation. Several features are common among all types of shock (cardinal findings), while other features may suggest a particular type of shock (suggestive findings).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardinal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardinal features of shock include hypotension, oliguria, abnormal mental status, metabolic acidosis, and, in some patients, cool and clammy skin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypotension &ndash; Hypotension occurs in the majority of shock patients. It may be absolute hypotension (eg, systolic blood pressure &lt;90 mmHg) or relative hypotension (eg, a drop in systolic blood pressure &gt;40 mmHg). Relative hypotension explains, in part, why a patient may be in shock despite having a high or normal blood pressure. Profound hypotension may occur, with vasopressors necessary to maintain adequate perfusion pressure as shock advances.",
"     </li>",
"     <li>",
"      Oliguria &ndash; Oliguria may be due to shunting of renal blood flow to other vital organs, intravascular volume depletion, or both. When intravascular volume depletion is a cause, it may be accompanied by orthostatic hypotension, poor skin turgor, absent axillary sweat, or dry mucous membranes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Suggestive findings'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Change in mental status &ndash; The continuum of mental status changes frequently encountered in shock begins with agitation, progresses to confusion or delirium, and ends in obtundation or coma.",
"     </li>",
"     <li>",
"      Cool, clammy skin &ndash; Potent vasoconstrictive mechanisms compensate for decreased tissue perfusion by redirecting blood from the periphery to the vital organs, thereby maintaining coronary, cerebral, and splanchnic perfusion. This causes the cool and clammy skin that is typical of shock. Not all patients with shock have cool and clammy skin, however. Patients with early distributive shock or terminal shock may have flushed, hyperemic skin. The former occurs prior to the onset of compensatory vasoconstriction, while the latter is due to failure of compensatory vasoconstriction.",
"     </li>",
"     <li>",
"      Metabolic acidosis &ndash; Metabolic acidosis develops as shock progresses, reflecting decreased clearance of lactate by the liver, kidneys, and skeletal muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/12\">",
"       12",
"      </a>",
"      ]. Lactate production may increase due to anaerobic metabolism if shock progresses to circulatory failure and tissue hypoxia, which can worsen the acidemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3781?source=see_link\">",
"       \"Causes of lactic acidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link&amp;anchor=H12#H12\">",
"       \"Arterial blood gases\", section on 'Interpretation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"       \"Simple and mixed acid-base disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Suggestive findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above described cardinal symptoms and signs of shock, there may be additional findings from the history, physical examination, laboratory studies, or imaging that suggest a particular type of shock. These findings are neither sensitive nor specific.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemic shock &ndash; Depending upon the cause of the hypovolemic shock, patients may report hematemesis, hematochezia, melena, vomiting, diarrhea, or abdominal pain. There may be evidence of blunt or penetrating trauma, or the patient may be postoperative. Physical manifestations may include decreased skin turgor (in younger patients), dry skin, dry axillae, dry tongue, or dry oral mucosa. In addition, patients may have postural hypotension, decreased jugular venous pressure, or diminished central venous pressure. There may be anemia, or the amylase and lipase may be elevated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiogenic shock &ndash; Depending upon the cause of the cardiogenic shock, patients may report dyspnea, chest pain, or palpitations. Many patients have a history of cardiovascular disease. Lung examination may reveal diffuse crackles and cardiac examination may reveal a new murmur, gallops, or soft heart sounds. The jugular venous pressure and central venous pressure may be increased, while the distal arterial pulses may be diminished. There may be evidence of pulmonary congestion or pulmonary edema on a chest radiograph, as well as recent or current ischemia on an electrocardiogram. Cardiac enzymes may be elevated. An echocardiogram may demonstrate the etiology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Distributive shock &ndash; Depending upon the cause of the distributive shock, patients may report dyspnea, productive cough, dysuria, hematuria, chills, myalgias, rashes, fatigue, malaise, headache, photophobia, pain, or a recent ingestion. There may be fever, tachypnea, tachycardia, leukocytosis, an abnormal mental status, or flushing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"       \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for the cause of shock is narrowed by determining which type of shock likely exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypovolemic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemic shock can be divided into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhage-induced &ndash; Causes include blunt or penetrating trauma, upper or lower gastrointestinal bleeding, ruptured hematoma, hemorrhagic pancreatitis, fractures, or a ruptured aortic, abdominal, or left ventricular free wall aneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fluid loss-induced &ndash; Causes include diarrhea, vomiting, heat stroke, inadequate repletion of insensible losses, burns, and \"third spacing\". Third-space losses are common postoperatively and in patients who have intestinal obstruction, pancreatitis, or cirrhosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of cardiac pump failure are diverse, but can be divided into four broad categories: myopathic, arrhythmic, mechanical, or extracardiac (obstructive).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiomyopathies &ndash; Cardiomyopathic causes of shock include myocardial infarction involving greater than 40 percent of the left ventricular myocardium, myocardial infarction of any size if accompanied by severe extensive ischemia due to multivessel coronary artery disease, right ventricular infarction, dilated cardiomyopathies, stunned myocardium following prolonged ischemia or cardiopulmonary bypass, myocardial depression due to advanced septic shock, and myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arrhythmias &ndash; Both atrial and ventricular arrhythmias can produce cardiogenic shock. Atrial fibrillation and atrial flutter reduce CO by interrupting coordinated atrial filling of the ventricles. Ventricular tachycardia, bradyarrhythmias, and complete heart block reduce CO, while ventricular fibrillation abolishes CO.",
"     </li>",
"     <li>",
"      Mechanical abnormalities &ndash; Mechanical causes of cardiogenic shock include valvular defects, ventricular septal defects or rupture, atrial myxomas, and a ruptured ventricular free wall aneurysm. Valvular defects include rupture of a papillary muscle or chordae tendineae, acute aortic insufficiency caused by retrograde dissection of the ascending aorta into the aortic valve ring, and critical aortic stenosis. An atrial myxoma can reduce ventricular filling, while a ruptured left ventricular free wall aneurysm can produce pump failure, hypovolemia, and sudden death if is not contained by the pericardial sac.",
"     </li>",
"     <li>",
"      Extracardiac abnormalities &ndash; Extracardiac (obstructive) causes of cardiogenic shock include massive pulmonary embolism, tension pneumothorax, severe constrictive pericarditis, pericardial tamponade, and severe pulmonary hypertension producing Eisenmenger's physiology. These conditions can also present clinically as hypovolemic shock when their primary physiologic disturbance is decreased preload, rather than pump failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"       \"Constrictive pericarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Distributive shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many causes of distributive (vasodilatory) shock, most of which are discussed in detail separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Septic shock (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"       \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Systemic inflammatory response syndrome (eg, pancreatitis, burns, multiple traumatic injuries) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"       \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Toxic shock syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anaphylaxis and anaphylactoid reactions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drug or toxin reactions, including insect bites, transfusion reactions, and heavy metal poisoning (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=see_link\">",
"       \"Use of blood products in the critically ill\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Addisonian crisis, which should be considered if clinical signs of sepsis exist without evidence of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/15\">",
"       15",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"       \"Clinical manifestations of adrenal insufficiency in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myxedema coma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=see_link\">",
"       \"Myxedema coma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neurogenic shock after a central nervous system or spinal cord injury (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"       \"Acute traumatic spinal cord injury\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute systemic inflammation following acute myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/16\">",
"       16",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Post-resuscitation syndrome, which follows the return of spontaneous circulation after cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Post-cardiopulmonary bypass (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient is suspected of having shock, diagnostic evaluation should occur at the same time as resuscitation. Resuscitative efforts should NOT be delayed for history, physical examination, laboratory testing, or imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Early management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients can provide a complete medical history despite profound shock, whereas others cannot provide any history. Historical data must instead be obtained from relatives or available medical records. The patient's baseline medical status, recent complaints, and recent activities may hold valuable information about the cause of shock. Additional clues include food and medicine allergies, recent changes in medications, potential acute or chronic drug intoxication, preexisting diseases, immunosuppressed states, and hypercoagulable conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination should be efficient and directed toward uncovering the type, severity, and cause of the shock. Physical findings are neither sensitive nor specific for identifying the cause of shock, but an examination that seeks the suggestive findings above may provide initial clues. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Suggestive findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests may help identify the cause of shock and early organ failure. They should be performed early in the evaluation of undifferentiated shock.",
"   </p>",
"   <p>",
"    Potentially helpful laboratory tests include basic chemistry tests (sodium, potassium, chloride, serum bicarbonate), blood urea nitrogen, creatinine, liver function tests, amylase, lipase, prothrombin time or international normalized ratio, partial thromboplastin time, fibrinogen, fibrin split products or dimer, cardiac enzymes (troponin or creatine phosphokinase isoenzymes), arterial blood gas, toxicology screen, and lactate level. In addition, a type and crossmatch should be performed for patients who are at risk for significant bleeding and the central venous oxygen saturation may be helpful in guiding resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H3877618#H3877618\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Interventions to restore perfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complete blood count with differential should be performed in patients with shock, since a leukocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bandemia may indicate that the shock is due to sepsis. In an observational study of 145 patients consecutively admitted to the ICU, infection was significantly more common among patients with a band count greater than 10 percent than among those with a lower band count (odds ratio 8.7, 95% CI 3.4-22.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/18\">",
"     18",
"    </a>",
"    ]. A band count greater than 10 percent predicted infection with a sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of 43 percent, 92 percent, 5.52, and 0.62, respectively.",
"   </p>",
"   <p>",
"    Venous whole blood lactate correlates with arterial lactate and can be used to screen for shock. In one observational study, increasing lactate levels were associated with increased mortality independent of organ dysfunction or hypotension among patients admitted to the hospital with severe sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/19\">",
"     19",
"    </a>",
"    ]. Increased serum lactate during shock results from increased production during anaerobic metabolism, mitochondrial derangements affecting oxygen utilization, and decreased clearance due to hepatic dysfunction.",
"   </p>",
"   <p>",
"    A chest radiograph, abdominal radiograph for intestinal obstruction, abdominal computed tomography (CT), head CT scan, electrocardiogram, echocardiogram, or urinalysis may also be helpful. Gram stain of material from sites of possible infection (sputum, urine, wounds) may give early clues to the etiology of infection while cultures are incubating. Blood should be taken from two distinct venipuncture sites and inoculated into standard blood culture media [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the data acquired from this evaluation, the cause of shock can usually be determined or narrowed to a few possibilities. For patients whose shock remains undifferentiated, pulmonary artery catheterization can provide additional information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pulmonary artery catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic measurements obtained by pulmonary catheterization can be helpful in determining the type of shock that exists, particularly the cardiac output, pulmonary artery occlusion pressure (ie, pulmonary capillary wedge pressure), and systemic vascular resistance (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ). These measurements can also be used to titrate vasopressors, assess the hemodynamic effects of changes in mechanical ventilator settings (eg, positive end expiratory pressure [PEEP]), and guide fluid resuscitation (in patients whose fluid responsiveness is uncertain) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=see_link\">",
"     \"Insertion of pulmonary artery catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these potential advantages, pulmonary arterial catheterization has never been shown to improve patient-important outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. As a result, the clinical risks versus benefits of pulmonary artery catheterization should be weighed on a patient-by-patient basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link&amp;anchor=H3#H3\">",
"     \"Pulmonary artery catheterization: Indications and complications\", section on 'Effect on survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of specific types of shock is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality due to shock is high. It is estimated that 35 to 60 percent of patients die within one month of the onset of septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/25\">",
"     25",
"    </a>",
"    ]. The mortality rate may be even higher among patients with cardiogenic shock; it is estimated to be 60 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Mortality due to hypovolemic shock is more variable. It depends upon the cause and the duration until recognition and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6120/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/24/24961?source=see_link\">",
"       \"Patient information: Shock (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shock is a physiologic state characterized by a significant reduction of systemic tissue perfusion, resulting in decreased oxygen delivery to the tissues. Prolonged oxygen deprivation may lead to sequential cell death, end-organ damage, multi-system organ failure, and death. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three types of shock are recognized: hypovolemic, cardiogenic, and distributive. They may coexist and they are distinguished from one another by the cardiac output and systemic vascular resistance (",
"      <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shock begins with an inciting event. This produces a systemic circulatory abnormality that may progress through several stages: preshock, shock, and end-organ dysfunction. The progression can culminate in irreversible end-organ damage and death. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Stages of shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several features of shock are common among all types of shock (cardinal findings), while other features may suggest a particular type of shock (suggestive findings). Cardinal features include hypotension, oliguria, cool and clammy skin, abnormal mental status, and metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for the cause of shock is narrowed by determining which type of shock likely exists. Hypovolemic shock may be hemorrhage-induced or fluid loss-induced. Cardiogenic shock may be due to a cardiomyopathy, arrhythmia, mechanical abnormality (eg, valvular dysfunction), or extracardiac abnormality (eg, pulmonary embolism). Distributive shock has many causes, such as septic shock, systemic inflammatory response syndrome, and anaphylaxis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient is suspected of having shock, diagnostic evaluation should occur at the same time as resuscitation. Resuscitative efforts should NOT be delayed for history, physical examination, laboratory testing, or imaging. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of shock can usually be determined or narrowed to a few possibilities using the data acquired from the medical history, physical examination, and laboratory evaluation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality due to shock is high. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/1\">",
"      Barber AE, Shires GT. Cell damage after shock. New Horiz 1996; 4:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/2\">",
"      Kristensen SR. Mechanisms of cell damage and enzyme release. Dan Med Bull 1994; 41:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/3\">",
"      Rodgers KG. Cardiovascular shock. Emerg Med Clin North Am 1995; 13:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/4\">",
"      Chittock DR, Russell JA. Oxygen delivery and consumption during sepsis. Clin Chest Med 1996; 17:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/5\">",
"      Hinshaw LB. Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit Care Med 1996; 24:1072.",
"     </a>",
"    </li>",
"    <li>",
"     Abboud, FM. Pathophysiology of hypotension and shock. In: Hurst, JW (Ed), The Heart, New York, McGraw-Hill, 1982. p. 452.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/7\">",
"      Shoemaker WC. Temporal physiologic patterns of shock and circulatory dysfunction based on early descriptions by invasive and noninvasive monitoring. New Horiz 1996; 4:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/8\">",
"      Chien S. Role of the sympathetic nervous system in hemorrhage. Physiol Rev 1967; 47:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/9\">",
"      Tuchschmidt JA, Mecher CE. Predictors of outcome from critical illness. Shock and cardiopulmonary resuscitation. Crit Care Clin 1994; 10:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/10\">",
"      Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/11\">",
"      Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/12\">",
"      Levraut J, Ciebiera JP, Chave S, et al. Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. Am J Respir Crit Care Med 1998; 157:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/13\">",
"      Lederle FA, Parenti CM, Chute EP. Ruptured abdominal aortic aneurysm: the internist as diagnostician. Am J Med 1994; 96:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/14\">",
"      Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994; 330:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/15\">",
"      Bouachour G, Tirot P, Varache N, et al. Hemodynamic changes in acute adrenal insufficiency. Intensive Care Med 1994; 20:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/16\">",
"      Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/17\">",
"      Adrie C, Laurent I, Monchi M, et al. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Curr Opin Crit Care 2004; 10:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/18\">",
"      Cavallazzi R, Bennin CL, Hirani A, et al. Is the band count useful in the diagnosis of infection? An accuracy study in critically ill patients. J Intensive Care Med 2010; 25:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/19\">",
"      Mikkelsen ME, Miltiades AN, Gaieski DF, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med 2009; 37:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/20\">",
"      Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/21\">",
"      Mimoz O, Rauss A, Rekik N, et al. Pulmonary artery catheterization in critically ill patients: a prospective analysis of outcome changes associated with catheter-prompted changes in therapy. Crit Care Med 1994; 22:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/22\">",
"      Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996; 276:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/23\">",
"      Harvey S, Harrison DA, Singer M, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005; 366:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/24\">",
"      Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA 2005; 294:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/25\">",
"      Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 1992; 268:3452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/26\">",
"      Moscucci M, Bates ER. Cardiogenic shock. Cardiol Clin 1995; 13:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6120/abstract/27\">",
"      Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 1995; 91:873.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1594 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6120=[""].join("\n");
var outline_f5_62_6120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF SHOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypovolemic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiogenic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Distributive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Combined",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      STAGES OF SHOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Preshock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      End-organ dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardinal findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Suggestive findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypovolemic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Distributive shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pulmonary artery catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1594\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1594|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/34/17963\" title=\"table 1\">",
"      Types of shock",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3781?source=related_link\">",
"      Causes of lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=related_link\">",
"      Insertion of pulmonary artery catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=related_link\">",
"      Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/24/24961?source=related_link\">",
"      Patient information: Shock (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_62_6121="Practice Changing UpDates";
var content_f5_62_6121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Practice Changing UpDates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6121/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6121/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6121/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/62/6121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section highlights specific new recommendations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    updates that we anticipate may change usual clinical practice. These concepts, reflecting changes to UpToDate over the past year, are presented chronologically, and are discussed in greater detail in the identified topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY CARE, FAMILY MEDICINE, CARDIOLOGY, ONCOLOGY (APRIL 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aspirin for the primary prevention of cardiovascular disease and cancer",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For individuals age &ge;50 years without excess bleeding risk, we suggest low-dose daily aspirin (75 to 100 mg)&nbsp;((",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      )). Patients who are more concerned about the bleeding risks than the potential benefits (prevention of cardiovascular events and cancer) may reasonably choose to not take aspirin for primary prevention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials have shown aspirin to reduce the risk of non-fatal myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/1\">",
"     1",
"    </a>",
"    ],&nbsp;and long-term aspirin use reduces overall cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/2\">",
"     2",
"    </a>",
"    ]. While several published guidelines have considered the benefit of aspirin for&nbsp;the prevention of either cardiovascular disease (CVD)&nbsp;or cancer versus&nbsp;the risk of increased bleeding, most have not addressed the&nbsp;potential net benefit of aspirin in preventing both CVD and cancer.&nbsp;A meta-analysis addressing this combined outcome suggests that aspirin use in 1000 average risk patients at age 60 years would be expected to result, over a 10-year period, in&nbsp;six fewer deaths, 19 fewer non-fatal myocardial infarctions, 14 fewer cancers, and 16 more major bleeding events (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ).&nbsp;For individuals age 50 years or greater without excess bleeding risks, we suggest daily aspirin at a dose of 75 to 100 mg. Patients who are more concerned about the bleeding risks than the potential benefits may reasonably choose to not take aspirin for primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=see_link&amp;anchor=H1761594#H1761594\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\", section on 'Recommendations for primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HEMATOLOGY (MARCH 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chlorambucil for older adults with chronic lymphocytic leukemia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For older adults with symptomatic CLL, we suggest initial treatment with chlorambucil rather than fludarabine or other agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no agreed upon standard treatment regimen for patients with&nbsp;previously untreated, symptomatic chronic lymphocytic leukemia (CLL). The choice of therapy is particularly difficult&nbsp;for patients &gt;70 years who have varying levels of co-morbidities and performance status. While many clinicians prefer fludarabine-containing&nbsp;regimens for younger adults, older adults have a higher rate of toxicities and opportunistic infections with these regimens. An analysis of&nbsp;over 650&nbsp;CLL patients enrolled&nbsp;in several&nbsp;trials of initial therapy demonstrated a survival benefit for fludarabine compared with chlorambucil among patients younger than 70 years, but not in those over 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/3\">",
"     3",
"    </a>",
"    ]. Based upon these and other data, we&nbsp;suggest initial treatment with chlorambucil rather than fludarabine or other agents for most older adults with symptomatic CLL; selected older patients in general good health other than CLL may reasonably be initially treated with other agents.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link&amp;anchor=H5624031#H5624031\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Older adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HEMATOLOGY (FEBRUARY 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bendamustine plus rituximab for newly diagnosed follicular lymphoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with previously untreated advanced stage&nbsp;follicular lymphoma&nbsp;who require therapy, we recommend treatment with an immunotherapy-based regimen rather than chemotherapy alone or hematopoietic cell transplantation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A choice among the various regimens depends upon patient characteristics and physician comfort. We suggest&nbsp;bendamustine plus rituximab (BR)&nbsp;rather than other regimens (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rituximab is central to the treatment of patients with advanced stage follicular lymphoma (FL). It can&nbsp;be administered either alone or in combination with chemotherapy, although the&nbsp;optimal chemotherapy regimen is not clear. The relatively new combination of bendamustine plus rituximab (BR) was compared with standard R-CHOP in a randomized, phase III trial of&nbsp;over 500&nbsp;patients with advanced stage indolent non-Hodgkin lymphoma, including FL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/4\">",
"     4",
"    </a>",
"    ]. BR resulted in superior median progression-free survival and&nbsp;equivalent overall survival,&nbsp;with less toxicity. The long-term toxicity profile and impact on future treatments, including hematopoietic stem cell collection, are unknown.&nbsp;For&nbsp;most patients with advanced stage&nbsp;FL, we now prefer BR over R-CHOP.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675543#H19675543\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Chemoimmunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OBSTETRICS, INFECTIOUS DISEASES (FEBRUARY 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Three-dose intermittent preventive treatment of malaria during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For pregnant women who reside in areas of medium and high malaria transmission, we recommend Intermittent Preventive Treatment during pregnancy (IPTp) with three doses of sulfadoxine pyrimethamine rather than two doses (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The previous recommendation for delivering Intermittent Preventive Treatment (IPTp) for malaria to pregnant women in areas of medium and high malaria transmission was a two-dose regimen. In a systematic review and meta-analysis, use of an IPTp&nbsp;regimen that&nbsp;included three or more doses,&nbsp;rather than&nbsp;a&nbsp;two-dose regimen, resulted in fewer low birth weight infants, less placental malaria, and less moderate to severe maternal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, for pregnant women who reside in areas of medium and high malaria transmission, we recommend treatment with three doses of sulfadoxine pyrimethamine as Intermittent Preventive Treatment (IPTp), rather than two doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and prevention of malaria in pregnancy\", section on 'Chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ONCOLOGY, GYNECOLOGY (FEBRUARY 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chemotherapy plus bevacizumab for recurrent, advanced, or metastatic cervical cancer",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with recurrent&nbsp;cervical cancer, those with advanced disease&nbsp;who are not surgical candidates, and those who present with metastatic disease, we suggest first-line treatment with chemotherapy plus bevacizumab rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with recurrent, metastatic, or advanced cervical cancer should receive treatment consisting of a platinum-based combination chemotherapy plus the angiogenesis inhibitor bevacizumab. This recommendation is based on the results of the GOG 240 study, in which over 400 women with stage IVB recurrent or persistent cervical squamous cell cancer or adenocarcinoma were randomly assigned to chemotherapy (paclitaxel plus either&nbsp;cisplatin or topotecan) with or without bevacizumab. Although the final data have yet to be reported, results from the second interim analysis showed the addition of bevacizumab to chemotherapy improved overall survival by four months compared to chemotherapy alone (17 versus 13 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    While we await the final analysis of GOG 240 to better evaluate the toxicity profile of treatment and whether the specific chemotherapy regimen had an impact on survival, bevacizumab should be incorporated into the first-line treatment of metastatic or recurrent cervical cancer. Although the preferred chemotherapy combination to use with bevacizumab has not been established, the choice of chemotherapy should mirror the approach to selection of agents for patients who do not receive bevacizumab. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H2177909474#H2177909474\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'First-line treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ALLERGY AND IMMUNOLOGY, ADULT PRIMARY CARE, FAMILY MEDICINE (JANUARY 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Egg-free influenza vaccine",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients age 18 or older with egg allergy, we recommend administration of&nbsp;an age-appropriate,&nbsp;egg-free, trivalent inactivated influenza vaccine (TIV) rather than an egg-based inactivated vaccine (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). However, if&nbsp;an egg-free&nbsp;vaccine is not readily available, immunization should proceed with egg-based vaccination with appropriate precautions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A trivalent inactivated influenza vaccine (Optaflu), produced using cultured mammalian cells, was approved in Europe for use in adults beginning in the 2007-2008 influenza season. This same vaccine (called Flucelvax) was approved for individuals &ge;18 years of age for the 2012-2013 season by the US Food and Drug Administration in November 2012&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A second egg-free vaccine (Flublok), made using an insect virus (baculovirus) expression system and recombinant DNA technology, was approved in January 2013 by the FDA for adults aged 18 to 49 years. The efficacy and rates of serious adverse events seen with&nbsp;both egg-free&nbsp;vaccines were comparable to standard available influenza vaccines. For&nbsp;patients age 18 or older with egg allergy, we recommend administration of&nbsp;an age-appropriate,&nbsp;egg-free, trivalent inactivated influenza vaccine (TIV) rather than an egg-based inactivated vaccine. However, if the&nbsp;an egg-free&nbsp;vaccine is not readily available, immunization should proceed with egg-based vaccination with appropriate precautions (eg, observation for 30 minutes following vaccination in patients with mild allergic reactions to egg, and immunization supervised by an allergy specialist for patients with a history of severe egg allergic reactions).",
"    <br/>",
"    <br/>",
"    We recommend not using&nbsp;the egg-free vaccine in patients younger than age 18, since the",
"    <span class=\"nowrap\">",
"     baculovirus/recombinant",
"    </span>",
"    DNA-based vaccine appears to be less immunogenic in young children and the immunogenicity of these vaccines and the rates of side effects in this population are otherwise not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H8#H8\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Alternative methods of vaccine production'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H9#H9\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Options for testing and administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PRIMARY CARE, GYNECOLOGY, GERIATRICS (JANUARY 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     ACOG guidelines for screening for cervical cancer",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that women aged 21 to 65 years who have a cervix receive screening for cervical cancer (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).&nbsp;We suggest Pap smear screening at intervals of every three years for average-risk women aged 21 through 29 years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For average-risk women aged 30 to 65 years, we suggest either Pap smear screening every three years, or a combination of Pap smear and HPV testing every five years, if both initial tests are negative (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    New guidelines for screening for cervical cancer have been issued by the U.S. Preventive Services Task Force (USPSTF) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/9\">",
"     9",
"    </a>",
"    ] and by a combined group representing the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology",
"    <span class=\"nowrap\">",
"     (ACS/ASCCP/ASCP)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/10\">",
"     10",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists (ACOG) also issued revised guidelines for cervical cancer in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/11\">",
"     11",
"    </a>",
"    ]. The three sets of guidelines overlap in their major recommendations (",
"    <a class=\"graphic graphic_table graphicRef82951 \" href=\"UTD.htm?24/21/24925\">",
"     table 3",
"    </a>",
"    ) and advise initiating cervical cancer screening for average-risk women at age 21 and discontinuing screening at age 65 for women who have had adequate negative prior screening. Average-risk women have no history of cervical cancer, DES in utero exposure, or significant immunocompromise (such as HIV infection). Women aged 21 to 29 should be screened every three years with Pap test (cytology) only, and women aged 30 to 65 should be screened by either cytology alone every three years, or co-testing (HPV test plus cytology) every five years. The",
"    <span class=\"nowrap\">",
"     ACS/ASCCP/ASCP",
"    </span>",
"    and the ACOG guidelines prefer the co-testing strategy, while the USPSTF suggests co-testing as an alternative for those women who wish to lengthen their screening interval while accepting an increased risk that colposcopy would be needed. All guidelines advise that cervical cancer screening is not indicated for women who have had a hysterectomy, in the absence of a history of cervical cancer or high grade cervical cancer precursor.",
"    <br/>",
"    <br/>",
"    There are no randomized trials comparing different screening intervals, and the decision to lengthen the interval for screening is based largely upon modeling studies. These studies indicate that screening with cytology every three years and screening with a combination of cytology and HPV testing every five years are equally effective in identifying cervical cancer in women greater than age 30. Furthermore, the longer screening intervals now suggested, compared with annual or biannual screening, have only a marginal impact on the predicted lifetime cancer risk while greatly decreasing the risk of harms associated with screening, including need for colposcopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H32#H32\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Recommendations of professional organizations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H24#H24\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Screening frequency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GASTROENTEROLOGY, ADULT PRIMARY CARE, FAMILY MEDICINE, HOSPITAL MEDICINE, SURGERY, HEMATOLOGY, CARDIOVASCULAR MEDICINE (JANUARY 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Blood transfusion thresholds for acute upper GI bleeding",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses, we recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      rather than &ge;9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. For patients at increased risk of suffering adverse events in the setting of significant anemia, such as those with unstable coronary artery disease, we suggest transfusing to maintain the hemoglobin at &ge;9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      rather than &ge;7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to initiate blood transfusions in patients with acute upper gastrointestinal bleeding is based on the rapidity of bleeding and the patients' comorbid conditions. A randomized trial of patients with and without cardiovascular disease suggests that in patients who are not at increased risk for complications from anemia, outcomes are improved if a lower hemoglobin threshold (&lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is used for initiating blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients transfused when the hemoglobin was &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had lower mortality rates, were less likely to have further bleeding, and were less likely to suffer complications.",
"    <br/>",
"    <br/>",
"    We recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    rather than &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    for the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses. However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. Additionally, we suggest transfusing to maintain the hemoglobin at &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients at increased risk of adverse events in the setting of significant anemia, such as those with unstable coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ONCOLOGY, GYNECOLOGY, GENERAL SURGERY (JANUARY 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Duration of adjuvant tamoxifen for breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with breast cancer who are receiving tamoxifen because they are not candidates for an aromatase inhibitor, and who are tolerating tamoxifen treatment well, we recommend treatment with tamoxifen for 10 years rather than five years (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This is particularly important for patients with a relatively poor prognosis (ie, pathologically involved lymph nodes at diagnosis, large tumor size, higher tumor grade).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women taking tamoxifen as adjuvant therapy for breast cancer, the usual recommendation is for a five year course of therapy. However, the results of the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial found that women who took tamoxifen for ten years had a significantly lower risk of recurrence and mortality compared to women who took tamoxifen for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/13\">",
"     13",
"    </a>",
"    ]. A longer course of tamoxifen, however, also resulted in a significantly higher incidence of adverse events including endometrial cancer, pulmonary embolus, and ischemic heart disease. Overall, these results support the use of tamoxifen for ten years in women who are tolerating treatment rather than five years. This is particularly true for patients with a relatively higher risk of recurrence based on their tumor characteristics (ie, pathological node involvement, large tumor size, or high tumor grade). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OBSTETRICS, INFECTIOUS DISEASES, PRIMARY CARE, FAMILY MEDICINE (JANUARY 2013)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Tdap during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend administration of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) to all pregnant women in each pregnancy between 27 and 36 weeks of gestation, even if the woman has a previous history of pertussis or vaccination (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of pertussis in the United States has been increasing, in part because pertussis immunity after vaccination or disease wanes over time. Infants younger than three months of age are at highest risk of morbidity and mortality from this infection, and many infants contract pertussis from their mothers. Vaccination of the mother can thus significantly decrease the risk of infant exposure, and placental transfer of maternal antibodies may additionally provide a degree of passive protection to the infant for two to six months. In 2013, the United States Advisory Committee on Immunization Practices (ACIP) recommended that all pregnant women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during",
"    <strong>",
"     each",
"    </strong>",
"    pregnancy, optimally between 27 and 36 weeks of gestation, regardless of prior vaccination status, to increase the likelihood of optimal protection against pertussis for both the mother and her infant during the first few months of the infant&rsquo;s life [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/14\">",
"     14",
"    </a>",
"    ]. Previously, Tdap was recommended only for pregnant women who had not previously received the acellular pertussis vaccine during adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR MEDICINE (NOVEMBER 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Optimal programming for primary prevention ICDs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients receiving an implantable cardioverter-defibrillator (ICD) for primary prevention, we recommend strategies that delay therapy or only institute therapy for very high heart rates, rather than a \"conventional\" ICD strategy that rapidly administers therapy with minimal delay (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest using a high-rate therapy programming strategy (therapy only for heart rate &ge;200 beats per minute with a 2.5 second delay) rather than a delayed therapy programming strategy (therapy with a 60 second delay for heart rates 170 to 199 beats per minute and shorter delay for higher rates) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal strategy for implantable cardioverter-defibrillator (ICD) programming, until now, has been to deliver antitachycardia therapy (either pacing or shocks) with minimal delay for any sustained ventricular arrhythmia. In MADIT-RIT, 1500 patients receiving an ICD for primary prevention were randomly assigned to one of three different ICD programming and therapy strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Conventional\" therapy programming &ndash; 2.5 second delay at rates of 170 to 199 beats per minute; 1 second delay at rates of 200 or more beats per minute.",
"     </li>",
"     <li>",
"      Delayed therapy programming &ndash; 60 second delay at rates of 170 to 199 beats per minute; 12 second delay at rates of 200 to 249 beats per minute; 2.5 second delay at rates of 250 or more beats per minute.",
"     </li>",
"     <li>",
"      High-rate therapy programming &ndash; No therapy at rates of 170 to 199 beats per minutes; 2.5 second delay at rates of 200 or more beats per minute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both high-rate and delayed therapy programming led to significant reductions in the primary outcome of inappropriate ICD therapies; reduced mortality was also seen with both strategies but was statistically significant only with high-rate programming. In patients receiving an ICD for primary prevention, we recommend strategies that delay therapy or only institute therapy for very high heart rates, rather than a \"conventional\" ICD strategy that rapidly administers therapy with minimal delay. For the two alternative strategies investigated in MADIT-RIT, we suggest using the high-rate therapy programming strategy rather than the delayed therapy programming strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H9233111#H9233111\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Optimal ICD programming'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ONCOLOGY (OCTOBER 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Regorafenib for metastatic colorectal cancer",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, and (if K-ras wild type) anti-EGFR therapy, and who require additional therapy, we suggest single agent regorafenib (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regorafenib is an orally active inhibitor of angiogenic receptor tyrosine kinases (including the vascular endothelial growth factor [VEGF] receptors 1,2, and 3) and other membrane and intracellular kinases. Regorafenib has been approved in the United States for the treatment of metastatic colorectal cancer (mCRC) in patients previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, and if",
"    <em>",
"     K-ras",
"    </em>",
"    wild type, therapy targeting the epidermal growth factor receptor (EGFR). Approval was based upon the CORRECT trial, which compared best supportive care plus either regorafenib or placebo in 760 patients with chemorefractory mCRC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/16\">",
"     16",
"    </a>",
"    ]. Regorafenib was associated with significant improvement in median overall and progression-free survival. Based upon these findings, we suggest single agent regorafenib for such chemotherapy refractory patients with mCRC who require additional therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link&amp;anchor=H56909045#H56909045\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Regorafenib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44058?source=see_link&amp;anchor=H4893926#H4893926\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Regorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR MEDICINE (SEPTEMBER 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Intraaortic balloon pump in acute MI with cardiogenic shock",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with acute MI and cardiogenic shock in whom mechanical complications (eg, acute mitral regurgitation or rupture of the ventricular septum) are not present and for whom revascularization is planned, we suggest not placing an intraaortic balloon pump (IABP) as a routine strategy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Placement of an intraaortic balloon pump (IABP) in patients with acute myocardial infarction (MI) complicated by cardiogenic shock is routine in many institutions in North America and Europe. However, the randomized IABP-SHOCK II trial, which compared use of the device or no device in 600 patients with cardiogenic shock complicating acute MI (STEMI and NSTEMI), found no difference in the rate of all-cause mortality at 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/17\">",
"     17",
"    </a>",
"    ]. We suggest not routinely placing an IABP in patients with acute MI and cardiogenic shock in whom percutaneous coronary intervention is intended.",
"    <br/>",
"    <br/>",
"    However, placement of an IABP may be a reasonable option for carefully selected patients with MI who have specific indications, including rapidly deteriorating hemodynamic parameters and clinical status despite vasopressor and inotropic support, or hemodynamically compromising mechanical defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H24#H24\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Intraaortic balloon pump'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     INFECTIOUS DISEASES (AUGUST 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Pre-exposure prophylaxis against HIV",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to counseling on other risk reduction methods, including consistent condom use, for HIV-uninfected adults who are at high risk for sexually-acquired HIV and are committed to medication adherence and close follow-up, we suggest pre-exposure prophylaxis with tenofovir-emtricitabine (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In July 2012, the US Food and Drug Administration approved the use of tenofovir-emtricitabine for pre-exposure prophylaxis among confirmed HIV-negative individuals at high risk for sexually acquired HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/18\">",
"     18",
"    </a>",
"    ]. Several trials in various populations, including men who have sex with men, heterosexual individuals with an HIV-infected partner, and heterosexual individuals in areas of high HIV prevalence, have demonstrated a reduction in the risk of HIV infection by 48 to 75 percent with daily use of tenofovir-emtricitabine compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Patients who opt for pre-exposure prophylaxis should be counseled extensively on the importance of adherence and close monitoring to optimize efficacy and safety. Evaluation for HIV infection prior to initiation and during administration of pre-exposure prophylaxis is critical to avoid selection of mutations that confer antiretroviral drug resistance. Additionally, although there was no excess of serious adverse events with tenofovir-emtricitabine in the studies, concerns about renal and bone toxicity with longer exposures persist and warrant routine monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     GASTROENTEROLOGY. PRIMARY CARE, INFECTIOUS DISEASES (AUGUST 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Screening for hepatitis C virus (HCV)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In agreement with recommendations from the Centers for Disease Control, individuals born in the United States between 1945 and 1965 should be screened one time with an antibody test for hepatitis C virus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, the prevalence of chronic hepatitis C virus (HCV) infection in patients born between 1945 and 1965 is estimated to be 3.25 percent, with this cohort accounting for approximately 75 percent of cases of chronic HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/22\">",
"     22",
"    </a>",
"    ]. Studies suggest that screening in this population would be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As a result, in addition to screening those at increased risk for HCV (eg, patients with a history of injection drug use), the Centers for Disease Control and Prevention now recommend birth cohort screening for all persons born in the United States between 1945 and 1965 with a one-time antibody test for HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\", section on 'Who should be tested'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\", section on 'Testing approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     ADULT PRIMARY CARE, FAMILY MEDICINE (MAY 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Treatment of acute bacterial rhinosinusitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend treatment with an antibiotic for patients whose clinical symptoms meet criteria for acute bacterial rhinosinusitis (ABRS) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In light of increasing microbial resistance to antibiotics, we suggest initial empiric treatment with amoxicillin-clavulanate&nbsp;rather than macrolides (clarithromycin&nbsp;or azithromycin), trimethoprim-sulfamethoxazole, or oral second- or third-generation cephalosporins (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines for the treatment of acute bacterial rhinosinusitis (ABRS) have been released from the Infectious Disease Society of American (IDSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/26\">",
"     26",
"    </a>",
"    ]. Although it is difficult to distinguish viral from bacterial acute rhinosinusitis (ARS), three features suggest the diagnosis of ABRS: 1) persistent symptoms or signs of ARS lasting 10 or more days with no clinical improvement; 2) onset with severe symptoms (fever &gt;39&deg;C or 102&deg;F and purulent nasal discharge or facial pain) lasting at least three consecutive days at the beginning of illness; or 3) onset with worsening symptoms following a viral upper respiratory infection that lasted five to six days and was initially improving. Patients who meet criteria for ABRS should be treated with an antibiotic.",
"    <br/>",
"    <br/>",
"    In light of increasing microbial resistance, we no longer recommend treatment with amoxicillin, trimethoprim-sulfamethoxazole, or a macrolide as initial therapy for ABRS. We agree with the guidelines in advising an empiric course of amoxicillin-clavulanate (500",
"    <span class=\"nowrap\">",
"     mg/125",
"    </span>",
"    mg orally three times daily or 875",
"    <span class=\"nowrap\">",
"     mg/125",
"    </span>",
"    mg orally twice daily) for five to seven days for most patients; doxycycline is a reasonable alternative. Doxycycline or a respiratory fluoroquinolone may be used in patients with penicillin allergy. Because of high rates of microbial resistance, macrolides (clarithromycin or azithromycin), trimethoprim-sulfamethoxazole, or oral second- or third-generation cephalosporins should",
"    <strong>",
"     not",
"    </strong>",
"    be used for empiric treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link&amp;anchor=H11974584#H11974584\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\", section on 'Community-acquired acute bacterial rhinosinusitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     INFECTIOUS DISEASES (MAY 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Initiating treatment for HIV infection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guidelines from the United States Department of Health and Human Services have been revised to recommend treatment of all patients with HIV infection regardless of CD4 T cell counts. For patients with a CD4 cell count",
"      <span class=\"nowrap\">",
"       &gt;500/mm3,",
"      </span>",
"      who are motivated to be treated, we suggest initiation of antiretroviral therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The expert panel of the United States Department of Health and Human Services (DHHS) issued a major change in the previously-issued HIV treatment guidelines; antiretroviral therapy (ART) is now recommended in all HIV-infected patients, regardless of CD4 cell counts&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/27\">",
"     27",
"    </a>",
"    ].&nbsp;Supportive arguments for this significant shift in treatment recommendations include the availability of more potent agents with less toxicity and recognition that untreated HIV infection has been associated with increased morbidity and mortality related to complications including cardiovascular, kidney, and liver disease and malignancy. Additionally, earlier therapy may lead to a more robust immunologic recovery compared with deferred therapy, and suppressive ART decreases the risk of sexual transmission and thereby provides a potential public health benefit.",
"    <br/>",
"    <br/>",
"    Previously, we had recommended initiating ART for patients with a CD4 cell count between 350 and 500",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    based on clinical trial data supporting a benefit in reducing AIDS- and non-AIDS-related complications and potential mortality-risk reduction. There is less robust evidence for the benefits of treatment at earlier stages of HIV infection, and a clinical trial is in progress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H26#H26\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Treatment recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PRIMARY CARE, PSYCHIATRY (APRIL 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Maximum dosing for citalopram",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians should not prescribe citalopram at doses that exceed 40 mg per day because of dose-dependent QT interval prolongation. The dose should not exceed 20 mg per day in patients with risk factors for increased serum concentrations of citalopram, including hepatic impairment, age &gt;60 years, CYP2C19 variants that slowly metabolize citalopram, and concomitant medications that inhibit CYP2C19.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The US Food and Drug Administration (FDA) issued new warnings about the dose-dependent effect of citalopram on QT interval prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/28\">",
"     28",
"    </a>",
"    ]. In August 2011, the FDA warned that doses of citalopram for all patients should not exceed 40 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/29\">",
"     29",
"    </a>",
"    ]. The new warning, issued in March 2012, advises that the dose of citalopram be limited to 20 mg in patients at risk for increased serum concentrations of citalopram. Risk factors include hepatic impairment, age &gt;60 years, CYP2C19 variants that slowly metabolize citalopram, and concomitant medications that inhibit CYP2C19. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H31651631#H31651631\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Cardiac'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     ONCOLOGY (APRIL 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Pazopanib for advanced soft tissue sarcoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with advanced or metastatic soft tissue sarcoma (other than liposarcoma or gastrointestinal stromal tumor [GIST]) who progress after an anthracycline-containing regimen, we recommend pazopanib (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In April 2012, pazopanib was approved by the US Food and Drug Administration for treatment of advanced soft tissue sarcoma in patients who have received prior anthracycline-containing chemotherapy. Approval was based upon the placebo-controlled phase III PALETTE trial, which demonstrated significantly improved progression-free survival with pazopanib [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/30\">",
"     30",
"    </a>",
"    ]. Benefit was consistent across all histologic subtypes, although patients with liposarcoma or gastrointestinal stromal tumor (GIST) were excluded from the trial. For patients with advanced or metastatic soft tissue sarcoma (other than liposarcoma or GIST) who progress after an anthracycline-containing regimen, we recommend pazopanib. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link&amp;anchor=H26#H26\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\", section on 'Antiangiogenic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     GASTROENTEROLOGY, PRIMARY CARE, GERIATRICS (MARCH 2012)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Treatment for constipation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients over the age of 70 years being treated with enemas for constipation, we suggest that patients receive warm water enemas rather than sodium phosphate enemas (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Constipation is a common complaint in older adults and one commonly used treatment is sodium phosphate enemas. However, there is evidence that the use of sodium phosphate enemas may be associated with serious adverse events. In a retrospective series, the use of sodium phosphate enemas in older adults (mean age 80 years, only one of whom was younger than age 70 years) for the treatment of constipation was associated with complications including hypotension and volume depletion, hyperphosphatemia, hypo- or hyperkalemia, metabolic acidosis, severe hypocalcemia, renal failure, and EKG changes (prolonged QT interval) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6121/abstract/31\">",
"     31",
"    </a>",
"    ]. Therefore, we suggest alternative management for constipation in adults over 70 years of age.",
"    <br/>",
"    <br/>",
"    The preparation for flexible sigmoidoscopy also typically involves sodium phosphate enemas. In patients over the age of 70 years undergoing preparation for flexible sigmoidoscopy, the risks of sodium phosphate enemas must be weighed against the risks of oral preparations (eg, polyethylene glycol lavage or magnesium citrate) for each individual patient before deciding upon an appropriate preparation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35048?source=see_link&amp;anchor=H29212555#H29212555\">",
"     \"Constipation in the older adult\", section on 'Stool softeners, suppositories, and enemas'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/1\">",
"      Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/2\">",
"      Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/3\">",
"      Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol 2013; 31:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/4\">",
"      Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/5\">",
"      Kayentao K, Garner P, van Eijk AM, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA 2013; 309:594.",
"     </a>",
"    </li>",
"    <li>",
"     NCI Press Release: Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer. file://cancer.gov/newscenter/newsfromnci/2013/GOG240 (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     Flucelvax prescribing information. file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/9\">",
"      Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/10\">",
"      Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/11\">",
"      Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol 2012; 120:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/12\">",
"      Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/13\">",
"      Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012.",
"     </a>",
"    </li>",
"    <li>",
"     Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women &mdash; Advisory Committee on Immunization Practices (ACIP), 2012 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm?s_cid=mm6207a4_e (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/15\">",
"      Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/16\">",
"      Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/17\">",
"      Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367:1287.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves first drug for reducing the risk of sexually acquired HIV infection, July 16, 2012. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm (Accessed on August 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/19\">",
"      Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/20\">",
"      Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/21\">",
"      Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587.",
"     </a>",
"    </li>",
"    <li>",
"     Smith BD, Patel N, Beckett GA, et al. Hepatitis C virus antibody prevalence, correlates and predictors among persons born from 1945 through 1965, United States, 1999&ndash;2008 [Abstract]. American Association for the Study of Liver Disease; San Francisco, CA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/23\">",
"      Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/24\">",
"      McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012; 55:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/25\">",
"      Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/26\">",
"      Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses file://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). file://www.fda.gov/Drugs/DrugSafety/ucm269086.htm (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/30\">",
"      van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6121/abstract/31\">",
"      Ori Y, Rozen-Zvi B, Chagnac A, et al. Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience. Arch Intern Med 2012; 172:263.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16722 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6121=[""].join("\n");
var outline_f5_62_6121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY CARE, FAMILY MEDICINE, CARDIOLOGY, ONCOLOGY (APRIL 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aspirin for the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HEMATOLOGY (MARCH 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chlorambucil for older adults with chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HEMATOLOGY (FEBRUARY 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bendamustine plus rituximab for newly diagnosed follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OBSTETRICS, INFECTIOUS DISEASES (FEBRUARY 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Three-dose intermittent preventive treatment of malaria during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ONCOLOGY, GYNECOLOGY (FEBRUARY 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chemotherapy plus bevacizumab for recurrent, advanced, or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ALLERGY AND IMMUNOLOGY, ADULT PRIMARY CARE, FAMILY MEDICINE (JANUARY 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Egg-free influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PRIMARY CARE, GYNECOLOGY, GERIATRICS (JANUARY 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ACOG guidelines for screening for cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GASTROENTEROLOGY, ADULT PRIMARY CARE, FAMILY MEDICINE, HOSPITAL MEDICINE, SURGERY, HEMATOLOGY, CARDIOVASCULAR MEDICINE (JANUARY 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Blood transfusion thresholds for acute upper GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ONCOLOGY, GYNECOLOGY, GENERAL SURGERY (JANUARY 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Duration of adjuvant tamoxifen for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OBSTETRICS, INFECTIOUS DISEASES, PRIMARY CARE, FAMILY MEDICINE (JANUARY 2013)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Tdap during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CARDIOVASCULAR MEDICINE (NOVEMBER 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Optimal programming for primary prevention ICDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ONCOLOGY (OCTOBER 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Regorafenib for metastatic colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CARDIOVASCULAR MEDICINE (SEPTEMBER 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Intraaortic balloon pump in acute MI with cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      INFECTIOUS DISEASES (AUGUST 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Pre-exposure prophylaxis against HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      GASTROENTEROLOGY. PRIMARY CARE, INFECTIOUS DISEASES (AUGUST 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Screening for hepatitis C virus (HCV)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      ADULT PRIMARY CARE, FAMILY MEDICINE (MAY 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Treatment of acute bacterial rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      INFECTIOUS DISEASES (MAY 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Initiating treatment for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PRIMARY CARE, PSYCHIATRY (APRIL 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Maximum dosing for citalopram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      ONCOLOGY (APRIL 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Pazopanib for advanced soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      GASTROENTEROLOGY, PRIMARY CARE, GERIATRICS (MARCH 2012)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Treatment for constipation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PCU/16722\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PCU/16722|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/47/40702\" title=\"table 1\">",
"      Aspirin for CVD and cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/31/42494\" title=\"table 2\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/21/24925\" title=\"table 3\">",
"      US recs cerv cancer screen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=related_link\">",
"      Aspirin in the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35048?source=related_link\">",
"      Constipation in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=related_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=related_link\">",
"      Pre-exposure prophylaxis against HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=related_link\">",
"      Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_62_6122="Prevention and management of complex regional pain syndrome in adults";
var content_f5_62_6122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and management of complex regional pain syndrome in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6122/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6122/contributors\">",
"     Salahadin Abdi, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6122/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6122/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/62/6122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/62/6122/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/62/6122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex regional pain syndrome (CRPS) is a disorder of the extremities that is characterized by pain, swelling, limited range of motion, vasomotor instability, skin changes, and patchy bone demineralization. It frequently begins following an injury, surgery, or vascular event such as a myocardial infarction or stroke.",
"   </p>",
"   <p>",
"    Alternative names for CRPS in the literature include reflex sympathetic dystrophy, algodystrophy, causalgia, Sudeck&rsquo;s atrophy, transient osteoporosis, and acute atrophy of bone. Upper extremity involvement following stroke or myocardial infarction is sometimes referred to as the &ldquo;shoulder-hand syndrome.&rdquo; A consensus development conference in 1995 grouped these disorders under a single heading of complex regional pain syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention and management of CRPS will be reviewed here. The clinical manifestations and diagnosis of CRPS in adults, the issues related to CRPS in children, and a detailed overview and discussion of the treatment of chronic pain, including neuropathic pain, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=see_link\">",
"     \"Complex regional pain syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of CRPS requires the presence of regional pain and sensory changes, typically following a noxious event. The pain is of a severity greater than that expected from the inciting injury and is often associated with such findings as abnormal skin color, temperature change, abnormal sudomotor activity, or edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES AND STAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of CRPS have been recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I corresponds to patients with CRPS without a definable nerve lesion and represents about 90 percent of clinical presentations.",
"     </li>",
"     <li>",
"      Type II was formerly termed causalgia and refers to cases in which a definable nerve lesion is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three stages can occur during the course of CRPS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1 &mdash; Either following an event or without apparent cause, the patient develops pain in a limb. The essential features include burning and sometimes throbbing pain, diffuse uncomfortable aching, sensitivity to touch or to cold, and localized edema. Vasomotor disturbances occur with variable intensity, producing altered color and temperature. The radiograph is either normal or shows patchy demineralization.",
"     </li>",
"     <li>",
"      Stage 2 &mdash; The second stage is marked by progression of the soft tissue edema, thickening of the skin and of articular soft tissues, muscle wasting, and the development of brawny skin. This may last for three to six months.",
"     </li>",
"     <li>",
"      Stage 3 &mdash; The third stage is most severe. It is characterized by limitation of movement, the shoulder-hand syndrome (capsular retraction producing a frozen shoulder), contractures of the digits, waxy trophic skin changes, and brittle ridged nails (",
"      <a class=\"graphic graphic_picture graphicRef50460 \" href=\"UTD.htm?6/4/6223\">",
"       picture 1",
"      </a>",
"      ). Bone radiography reveals severe demineralization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best treatment of CRPS is prevention. Early mobilization may reduce the risk of developing CRPS. Supplementation with vitamin C is another preventive measure that has been used in the setting of fracture management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Early mobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that early mobilization following stroke reduces the risk of CRPS. The following are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hemiplegia were randomly assigned to mobilization or to ordinary care [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/2\">",
"       2",
"      </a>",
"      ]. The group that received early mobilization had a significantly lower incidence of CRPS (8 versus 27 percent, respectively).",
"     </li>",
"     <li>",
"      A comparison of non-contemporaneous cohorts noted lower rates of CRPS in those who received early mobilization versus those who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus early mobilization after injury or following a myocardial infarction or stroke should be encouraged. Prolonged use of intravenous therapy should be accompanied by intermittent passive shoulder motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vitamin C following fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture of the distal radius may lead to CRPS of the upper extremity. The incidence of this complication is uncertain; reported rates range from less than 1 to 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The prophylactic use of vitamin C after wrist fracture may lower the risk of CRPS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 123 patients with 127 wrist fractures, patients were randomly assigned to receive either vitamin C (500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo for 50 days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/5\">",
"       5",
"      </a>",
"      ]. The incidence of CRPS was significantly decreased in the active therapy group (7 versus 22 percent).",
"     </li>",
"     <li>",
"      A larger, multicenter study randomly assigned 416 older women with wrist fractures to receive placebo or one of three daily doses (200, 500, or 1500 mg) of vitamin C for 50 days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/6\">",
"       6",
"      </a>",
"      ]. CRPS was less prevalent in those who received vitamin C (any dose versus placebo, 2.4 versus 10.1 percent). Each of the three doses was statistically superior to placebo, and the higher doses (500 and 1500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      had greater mean reductions in the relative risk (RR) of CRPS than the lower dose (RR 0.13, 0.17, and 0.41, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the mechanism underlying the beneficial effect of vitamin C is uncertain, there is little risk from use. The optimal dose of vitamin C remains uncertain. Doses of 500 to 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    may be more effective than lower doses. There appears to be no clinically significant difference between 500 mg and 1500 mg daily. A dose of 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was more efficacious than placebo in both randomized trials for post wrist fracture prophylaxis and is the dose that is suggested by the authors of the largest clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/6\">",
"     6",
"    </a>",
"    ] and, independently, by others [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend early mobilization and use of supplemental vitamin C for those with wrist fractures as preventive measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multidisciplinary approach is suggested in a guideline for management of CRPS developed by a consensus of experts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/8\">",
"     8",
"    </a>",
"    ]. Clinical experience suggests that treatment is more effective when begun in stage 1, as soon as the diagnosis is established and before radiographic changes appear. However, it is uncertain whether immediate referral to a specialist in pain management results in superior outcomes compared with referral to physical or occupational therapy for protective and assisted mobilization of the affected limb within pain limits, supplemented by conservative pharmacologic interventions, to be followed by referral to an expert in pain management if the patient does not improve. On the other hand, early referral to an interventional pain specialist for appropriate nerve block can reduce pain and can enable CRPS patients to tolerate aggressive physical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient participation in physical and occupational therapy may be facilitated by an explanation that neuropathic pain does not indicate tissue damage in the hyperalgic region but arises from nerve damage from a known or unknown cause. Prior to a referral to a specialist in rehabilitation or to a physical or occupational therapist, the clinician should stress the importance of working to regain use of the affected limb while recognizing the difficulty of doing so in the face of ongoing pain.",
"   </p>",
"   <p>",
"    The patient should be provided with addresses of a support groups; examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States &mdash; The Reflex Sympathetic Dystrophy Syndrome Association at PO Box 921, Haddonfield, NJ 08033 or at",
"      <a class=\"external\" href=\"file://www.rsds.org/\">",
"       www.rsds.org",
"      </a>",
"     </li>",
"     <li>",
"      In the United Kingdom &mdash; Reflex sympathetic dystrophy-Complex regional pain syndrome UK at",
"      <a class=\"external\" href=\"file://www.rsd-crps.co.uk/rsduk.htm\">",
"       file://www.rsd-crps.co.uk/rsduk.htm",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Psychologic assessment and counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Job and interpersonal relationships should be evaluated in all patients. Stress-management techniques may reduce the effect of stress on the autonomic and central nervous system.",
"   </p>",
"   <p>",
"    Patients with later stage CRPS may benefit from assessment by a clinical psychologist and from cognitive behavioral therapy. Although psychologic assessment and therapy have not been well-studied in patients with CRPS, their usefulness in other chronic painful disorders suggests that this approach may be beneficial to those with CRPS. Graded motor imagery is a three-stage rehabilitation process that uses a psychologic approach that targets cortical networks involved in sensory-motor processing of pain; this process may be helpful in reducing pain and in improving function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. However, its use and effects are controversial. A psychologist may also help to identify comorbid mood or other psychiatric disorders and to assist the patient in identifying and coping with ongoing life stresses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest consulting a clinical psychologist if any of the following are present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CRPS of more than two months&rsquo; duration at presentation",
"     </li>",
"     <li>",
"      No response to treatment",
"     </li>",
"     <li>",
"      Suspected comorbid psychologic or psychiatric disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical and occupational therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the data on the effectiveness of physical and occupational therapy (PT and OT) in prevention of CRPS, randomized and controlled clinical trials of PT and OT for patients with CRPS have produced disparate results as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No advantage of PT and OT over care that did not involve these interventions [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      PT and OT better than control [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Less pain with PT and OT but no significant difference in range of motion after one year [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aside from cost and inconvenience, there is little downside to arranging for PT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    OT evaluation and treatment of patients with CRPS. We suggest referral to an appropriate therapist soon after the diagnosis is established. Physical therapy, which can be performed twice daily at home for patients in all stages of disease, should ideally begin before limitation of movement occurs. If physical or occupational therapy is delayed to stage 3, impairment is not likely to improve. Resting splints for the affected limb are sometimes used with a goal of preventing progressive joint contractures. However, the effectiveness of splinting is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking appears to be a risk factor for CRPS. As an example, a retrospective study of 53 patients with CRPS found that there was a higher incidence of smoking in patients with CRPS compared with controls (68 versus 37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/16\">",
"     16",
"    </a>",
"    ]. Although a beneficial effect of smoking cessation has not been assessed for CRPS per se, the possible risk enhancing effect of smoking provides another rationale for advising smoking cessation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pharmacologic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a few pharmacologic agents have been studied in well-designed clinical trials in patients with CRPS. Medications that appear to be significantly better than placebo in relieving pain due to CRPS include some agents in the following drug classes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anticonvulsants",
"     </li>",
"     <li>",
"      Bisphosphonates",
"     </li>",
"     <li>",
"      Oral glucocorticoids",
"     </li>",
"     <li>",
"      Nasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though not specifically studied in CRPS, antidepressant medications are often effective in reducing neuropathic pain. The author&rsquo;s clinical experience suggests that tricyclic antidepressants reduce pain and are a valuable addition to physical therapy for patients with CRPS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines developed by a consensus of experts in CRPS suggest beginning treatment for pain due to CRPS with a tricyclic antidepressant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ), with an anticonvulsant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ), with a nonsteroidal antiinflammatory drug (NSAID), and, for those with severe pain, with an opioid [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other pharmacologic approaches with some evidence of efficacy require more invasive methods of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/17\">",
"     17",
"    </a>",
"    ]. These include epidural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    injections and intravenous regional sympathetic block with bretylium or a",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"      lidocaine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"      labetalol",
"     </a>",
"    </span>",
"    combination. Other systemic, intravenous infusions include lidocaine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    . Local sympathetic blocks (eg, stellate ganglion block) with local anesthetic, while of unproven benefit in terms of the long-term outcome, nevertheless may provide a short-term decrease in pain that can be diagnostically useful and that can help with mobilization of the affected limb. A peripheral nerve stimulator, spinal cord stimulator, or intrathecal drug delivery device can be utilized to deliver drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    , local anesthetics, clonidine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    opioids intrathecally.",
"   </p>",
"   <p>",
"    Anticonvulsants are beneficial in chronic pain, particularly with pain that is lancinating, burning, or sharp. Successful use in some cases of CRPS type I has been reported for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    is a relatively newer agent which can be used as alternative to gabapentin. The key in using these medications is to start slowly and to titrate the dose as needed and tolerated. Although unproven in CRPS, these drugs have a good margin of safety and may be useful if NSAIDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    are inadequate for pain management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple treatment modalities are available to provide pain relief in patients with CRPS. The key to success is to use whatever works to reduce pain so that patients can tolerate physical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Topical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    cream is used for treating neuropathic pain. By analogy with treatment of painful diabetic neuropathy, capsaicin cream may be applied topically four times daily over painful areas. Local burning and skin irritation can occur, but this may become less of a problem with continued use. This agent is probably best used in patients with stage 1 CRPS and with residual mild to moderate pain despite the use of tricyclic antidepressants and NSAIDs. Three to five days of use may suffice to assess effectiveness and tolerability of topical capsaicin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates, which have been used to prevent bone resorption in patients with CRPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/20\">",
"     20",
"    </a>",
"    ], may also be useful for pain relief. This was illustrated in a trial that randomly assigned 32 patients with stage 1 CRPS either to 300 mg of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    given daily for 10 days or to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/21\">",
"     21",
"    </a>",
"    ]. After 40 days, pain decreased by a mean of 36 mm and 6 mm (on a 100 mm visual analog pain scale) in the clodronate and placebo groups, respectively, a difference that was statistically significant. The only side effect of active therapy was hypocalcemia, which was documented in three patients, none of whom were symptomatic.",
"   </p>",
"   <p>",
"    Studies of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/22\">",
"     22",
"    </a>",
"    ] and parenteral or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/23,24\">",
"     23,24",
"    </a>",
"    ] have also yielded encouraging results. However, pamidronate may cause symptomatic hypocalcemia, and relapse occurred in 40 percent of those who initially responded to alendronate. Serious adverse effects of bisphosphonates include esophageal ulceration with oral use and osteonecrosis of the jaw.",
"   </p>",
"   <p>",
"    Patients who have difficulty swallowing, those with disordered esophageal motility, and those who cannot sit or stand for 30 minutes should not receive oral bisphosphonate therapy.",
"   </p>",
"   <p>",
"    Most reported cases of osteonecrosis have been in patients with malignant disease receiving potent intravenous bisphosphonates. However, osteonecrosis has been reported in some patients receiving oral bisphosphonates for benign disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=see_link\">",
"     \"Pharmacology of bisphosphonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral glucocorticoids (eg, divided doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 30 to 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/25\">",
"     25",
"    </a>",
"    ]. Data from two small randomized placebo controlled trials in post-traumatic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/26\">",
"     26",
"    </a>",
"    ] and upper extremity CRPS due to stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/2\">",
"     2",
"    </a>",
"    ] suggest a beneficial effect of a short course of glucocorticoids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 23 patients with post-traumatic CRPS type I who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (10 mg three times daily) or to placebo, all 13 patients in the prednisone-treated group showed more than 75 percent clinical improvement within the 12-week period; of the 10 patients who received placebo, only two reported improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Of 36 patients with stroke and CRPS (shoulder-hand syndrome), 31 were nearly symptom-free following 10 days of low-dose glucocorticoid treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral glucocorticoids may be significantly more effective than NSAIDs. This was illustrated in a study that randomly assigned 60 patients with CRPS following stroke to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (40 mg daily) or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    (20 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/27\">",
"     27",
"    </a>",
"    ]. At the end of one month, a significantly greater proportion of patients in the prednisolone group than those receiving piroxicam met criteria for improvement (83 versus 17 percent, respectively). The mean changes in CRPS score (6.5 versus 0.5) and in a functional index (7.9 versus 4.5) were also significantly different.",
"   </p>",
"   <p>",
"    Increased activity in the affected limb on technetium-99m bone scan may predict a good response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/25\">",
"     25",
"    </a>",
"    ]. The dose is tapered quickly as the patient responds; continued low-dose glucocorticoid treatment may be necessary for a prolonged period in severe cases.",
"   </p>",
"   <p>",
"    According to the experience of some clinicians, the treatment of reflex sympathetic dystrophy with glucocorticoid prior to contracture can be very effective, particularly when used in conjunction with a tricyclic antidepressant and with physical therapy. However, patients with stage 3 disease usually do not respond to glucocorticoids. Although limited data suggest that glucocorticoids are more effective than NSAIDS, we suggest using NSAIDs first and reserving use of glucocorticoids for those who do not respond to NSAIDs and antidepressants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Calcitonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    involves the ability of this hormone to retard bone resorption and a putative analgesic effect. The mechanism responsible for analgesia is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=see_link\">",
"     \"Calcitonin in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of the treatment of CRPS in 2001 included a meta-analysis of the results of five clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    and concluded that calcitonin &ldquo;does seem to be effective&rdquo; in treating pain due to CRPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/28\">",
"     28",
"    </a>",
"    ]. This conclusion was principally based upon two randomized placebo-controlled trials that included a total of 106 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Doses used in these latter trials were 300 to 400 international units per day administered by injection or by nasal spray. A small decrement in serum calcium may occur, but symptomatic hypocalcemia is unlikely. Cost is an issue.",
"   </p>",
"   <p>",
"    The optimal dose and duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    treatment is uncertain. An initial dose of 200 international units twice daily was used in one clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast, the combination of a lower dose (200 international units of salmon calcitonin once daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    was no more effective than acetaminophen alone in a subsequent study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/31\">",
"     31",
"    </a>",
"    ]. If pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function are improved with use, it can be continued, tapered, and discontinued as tolerated.",
"   </p>",
"   <p>",
"    Considering the evidence for efficacy and the low risk associated with its use, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    for patients with CRPS in combination with physical therapy for patients who have mild or moderate symptoms despite use of NSAIDs and tricyclic antidepressants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sympathetic blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review and meta-analysis of 12 clinical trials of sympathetic blockers or sympatholytics (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    , or guanethidine) orally or by intravenous regional sympathetic block concluded that the effect size was not statistically significant for these agents compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Regional sympathetic nerve block'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sympathetically maintained pain may respond to the addition of an alpha-1 adrenoceptor antagonist, which is supported by the author&rsquo;s experience and which has been suggested by experts who recommend a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38916?source=see_link\">",
"     phenoxybenzamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/8\">",
"     8",
"    </a>",
"    ]. The author has noted apparent benefit in some patients with the use of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    (1 to 6",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as tolerated) or phenoxybenzamine (10 to 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as tolerated). Hypotension can be a limiting side effect of alpha-adrenergic blockers. The author has also treated patients using a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    patch (0.1 mg), which is changed every seven days, usually in combination with anticonvulsants",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antidepressants; this approach has generally not resulted in significant side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Monitoring response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage 1 disease are seen on a weekly basis, and the treatment is changed if the response is suboptimal. Decreased pain, improved mobility, and better function are goals of therapy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Types and stages'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients in stage 1 who are not improving despite two weeks of the oral treatments discussed above combined with physical therapy should be considered for invasive forms of treatment. Stage 2 and stage 3 CRPS patients are also candidates for invasive therapies if pain and function are not rapidly improved. (See below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Invasive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving noninvasive therapy who are not improving are offered increasingly invasive interventions, allowing two weeks for improvement before moving on to the next type of treatment. In tertiary centers, consideration for spinal cord stimulation, arguably the most invasive therapy, would be considered by 12 to 16 weeks from the time therapy for CRPS is initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Tender point injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tender points may be found about the shoulder girdle when CRPS is limited to the upper limb. These tender points (trigger points) are located in the trapezius and suprascapular muscles in most patients. If unilateral involvement occurs, the other side can be used for comparison. The author&rsquo;s clinical experience is that tender point injections are sometimes effective and are safer than other treatment modalities. Injection of each tender point with local anesthetics with or without glucocorticoids is used for patients with stage 1 disease, before proceeding to more invasive and risky procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical nerve stimulation may be helpful in some patients. Observational data suggest that transcutaneous electrical nerve stimulation (TENS unit) can be helpful in selected patients (eg, children and those with recent onset of lower limb CRPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/33\">",
"     33",
"    </a>",
"    ]. Long-term peripheral nerve stimulation with implanted programmable generators and plate-like electrodes are under investigation for the treatment of pain that is in the distribution of one major peripheral nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Epidural clonidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    administered by epidural injection or infusion may reduce the pain of CRPS, but side effects such as hypotension and sedation can occur depending upon the dose [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Transdermal clonidine may reduce pain, but the effect is localized to the skin beneath the patch, suggesting a local rather than a central nervous system effect [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/34\">",
"     34",
"    </a>",
"    ]. Potential complications of epidural injection have limited study of this treatment to patients with severe refractory CRPS; 26 such patients were randomly assigned to epidural clonidine (300 or 700 microgram bolus injection) or to placebo and were assessed for up to six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/35\">",
"     35",
"    </a>",
"    ]. Epidural clonidine provided significantly greater pain relief than placebo injections in patients with severe refractory pain.",
"   </p>",
"   <p>",
"    We suggest that epidural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    be used only for patients refractory to other, less invasive approaches. The author has experience in using clonidine in combination with local anesthetics for stellate ganglion and lumbar sympathetic nerve block successfully, but its value needs to be systematically studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Regional sympathetic nerve block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary sympathetic nerve block can be accomplished by infiltration of a local anesthetic into the region of the sympathetic ganglia or by intravenous regional infusion of a sympathetic blocker, typically in combination with a local anesthetic. A systematic review in 2005 identified two randomized double-blind trials that included a total of 23 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/36\">",
"     36",
"    </a>",
"    ]. Regional sympathetic blockade did not produce a significantly greater short-term improvement in pain that did a sham intervention (relative risk of achieving a 50 percent reduction in pain of 1.17, 95% CI 0.80-1.72). The authors of the systematic review cautioned that the small number of subjects precluded a conclusion on the effectiveness of regional sympathetic block for CRPS.",
"   </p>",
"   <p>",
"    Patients with objective cutaneous changes or any persistent loss of motion may be candidates for sympathetic nerve blocks. The clinician should consider referral to a regional pain center to have these blocks done appropriately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ganglion blocks &mdash; Sympathetic ganglion block with local anesthetic injection produces more and longer-lived pain relief than placebo injection; duration of analgesic effect was 3.5 versus 1 day in one controlled study [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients who respond to stellate ganglion blocks are said to have sympathetically-dependent pain; these patients are typically in the first stage of disease.",
"      <br/>",
"      <br/>",
"      Some centers use an infusion of 40 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"       phentolamine",
"      </a>",
"      with concurrent cardiovascular monitoring as a test for those who are likely to have sympathetically-dependent pain. However, there is a risk of severe hypotension associated with this procedure; autonomic testing as described elsewhere is a safer alternative. Intravenous hydration and a small dose of beta-blocker, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , are used prior to phentolamine infusion to prevent hypotension and tachycardia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link&amp;anchor=H10#H10\">",
"       \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\", section on 'Autonomic testing'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Stellate ganglion blocks may be performed at one week intervals and may be repeated several times. This treatment is abandoned if an immediate response (eg, improved temperature and decreased pain) does not occur following the first or second nerve block.",
"     </li>",
"     <li>",
"      Intravenous regional blocks &mdash; The efficacy of intravenous regional blocks (Bier blocks) is uncertain, since a 2001 meta-analysis of nine randomized trials in patients with CRPS type I found no significant analgesic effect [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/28\">",
"       28",
"      </a>",
"      ]. Nevertheless, this approach is still being used in some centers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral medications and intensive mobilizing physical therapy should continue in patients who receive sympathetic or Bier blocks. Each block should result in a longer duration of pain relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Spinal cord stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord stimulation (also termed dorsal column stimulation) may be helpful if traditional therapeutic modalities fail, particularly in patients with disease limited to one extremity. In a randomized study of 36 patients and 18 controls, electrical stimulation and physical therapy reduced pain and improved health-related quality of life more than physical therapy alone for up to two years; however, the addition of spinal cord stimulation did not change functional outcome measures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. It may be significant that the controls did not undergo a sham intervention. No significant difference in pain was present during the period from three to five years following implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/40\">",
"     40",
"    </a>",
"    ]. Complications of this technique are common and are mostly associated with improper positioning of the electrode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Sympathectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympathectomy has not been compared with sham surgery. Chemical or surgical sympathectomy may be considered when the disease progresses despite the use of less invasive measures discussed above. A study of 35 patients referred to a surgical clinic for sympathectomy found excellent results in 26 (74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/41\">",
"     41",
"    </a>",
"    ]. However, a systematic review concluded that the evidence for the effectiveness was poor and noted high rates of adverse effects that included increased pain, new neuropathic pain, and bothersome sweating [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with stage 3 disease (eg, significant skin disease and contractures) may benefit from sympathectomy. However, in the author&rsquo;s experience, aggressive physical therapy, pain management, and encouragement of the patient to work beyond the pain typically obviated the need for this type of treatment. Sympathectomy should only be used in patients who have shown a previous response to nerve blockade (eg, who have sympathetically-dependent pain) and who are fully informed about the potential complications of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    may relieve dystonia in patients with CRPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/43\">",
"     43",
"    </a>",
"    ]. Case reports and personal experience suggest that a skilled hypnotherapist can be helpful for patients with heightened arousal, manifested by features of fear, anxiety, excessive sweating, and weakness, in whom exercise is otherwise impossible [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Hypnosis allowed physical therapy to progress in some patients with otherwise intractable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Experimental approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different approaches have been of interest for the treatment of longstanding or refractory CRPS, including intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , intravenous magnesium,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    , mirror therapy, and intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       Ketamine",
"      </a>",
"      infusion &mdash; Ketamine infusion was used in a randomized trial of 60 patients with type I CRPS, in whom it was effective in providing pain relief, with analgesia outlasting the treatment period by 50 days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/48\">",
"       48",
"      </a>",
"      ]. The authors suggest that ketamine initiated a cascade of events, including desensitization of excitatory receptor systems in the central nervous system, which persisted but slowly abated when ketamine molecules were no longer present. Another study reported ketamine-induced pain relief; however, patients did not have improvement in function [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravenous immunoglobulin &mdash; A randomized crossover trial involving 13 patients refractory to standard treatment found that treatment with intravenous immunoglobulin (IVIG) can reduce pain at 6 to 19 days following infusion, by a statistically significant but modest degree, compared with normal saline (1.6 units in a 0 to 10 pain score, 95% CI 1.3-1.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/50\">",
"       50",
"      </a>",
"      ]. Given the limitations of the study, there is a need for further trials to assess the efficacy of this intervention and its role relative to other therapeutic options [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mirror visual feedback therapy &mdash; An advanced mirror visual feedback system with virtual reality technology has been used successfully in phantom limb pain and stroke and is under investigation for treatment of CRPS [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/51-53\">",
"       51-53",
"      </a>",
"      ]. In a preliminary report, five patients with complex regional pain syndrome received virtual reality mirror visual feedback therapy once weekly for five to eight sessions. Patients were monitored for continued medication use and pain intensity. Four of the five patients showed &gt;50 percent reduction in pain intensity [",
"      <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2955100\">",
"    <span class=\"h2\">",
"     Recurrent CRPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence to guide strategies for the prevention and treatment of recurrences or relapses of CRPS. Elective surgery should be performed when features of previous episodes of CRPS have improved and when the patient is stable, and surgery should be avoided during exacerbations. Additional perioperative and surgical strategies include maintenance of optimal perfusion of the affected limb, avoidance of tourniquet hemostasis, and perioperative intravenous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . In one series of 47 patients with CRPS undergoing surgery involving a previously affected extremity, use of these measures was associated with a recurrence rate of CRPS of 13 percent. The recurrence was mild and temporary in five of the six patients in whom it occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with exacerbations or recurrence due to exposure to cold, new surgery, or emotional trauma, small doses of tricyclic antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ) and anticonvulsants have been helpful in our experience. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pharmacologic approaches'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other measures that have been proposed to prevent or minimize risk of recurrence include intensive rehabilitation, sympathetic block before surgery, regional",
"    <span class=\"nowrap\">",
"     anesthesia/analgesia",
"    </span>",
"    techniques, pretreatment with perioperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    prophylaxis, and neuromodulation post surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. However, the data supporting use of these approaches are limited. Most reports are of small case series, and some are limited to children. Thus, these approaches have not been tested in randomized trials, and it is uncertain whether the results in children can be generalized to CRPS in adults. CRPS in children is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=see_link\">",
"     \"Complex regional pain syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of CRPS type I, which accounts for more than 90 percent of cases of CRPS, is generally favorable. This was illustrated in a population-based study in which 74 percent of patients reported resolution of symptoms, some spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/60\">",
"     60",
"    </a>",
"    ]. Litigation and work-related compensation issues are involved in a substantial proportion of cases of CRPS cared for in tertiary pain-management clinics, present in 17 and 54 percent, respectively, in one study in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence of CRPS is not uncommon; estimates of recurrence range from about 10 to 30 percent, with the higher rates occurring in younger patients, including children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Recurrences can occur spontaneously or with cold exposure, but they also appear to be triggered by trauma or new surgery of the affected limb or of an unaffected remote site and by emotional trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/55,56,63,64\">",
"     55,56,63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=see_link\">",
"     \"Complex regional pain syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 1183 consecutive patients with CRPS, recurrences were seen in 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/62/6122/abstract/63\">",
"     63",
"    </a>",
"    ]. The recurrence of CRPS occurred twice as often in a different limb than in the initial episode (76 patients) compared with recurrence in the originally affected limb that had become largely asymptomatic (34 patients). In 10 patients, CRPS started in symmetrical limbs. Recurrences were most often spontaneous (53 percent) and were often associated with few signs and symptoms. Most of the remainder was associated with trauma or surgery (32 and 12 percent). The estimated incidence of a recurrence was 1.8 percent per patient per year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9490?source=see_link\">",
"       \"Patient information: Complex regional pain syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complex regional pain syndrome (CRPS) is a chronic pain condition of the extremities that is out of proportion to the severity of the initial injury. Pain is accompanied by swelling, by vasomotor dysregulation, by skin changes, and, in later stages, by limited range of motion, contractures, and patchy bone demineralization. It frequently begins following an injury, surgery, or stroke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To prevent CRPS following stroke, we recommend early mobilization (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also suggest early mobilization as a preventive strategy for those with CRPS due to injuries, with the recognition that casting for fractures and activity limitations may be unavoidable. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Early mobilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with wrist fractures, we recommend supplemental vitamin C, which has low risk and which may be beneficial (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A typical dose is 500 mg daily, and the duration is 50 days. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Vitamin C following fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some interventions that are appropriate for all patients include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient education, including provision of contact information for patient support groups (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Patient education'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Assessment of job and interpersonal relationships (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Psychologic assessment and counseling'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Physical therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occupational therapy assessment and treatment, which are initiated as quickly as is practical following diagnosis of CRPS (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical and occupational therapy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Smoking cessation, which should be encouraged (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Smoking cessation'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacologic and invasive procedures are utilized in an escalating fashion, beginning with those which are relatively safe and for which there is some evidence of effectiveness and progressing to more risky interventions if a desired response is not achieved after a few weeks of therapeutic trial. Our suggested approach is based on the clinical stage at presentation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types and stages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regardless of the clinical stage, the goals of pain management are to allow active participation in a rehabilitation regimen and to restore movement and strength of the affected limb. The clinician must emphasize this, particularly to reluctant patients.",
"     </li>",
"     <li>",
"      For patients with clinical stage 1 (eg, with burning and sometimes throbbing pain; diffuse uncomfortable aching; sensitivity to touch or cold; localized edema and vasomotor disturbances of variable intensity that produce altered color and temperature; and a radiograph that is either normal or that shows patchy demineralization) the following approach is suggested. We suggest starting a combination of agents that includes the following (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      cream (0.075 percent), which may be discontinued if it is too irritating or if there is no benefit after three to five days of use",
"     </li>",
"     <li>",
"      An antidepressant that is effective for neuropathic pain. We typically start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      (10 to 25 mg at bedtime) and increase the dose, as tolerated, to 150 mg. Other tricyclic antidepressants and dual uptake inhibitors that are indicated for treatment of neuropathic pain are alternatives to amitriptyline.",
"     </li>",
"     <li>",
"      An anticonvulsant, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , in addition to or instead of the above antidepressants. If pain persists, we suggest adding either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"      or a bisphosphonate (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). If cost is not an overriding issue, we use calcitonin nasal spray; a typical dose would be 400 international units per day (eg, 200 international units twice daily). If the cost of calcitonin is prohibitive, we use a bisphosphonate. Intravenously administered bisphosphonates (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"       clodronate",
"      </a>",
"      300 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or oral agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      70 mg weekly) may be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"       \"Overview of the treatment of chronic pain\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Bisphosphonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A nonsteroidal antiinflammatory drug. A typical initial regimen is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      250 to 500 mg twice daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who do not have a satisfactory response to initial therapy after a few weeks, one or more of the following may be tried sequentially:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If there are muscular tender points, we suggest performing trigger point injections either with local anesthetics alone or with a mixture of local anesthetic and long-acting glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Tender point injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CRPS type I and clinical stage 1 who remain symptomatic despite the interventions described above or who are evolving signs of having clinical stage 2, we recommend use of an oral glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A typical regimen is a therapeutic trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for three days. If effective, prednisone is continued and tapered over the ensuing three weeks. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with clinical stage 2 CRPS (eg, persistent soft tissue edema, accompanied by thickening of the skin and periarticular soft tissues, muscle wasting, and the development of brawny skin changes), we suggest the same initial combination described above for clinical stage 1 plus glucocorticoids either orally or by soft tissue injection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Referral to a pain management specialist with experience in management of CRPS is appropriate for patients with clinical stage 2 CRPS. Depending upon the expertise of the specialist, regional sympathetic block or sympathetic ganglion block may be the preferred initial intervention. Other invasive treatments that are typically reserved for those with severe and refractory disease include epidural",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      , implantable peripheral nerve stimulators, and spinal cord stimulators. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Invasive therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative approach, suitable for patients who are unwilling to consider invasive therapies, is the sequential addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"      or a bisphosphonate to an ongoing regimen consisting of an antidepressant, an anticonvulsant, an NSAID, and, if necessary to control severe pain, an opioid analgesic. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pharmacologic approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with clinical stage 3 CRPS should be referred to an experienced pain management specialist at a tertiary care center.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20818832\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Robert P Sheon, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/1\">",
"      Stanton-Hicks M, J&auml;nig W, Hassenbusch S, et al. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain 1995; 63:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/2\">",
"      Braus DF, Krauss JK, Strobel J. The shoulder-hand syndrome after stroke: a prospective clinical trial. Ann Neurol 1994; 36:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/3\">",
"      Petchkrua W, Weiss DJ, Patel RR. Reassessment of the incidence of complex regional pain syndrome type 1 following stroke. Neurorehabil Neural Repair 2000; 14:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/4\">",
"      Dijkstra PU, Groothoff JW, ten Duis HJ, Geertzen JH. Incidence of complex regional pain syndrome type I after fractures of the distal radius. Eur J Pain 2003; 7:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/5\">",
"      Zollinger PE, Tuinebreijer WE, Kreis RW, Breederveld RS. Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial. Lancet 1999; 354:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/6\">",
"      Zollinger PE, Tuinebreijer WE, Breederveld RS, Kreis RW. Can vitamin C prevent complex regional pain syndrome in patients with wrist fractures? A randomized, controlled, multicenter dose-response study. J Bone Joint Surg Am 2007; 89:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/7\">",
"      Stevermer JJ, Ewigman B. Give vitamin C to avert lingering pain after fracture. J Fam Pract 2008; 57:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/8\">",
"      Stanton-Hicks MD, Burton AW, Bruehl SP, et al. An updated interdisciplinary clinical pathway for CRPS: report of an expert panel. Pain Pract 2002; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/9\">",
"      Moseley GL. Graded motor imagery for pathologic pain: a randomized controlled trial. Neurology 2006; 67:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/10\">",
"      Moseley GL. Graded motor imagery is effective for long-standing complex regional pain syndrome: a randomised controlled trial. Pain 2004; 108:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/11\">",
"      Johnson S, Hall J, Barnett S, et al. Using graded motor imagery for complex regional pain syndrome in clinical practice: failure to improve pain. Eur J Pain 2012; 16:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/12\">",
"      Bruehl S, Chung OY. Psychological and behavioral aspects of complex regional pain syndrome management. Clin J Pain 2006; 22:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/13\">",
"      Oerlemans HM, Goris JA, de Boo T, Oostendorp RA. Do physical therapy and occupational therapy reduce the impairment percentage in reflex sympathetic dystrophy? Am J Phys Med Rehabil 1999; 78:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/14\">",
"      Oerlemans HM, Oostendorp RA, de Boo T, et al. Adjuvant physical therapy versus occupational therapy in patients with reflex sympathetic dystrophy/complex regional pain syndrome type I. Arch Phys Med Rehabil 2000; 81:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/15\">",
"      Oerlemans HM, Oostendorp RA, de Boo T, Goris RJ. Pain and reduced mobility in complex regional pain syndrome I: outcome of a prospective randomised controlled clinical trial of adjuvant physical therapy versus occupational therapy. Pain 1999; 83:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/16\">",
"      An HS, Hawthorne KB, Jackson WT. Reflex sympathetic dystrophy and cigarette smoking. J Hand Surg Am 1988; 13:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/17\">",
"      Quisel A, Gill JM, Witherell P. Complex regional pain syndrome: which treatments show promise? J Fam Pract 2005; 54:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/18\">",
"      Mellick LB, Mellick GA. Successful treatment of reflex sympathetic dystrophy with gabapentin. Am J Emerg Med 1995; 13:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/19\">",
"      Mellick GA, Mellicy LB, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage 1995; 10:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/20\">",
"      Chapurlat RD, Duboeuf FP, Liens D, Meunier PJ. Dual energy X-ray absorptiometry in patients with lower limb reflex sympathetic dystrophy syndrome. J Rheumatol 1996; 23:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/21\">",
"      Varenna M, Zucchi F, Ghiringhelli D, et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol 2000; 27:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/22\">",
"      Cortet B, Flipo RM, Coquerelle P, et al. Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate. Clin Rheumatol 1997; 16:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/23\">",
"      Adami S, Fossaluzza V, Gatti D, et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997; 56:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/24\">",
"      Manicourt DH, Brasseur JP, Boutsen Y, et al. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum 2004; 50:3690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/25\">",
"      Kozin F, McCarty DJ, Sims J, Genant H. The reflex sympathetic dystrophy syndrome. I. Clinical and histologic studies: evidence for bilaterality, response to corticosteroids and articular involvement. Am J Med 1976; 60:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/26\">",
"      Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids. Acta Chir Scand 1982; 148:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/27\">",
"      Kalita J, Vajpayee A, Misra UK. Comparison of prednisolone with piroxicam in complex regional pain syndrome following stroke: a randomized controlled trial. QJM 2006; 99:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/28\">",
"      Perez RS, Kwakkel G, Zuurmond WW, de Lange JJ. Treatment of reflex sympathetic dystrophy (CRPS type 1): a research synthesis of 21 randomized clinical trials. J Pain Symptom Manage 2001; 21:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/29\">",
"      Bickerstaff DR, Kanis JA. The use of nasal calcitonin in the treatment of post-traumatic algodystrophy. Br J Rheumatol 1991; 30:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/30\">",
"      Gobelet C, Waldburger M, Meier JL. The effect of adding calcitonin to physical treatment on reflex sympathetic dystrophy. Pain 1992; 48:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/31\">",
"      Sahin F, Yilmaz F, Kotevoglu N, Kuran B. Efficacy of salmon calcitonin in complex regional pain syndrome (type 1) in addition to physical therapy. Clin Rheumatol 2006; 25:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/32\">",
"      Stanton-Hicks M. Complex regional pain syndrome: manifestations and the role of neurostimulation in its management. J Pain Symptom Manage 2006; 31:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/33\">",
"      Hassenbusch SJ, Stanton-Hicks M, Schoppa D, et al. Long-term results of peripheral nerve stimulation for reflex sympathetic dystrophy. J Neurosurg 1996; 84:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/34\">",
"      Kirkpatrick AF, Derasari M. Transdermal clonidine: treating reflex sympathetic dystrophy. Reg Anesth 1993; 18:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/35\">",
"      Rauck RL, Eisenach JC, Jackson K, et al. Epidural clonidine treatment for refractory reflex sympathetic dystrophy. Anesthesiology 1993; 79:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/36\">",
"      Cepeda MS, Carr DB, Lau J. Local anesthetic sympathetic blockade for complex regional pain syndrome. Cochrane Database Syst Rev 2005; :CD004598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/37\">",
"      Price DD, Long S, Wilsey B, Rafii A. Analysis of peak magnitude and duration of analgesia produced by local anesthetics injected into sympathetic ganglia of complex regional pain syndrome patients. Clin J Pain 1998; 14:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/38\">",
"      Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med 2000; 343:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/39\">",
"      Kemler MA, De Vet HC, Barendse GA, et al. The effect of spinal cord stimulation in patients with chronic reflex sympathetic dystrophy: two years' follow-up of the randomized controlled trial. Ann Neurol 2004; 55:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/40\">",
"      Kemler MA, de Vet HC, Barendse GA, et al. Spinal cord stimulation for chronic reflex sympathetic dystrophy--five-year follow-up. N Engl J Med 2006; 354:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/41\">",
"      Olcott C 4th, Eltherington LG, Wilcosky BR, et al. Reflex sympathetic dystrophy--the surgeon's role in management. J Vasc Surg 1991; 14:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/42\">",
"      Mailis A, Furlan A. Sympathectomy for neuropathic pain. Cochrane Database Syst Rev 2003; :CD002918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/43\">",
"      van Hilten BJ, van de Beek WJ, Hoff JI, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000; 343:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/44\">",
"      Gainer MJ. Hypnotherapy for reflex sympathetic dystrophy. Am J Clin Hypn 1992; 34:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/45\">",
"      Kawano M, Matsuoka M, Kurokawa T, et al. Autogenic training as an effective treatment for reflex neurovascular dystrophy: a case report. Acta Paediatr Jpn 1989; 31:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/46\">",
"      Birklein F, Sommer C. Intravenous immunoglobulin to fight complex regional pain syndromes: hopes and doubts. Ann Intern Med 2010; 152:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/47\">",
"      Schwartzman RJ, Alexander GM, Grothusen JR, et al. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 2009; 147:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/48\">",
"      Dahan A, Olofsen E, Sigtermans M, et al. Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain 2011; 15:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/49\">",
"      Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009; 145:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/50\">",
"      Goebel A, Baranowski A, Maurer K, et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. Ann Intern Med 2010; 152:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/51\">",
"      McCabe CS, Haigh RC, Blake DR. Mirror visual feedback for the treatment of complex regional pain syndrome (type 1). Curr Pain Headache Rep 2008; 12:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/52\">",
"      Cacchio A, De Blasis E, Necozione S, et al. Mirror therapy for chronic complex regional pain syndrome type 1 and stroke. N Engl J Med 2009; 361:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/53\">",
"      Sato K, Fukumori S, Matsusaki T, et al. Nonimmersive virtual reality mirror visual feedback therapy and its application for the treatment of complex regional pain syndrome: an open-label pilot study. Pain Med 2010; 11:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/54\">",
"      Veldman PH, Goris RJ. Surgery on extremities with reflex sympathetic dystrophy. Unfallchirurg 1995; 98:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/55\">",
"      Marx C, Wiedersheim P, Michel BA, Stucki G. Preventing recurrence of reflex sympathetic dystrophy in patients requiring an operative intervention at the site of dystrophy after surgery. Clin Rheumatol 2001; 20:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/56\">",
"      Shah RV, Day MR. Recurrence and spread of complex regional pain syndrome caused by remote-site surgery: a case report. Am J Orthop (Belle Mead NJ) 2006; 35:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/57\">",
"      Dadure C, Motais F, Ricard C, et al. Continuous peripheral nerve blocks at home for treatment of recurrent complex regional pain syndrome I in children. Anesthesiology 2005; 102:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/58\">",
"      Monacelli G, Valesini L, Rizzo MI, et al. [Complex Regional Pain (CRPS) Syndrome type II. Timing for surgery and therapeutic options: neuromodulation]. Clin Ter 2006; 157:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/59\">",
"      Brooke V, Janselewitz S. Outcomes of children with complex regional pain syndrome after intensive inpatient rehabilitation. PM R 2012; 4:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/60\">",
"      Sandroni P, Benrud-Larson LM, McClelland RL, Low PA. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain 2003; 103:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/61\">",
"      Allen G, Galer BS, Schwartz L. Epidemiology of complex regional pain syndrome: a retrospective chart review of 134 patients. Pain 1999; 80:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/62\">",
"      Zyluk A. Complex regional pain syndrome type I. Risk factors, prevention and risk of recurrence. J Hand Surg Br 2004; 29:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/63\">",
"      Veldman PH, Goris RJ. Multiple reflex sympathetic dystrophy. Which patients are at risk for developing a recurrence of reflex sympathetic dystrophy in the same or another limb. Pain 1996; 64:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/62/6122/abstract/64\">",
"      Akkus S, Yorgancigil H, Yener M. A case of recurrent and migratory complex regional pain syndrome type I: Prevention by gabapentin. Rheumatol Int 2006; 26:852.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5630 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6122=[""].join("\n");
var outline_f5_62_6122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES AND STAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Early mobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vitamin C following fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Psychologic assessment and counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical and occupational therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pharmacologic approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Topical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Calcitonin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sympathetic blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Monitoring response to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Invasive therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Tender point injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Epidural clonidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Regional sympathetic nerve block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Spinal cord stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Sympathectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Experimental approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2955100\">",
"      Recurrent CRPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20818832\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5630\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5630|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/4/6223\" title=\"picture 1\">",
"      Claw limb RSD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=related_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=related_link\">",
"      Complex regional pain syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9490?source=related_link\">",
"      Patient information: Complex regional pain syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=related_link\">",
"      Pharmacology of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_62_6123="Wheelchair transportation";
var content_f5_62_6123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for safe transportation of children in wheelchairs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       The wheelchair should be secured in a forward-facing position",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The wheelchair should be secured with four-point tie-down devices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lap boards or metal or plastic trays should be removed and secured separately",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       An occupant restraint that has been tested at 30 mph and 20G force conditions and that includes upper and lower torso restraint (ie, shoulder harness and lap belt) should be provided",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Head bands should not be used to restrain the child's head separately from the torso",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bull, M, Agran, P, Laraque, D, et al. American Academy of Pediatrics. Committee on Injury and Poison Prevention. Transporting children with special health care needs. Pediatrics 1999; 104:988. (Reaffirmed May, 2006).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6123=[""].join("\n");
var outline_f5_62_6123=null;
var title_f5_62_6124="NIH recommendationsfor antenatal steroids";
var content_f5_62_6124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for use of antenatal corticosteroids",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The benefits of antenatal administration of corticosteroids to fetuses at risk of preterm delivery vastly outweigh the potential risks. These benefits include not only a reduction in the risk of RDS, but also a substantial reduction in mortality and IVH.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All fetuses between 24 and 34 weeks of gestation at risk of preterm delivery should be considered candidates for antenatal treatment with corticosteroids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The decision to use antenatal corticosteroids should not be altered by fetal race or gender or by the availability of surfactant replacement therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients eligible for therapy with tocolytics should also be eligible for treatment with antenatal corticosteroids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment consists of either two doses of 12 mg of betamethasone given intramuscularly 24 hours apart or four doses of 6 mg of dexamethasone given intramuscularly 12 hours apart. Optimal benefit begins 24 hours after initiation of therapy and lasts seven days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Because treatment with corticosteroids for less than 24 hours is still associated with significant reductions in neonatal mortality, RDS, and IVH, antenatal corticosteroids should be given unless immediate delivery is anticipated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In premature rupture of membranes at less than 30 to 32 weeks of gestation in the absence of clinical chorioamnionitis, antenatal corticosteroid use is recommended because of the high risk of IVH at these early gestational ages.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In complicated pregnancies where delivery prior to 34 weeks of gestation is likely, antenatal corticosteroid use is recommended unless there is evidence that corticosteroids will have an adverse effect on the mother or delivery is imminent.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RDS: respiratory distress syndrome; IVH: intraventricular hemorrhage.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: data in the Report of the Consensus Development Conference on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. National Institute of Child Health and Human Development. November 1994. NIH Publication No. 95-3784.",
"     <br/>",
"     Antenatal Corticosteroids Revisited: Repeat Courses&mdash;National Institutes of Health Consensus Development Conference Statement, August 17&ndash;18, 2000. Obstet Gynecol 2001; 98:144-150.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6124=[""].join("\n");
var outline_f5_62_6124=null;
var title_f5_62_6125="Regulation of proximal pH";
var content_f5_62_6125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Determinant of proximal tubule cell pH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 229px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of lowering the HCO3- concentration and pH in the fluid in the tubular lumen or in the peritubular capillary on the proximal tubular cell pH. Only the change in peritubular capillary pH significantly lowers the cell pH, an effect that appears to be mediated by the Na+:3HCO3- cotransporter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Alpern, RJ, Chambers, M, J Clin Invest 1986; 78:502.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6125=[""].join("\n");
var outline_f5_62_6125=null;
var title_f5_62_6126="Therapy by stage COPD";
var content_f5_62_6126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of stable COPD: Therapy by GOLD disease category severity as assessed by symptoms and risk (as determined by exacerbations and airflow limitation)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested treatment",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        All",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Avoidance of risk factor(s), such as smoking",
"        </p>",
"        <p>",
"         Annual influenza vaccination",
"        </p>",
"        <p>",
"         Pneumococcal vaccination",
"        </p>",
"        <p>",
"         Regular physical activity",
"        </p>",
"        Long-term oxygen therapy if chronic hypoxemia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        A",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Less symptomatic",
"         </strong>",
"        </p>",
"        Mild or infrequent symptoms (ie, breathless with strenuous exercise or when hurrying on level ground or walking up a slight hill)* or CAT &lt;10",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Low risk",
"         </strong>",
"        </p>",
"        <p>",
"         FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC ratio &lt;0.7 and an FEV",
"         <sub>",
"          1",
"         </sub>",
"         &ge;50 percent predicted (GOLD I, II)",
"        </p>",
"        <p>",
"         AND",
"        </p>",
"        0 or 1 exacerbations in the past year",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          First choice:",
"         </strong>",
"         short-acting bronchodilator when needed: anticholinergic alone or beta-agonist alone",
"        </p>",
"        <p>",
"         <strong>",
"          Second choice:",
"         </strong>",
"         long-acting anticholinergic or long-acting beta agonist or short-acting beta-agonist and short-acting anticholinergic as needed",
"        </p>",
"        <strong>",
"         Alternative:",
"        </strong>",
"        theophylline",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        B",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          More symptomatic",
"         </strong>",
"        </p>",
"        Moderate to severe symptoms (ie, patient has to walk more slowly than others of same age due to breathlessness, has to stop to catch breath when walking on level ground at own pace, or has more severe breathlessness)* or CAT &ge;10",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Low risk",
"         </strong>",
"        </p>",
"        <p>",
"         FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC ratio &lt;0.7 and an FEV",
"         <sub>",
"          1",
"         </sub>",
"         &ge;50 percent predicted (GOLD I, II)",
"        </p>",
"        <p>",
"         AND",
"        </p>",
"        0 or 1 exacerbations in the past year",
"       </td>",
"       <td>",
"        <p>",
"         Short-acting bronchodilator when needed and pulmonary rehabilitation",
"        </p>",
"        <p>",
"         <strong>",
"          First choice:",
"         </strong>",
"         regular treatment with a long-acting bronchodilator",
"        </p>",
"        <p>",
"         <strong>",
"          Second choice:",
"         </strong>",
"         regular treatment with a long-acting anticholinergic and long-acting beta agonist",
"        </p>",
"        <strong>",
"         Alternatives:",
"        </strong>",
"        short-acting beta-agonist and/or short-acting anticholinergic, theophylline",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        C",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Less symptomatic",
"         </strong>",
"        </p>",
"        Mild or infrequent symptoms (ie, breathless with strenuous exercise or when hurrying on level ground or walking up a slight hill)* or CAT &lt;10",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          High risk",
"         </strong>",
"        </p>",
"        <p>",
"         FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC ratio &lt;0.7 and an FEV",
"         <sub>",
"          1",
"         </sub>",
"         &lt;50 percent predicted (GOLD III, IV)",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        &ge;2 exacerbations per year or one hospitalization for an exacerbation",
"       </td>",
"       <td>",
"        <p>",
"         Short-acting bronchodilator when needed and pulmonary rehabilitation",
"        </p>",
"        <p>",
"         <strong>",
"          First choice:",
"         </strong>",
"         regular treatment with a combination long-acting beta agonist and inhaled glucocorticoid or a long-acting anticholinergic",
"        </p>",
"        <p>",
"         <strong>",
"          Second choice:",
"         </strong>",
"         regular treatment with a long-acting anticholinergic and a long-acting beta agonist",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         phosphodiesterase-4 inhibitor, SABA and/or SAMA, theophylline",
"        </p>",
"        Consider surgical treatments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        D",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          More symptomatic",
"         </strong>",
"        </p>",
"        Moderate to severe symptoms (ie, patient has to walk slower than others of same age due to breathlessness, has to stop to catch breath when walking on level ground at own pace, or has more severe breathlessness)* or CAT &ge;10",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          High risk",
"         </strong>",
"        </p>",
"        <p>",
"         FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC ratio &lt;0.7 and an FEV",
"         <sub>",
"          1",
"         </sub>",
"         &lt;50 percent predicted (GOLD III, IV)",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        &ge;2 exacerbations per year or one hospitalization for an exacerbation",
"       </td>",
"       <td>",
"        <p>",
"         Short-acting bronchodilator when needed and pulmonary rehabilitation",
"        </p>",
"        <p>",
"         <strong>",
"          First choice:",
"         </strong>",
"         regular treatment with combination inhaled glucocorticoid and a long-acting beta agonist or a long-acting anticholinergic alone",
"        </p>",
"        <p>",
"         <strong>",
"          Second choice:",
"         </strong>",
"         regular treatment with one of the following combinations:",
"        </p>",
"        <p>",
"         - Inhaled glucocorticoid and long-acting anticholinergic",
"        </p>",
"        <p>",
"         - Inhaled glucocorticoid and a long-acting beta agonist PLUS a long acting anticholinergic",
"        </p>",
"        <p>",
"         - Inhaled glucocorticoid and a long-acting beta agonist PLUS a phosphodiesterase-4 inhibitor",
"        </p>",
"        <p>",
"         - Long-acting anticholinergic and a long-acting beta agonist",
"        </p>",
"        <p>",
"         - Long-acting anticholinergic and a phosphodiesterase-4 inhibitor",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         Carbocysteine, short-acting beta-agonist and/or short-acting anticholinergic, theophylline",
"        </p>",
"        Consider surgical treatments",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients must be taught how and when to use their treatments, and treatment choices are adjusted based on patient responses. Medications being prescribed for other conditions should be reviewed.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second; FVC: forced vital capacity; SABA: short acting beta agonist; SAMA: short acting muscarinic antagonist.",
"     <br/>",
"     * Symptom severity based on: modified Medical Research Council Dyspnea scale (mMRC).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Symptom severity based on: COPD Assessment Test (CAT): file://www.catestonline.org (Accessed on September 20, 2012).",
"     <br/>",
"     The mMRC and CAT are described in the topic on the diagnosis of COPD.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Global Initiative for Chronic Obstructive Pulmonary Disease, Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2011, www.goldcopd.com (Accessed October 23, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_62_6126=[""].join("\n");
var outline_f5_62_6126=null;
var title_f5_62_6127="Contents: Vasculitis";
var content_f5_62_6127=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Vasculitis",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Vasculitis",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antineutrophil cytoplasmic antibody associated",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/28/9674\">",
"           Clinical spectrum of antineutrophil cytoplasmic antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/56/21383\">",
"           Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/32/34314\">",
"           Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33097\">",
"           Pathogenesis of granulomatosis with polyangiitis (Wegener���������s) and related vasculitides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/33/35353\">",
"           Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Behcet's disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/18/298\">",
"           Clinical manifestations and diagnosis of Beh������et���������s disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/12/28874\">",
"           Pathogenesis of Beh������et���������s disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/45/33498\">",
"           Treatment of Beh������et���������s disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Central nervous system and retinal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/15/16631\">",
"           Eales' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/50/25386\">",
"           Primary angiitis of the central nervous system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/17/13590\">",
"           Retinal vasculitis associated with primary ocular disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/49/33561\">",
"           Retinal vasculitis associated with systemic disorders and infections",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Churg-Strauss syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/56/21383\">",
"           Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/33/35353\">",
"           Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Classification and diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/23/37241\">",
"           Classification of and approach to the vasculitides in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24968\">",
"           Gastrointestinal manifestations of vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cogan's syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/42/12968\">",
"           Cogan���������s syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cryoglobulinemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34040\">",
"           Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/63/22522\">",
"           Overview of cryoglobulins and cryoglobulinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/52/36682\">",
"           Treatment of the mixed cryoglobulinemia syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Giant cell arteritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/33/18969\">",
"           Clinical manifestations of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/50/34599\">",
"           Diagnosis of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/62/8166\">",
"           Pathogenesis of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/26/34217\">",
"           Treatment of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Henoch-Sch&ouml;nlein purpura",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40729\">",
"           Clinical manifestations and diagnosis of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28646\">",
"           Management of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/54/5993\">",
"           Renal manifestations of Henoch-Sch������nlein purpura",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypersensitivity vasculitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/57/30614\">",
"           Hypersensitivity vasculitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/40/8842\">",
"           Serum sickness and serum sickness-like reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/60/32714\">",
"           Urticarial vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polyarteritis nodosa",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/26/9641\">",
"           Clinical manifestations and diagnosis of polyarteritis nodosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28119\">",
"           Treatment and prognosis of polyarteritis nodosa",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polymyalgia rheumatica",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/32/13832\">",
"           Clinical manifestations and diagnosis of polymyalgia rheumatica",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/41/40598\">",
"           Treatment of polymyalgia rheumatica",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatoid vasculitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/13/20697\">",
"           Clinical manifestations and diagnosis of rheumatoid vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/26/42407\">",
"           Epidemiology and pathogenesis of rheumatoid vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/19/22841\">",
"           Treatment of rheumatoid vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Takayasu arteritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/19/13624\">",
"           Clinical features and diagnosis of Takayasu arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/60/3015\">",
"           Treatment of Takayasu arteritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/61/32727\">",
"           Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16008\">",
"           General principles of the use of cyclophosphamide in rheumatic and renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/32/25098\">",
"           General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/32/34314\">",
"           Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/50/2855\">",
"           Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/17/28949\">",
"           Overview of the management of the vasculitides in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/62/8170\">",
"           Thromboangiitis obliterans (Buerger's disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3321\">",
"           Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener���������s) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/52/36682\">",
"           Treatment of the mixed cryoglobulinemia syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Wegener's granulomatosis and microscopic PAN",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/61/32727\">",
"           Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22423\">",
"           Clinical manifestations of vasculitic neuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/53/16215\">",
"           Diagnosis and treatment of vasculitic neuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/32/34314\">",
"           Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33097\">",
"           Pathogenesis of granulomatosis with polyangiitis (Wegener���������s) and related vasculitides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3321\">",
"           Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener���������s) and microscopic polyangiitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3ED48D6AFA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_62_6127=[""].join("\n");
var outline_f5_62_6127=null;
